NZ795495A - Aminothiazole compounds as c-Kit inhibitors - Google Patents
Aminothiazole compounds as c-Kit inhibitorsInfo
- Publication number
- NZ795495A NZ795495A NZ795495A NZ79549517A NZ795495A NZ 795495 A NZ795495 A NZ 795495A NZ 795495 A NZ795495 A NZ 795495A NZ 79549517 A NZ79549517 A NZ 79549517A NZ 795495 A NZ795495 A NZ 795495A
- Authority
- NZ
- New Zealand
- Prior art keywords
- alkyl
- compound
- methyl
- optionally substituted
- heterocycloalkyl
- Prior art date
Links
Abstract
The invention relates to c-Kit inhibitors useful in the treatment of cancers, and other -threonine kinase mediated diseases, having the Formula: (I) wherein A, L, R1, R2, R3, and n are described herein.
Description
The ion relates to c-Kit inhibitors useful in the treatment of cancers, and other -threonine
kinase mediated diseases, having the Formula: (I) wherein A, L, R1, R2, R3, and n are described
herein.
NZ 795495
AMINOTHIAZOLE COMPOUNDS AS C-KIT INHIBITORS
Cross Reference to Related Applications
This application claims priority to United States Provisional Patent Application serial
number 62/434,845 filed on er 15, 2016, the entirety of which is hereby incorporated by
reference. The present application is a divisional of New Zealand patent application 755196, which
is the national phase entry of PCT international application (published as
Field of Invention
The present invention is directed to inhibitors of tyrosine-protein kinase Kit (c-Kit)
useful in the treatment of diseases or disorders associated with c-Kit. Specifically, the invention is
concerned with compounds and compositions ting c-Kit, methods of treating diseases or
disorders ated with c-Kit, and methods of synthesis of these compounds.
Background of the Invention
The discovery that the tyrosine kinase inhibitor (TKI) imatinib inhibits KIT, and its
introduction as a treatment, transformed the clinical ment of gastrointestinal stromal tumors
(GIST) (Corless, C.L. et al., Nat. Rev. Cancer 2011, 11: ). Nonetheless, most imatinibtreated
patients ultimately relapse due to outgrowth of clones with secondary, drug-resistant KIT
mutations ich, M.C., et al., J. Clin. Oncol. 2006, 24: 4). Secondary mutations typically
occur in the ATP binding pocket encoded by exons 13 and 14, and the activation loop (A-loop)
encoded by exons 17 and 18. The challenge of treating imatinib resistant GISTs is compounded by
mutational heterogeneity, as ts can harbor multiple different secondary mutations in distinct
tumor lesions, or even within different regions of the same lesion (Wardelmann E., et al., Clin.
Cancer Res. 2006, 12: 1743-9).
GIST patients with imatinib-resistant tumors are treated with sunitinib, which potently
inhibits KIT ATP-pocket s (Heinrich, M.C., et al., J Clin Oncol 2008; 26: 5352-9). However,
sunitinib is ctive against A-loop mutants, which t for 50% of imatinib-resistance
mutations. This may explain why overall response rates (ORR) are low (7%) and median
progression-free survival (PFS) is short (6.2 months; Demetri, G.D., et al., Lancet 2006; 368: 1329-
38). Regorafenib was recently approved as third line therapy, but also shows only moderate
activity, with ORR of 4.5% and median PFS of 4.8 months (Demetri, G.D., et al., Lancet 2013;
381: 295-302). The KIT inhibitory properties of regorafenib have not yet
been ed extensively, but both al and initial preclinical
data suggest a limited spectrum of sensitive KIT mutants (George, S., et al., J. Clin. Oncol.
2012, 30: , and Serrano-Garcia, C., et al., ASCO g Abstracts 2013,
31(15_supp1): 10510). Thus, additional agents are needed to overcome resistance mutations
in KIT, in particular those in the A-loop.
The KIT inhibitors imatinib, sunitinib and regorafenib are effective GIST
therapies, though most patients develop resistance to these drugs due to c acquisition
of polyclonal secondary KIT mutants. The lack of efficacy of any single agent against the
te set of potential nding pocket and A-loop secondary mutants makes
achievement of prolonged complete disease l in late stage ts challenging. To
address this unmet medical need, presented herein are compounds that target a broad range of
primary and secondary KIT mutants, including those within the .
Summary of the Invention
The present disclosure provides novel aminothiazole compounds and
pharmaceutically acceptable salts as effective c-Kit inhibitors.
A first aspect of the invention relates to compounds of Formula (I):
and pharmaceutically acceptable salts, hydrates, solvates, prodrugs, stereoisomers, and
tautomers thereof,
wherein:
L is —C(O)NR5- or —NR5C(O)-,
A is (C3-C8) cycloalkyl, o) aryl, or 5- to 10-membered heteroaryl wherein the
cycloalkyl, aryl, or heteroaryl is optionally substituted with one or more R4,
R1 is H, (C1-C6)alkyl, -(CH2)qC(O)OH, or —C(O)N(R7)2;
R2 is (C1-C6) alkyl, -C(O)Rg, or —C(O)NR9R10,
each R3 is independently at each occurrence (C1-C6) alkyl, (C1-C6) alkoxy,
(C1-C6) kyl, (C1-C6) haloalkoxy, halogen, or OH,
each R4 is independently at each occurrence (C1-C6) alkyl, (C1-C6) alkoxy,
(C1-C6) haloalkyl, (C1-C6) koxy, halogen, -OH, CN, -(C(R6)2)p-heterocycloalkyl
wherein the heterocycloalkyl comprises a 4- to 7-membered ring and l to 3 heteroatoms
selected from N, O, and S or -(C(R6)2)p-heteroaryl n the heteroaryl comprises a 5- or
6-membered ring and l to 3 heteroatoms selected from N, O, and S, and wherein the
heterocycloalkyl or heteroaryl is optionally tuted with one or more substituents each
independently selected from
(C1-C6) alkyl, -NH2, (C1-C6) alkylamino, and (C1-C6) dialkylamino,
R5 is H, (C1-C6) alkyl, or (C1-C6) haloalkyl,
each R6 is independently H or (C1-C6) alkyl,
each R7 is independently H or ) alkyl,
R8 is (C1-C6) alkyl, (C3-C7) lkyl, (C2-C6) alkenyl, (C1-C3) alkoxy, (C1-C6)
kyl, (C1-C6) haloalkoxy, or 4 to ered heterocycloalkyl comprising 1 to 3
heteroatoms selected from N, O, and S,
R9 is H, (C1-C6) alkyl, (C1-C6) kyl, (C3-C7) cycloalkyl, or 4 to 7-membered
heterocycloalkyl comprising 1 to 3 heteroatoms selected from N, O, or S,
R10 is H, (C1-C6) alkyl, (C1-C6) haloalkyl, (C3-C7) cycloalkyl, or 4 to 7-membered
heterocycloalkyl comprising 1 to 3 heteroatoms selected from N, O, or S, wherein the
cycloalkyl or heterocycloalkyl is optionally substituted with one or more tuents each
independently selected from (C1-C6) alkyl, -NH2, (C1-C6) alkylamino, (C1-C6) dialkylamino,
and -OH, and wherein the (C1-C6) alkyl is ally substituted with one or more R”,
or R9 and R10 together with the nitrogen atom to which they are attached form a 4- to
ered heterocycloalkyl ring comprising 1 to 3 heteroatom selected from N, O, and S,
optionally substituted with one or more substituent each independently selected from
(C1-C6) alkyl, (C1-C6) hydroxyalkyl, -(CH2)q-NH2, -(CH2)q-(C1-C6) alkylamino,
q-(C1-C6) dialkylamino, -C(O)(C1-C6) alkyl, -OH, and 4- to 7-membered
heterocycloalkyl comprising 1 to 3 heteroatom selected from N, O, and S, and optionally
substituted with one or more (C1-C6) alkyl,
R“ is ) alkoxy, -OH, -NH2, (C1-C6) alkylamino, ) dialkylamino, 5— or 6-
membered heteroaryl comprising 1 to 3 heteroatoms ed from N, O, or S, or 4- to 7-
membered heterocycloalkyl comprising 1 to 3 heteroatoms selected from N, O, or S, wherein
the heterocycloalkyl is optionally substituted with one or more substituents each
independently selected from (C1-C6) alkyl and OH, and
each n, p, and q is independently O, l or 2, and
provided that when A is phenyl and R1 is H, then R2 is not —C(O)CH3.
A second aspect of the invention relates to a method of treating a c-Kit-mediated
disease or disorder. The method comprises administering to a patient in need thereof an
effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt,
hydrate, e, prodrug, stereoisomer, or tautomer thereof.
Another aspect of the invention relates to a method of preventing a c-Kit-mediated
disease or disorder. The method comprises administering to a patient in need thereof an
effective amount of a compound of a (I), or a pharmaceutically acceptable salt,
hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.
r aspect of the ion relates to a method of inhibiting c-Kit. The
method comprises administering to a patient in need thereof an effective amount of a
compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug,
stereoisomer, or tautomer thereof.
Another aspect of the invention relates to a method of treating a e or
disorder associated with inhibiting c-Kit. The method comprises administering to a patient in
need thereof an effective amount of a nd of Formula (I), or a pharmaceutically
able salt, hydrate, e, prodrug, stereoisomer, or tautomer thereof.
Another aspect of the invention relates to a method of preventing a disease or
disorder associated with inhibiting c-Kit. The method comprises administering to a patient in
need thereof an effective amount of a compound of Formula (I), or a pharmaceutically
able salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.
Another aspect of the invention relates to a method of treating cancer. The
method comprises stering to a patient in need thereof an effective amount of a
compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug,
stereoisomer, or er thereof.
Another aspect of the invention is directed to pharmaceutical compositions
comprising a compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate,
prodrug, stereoisomer, or tautomer thereof and a pharmaceutically able carrier. The
pharmaceutical acceptable r may further include an excipient, diluent, or tant.
Another aspect of the present invention relates to a compound of Formula (I), or a
pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof,
for use in the manufacture of a medicament for treating a disease associated with inhibiting c-
r aspect of the present invention s to a compound of Formula (I), or a
pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof,
for use in the manufacture of a medicament for preventing a disease associated with inhibiting
c-Kit.
Another aspect of the present invention relates to the use of a compound of Formula
(I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer
thereof, in the treatment of a disease associated with inhibiting c-Kit.
Another aspect of the present invention relates to the use of a compound of Formula
(I), or a ceutically acceptable salt, hydrate, e, prodrug, stereoisomer, or tautomer
thereof, in the prevention of a disease ated with inhibiting c-Kit.
The present invention further provides methods of treating or preventing a disease
or disorder associated with modulation of c-Kit including, cancer, metastasis, inflammation
and auto-immune pathogenesis, comprising administering to a patient ing from at least
one of said diseases or er a nd of Formula (I), or a pharmaceutically acceptable
salt, hydrate, solvate, g, isomer, or tautomer thereof.
The present invention provides inhibitors of c-Kit that are therapeutic agents in the
treatment of diseases such as cancer, asis, inflammation and auto-immune pathogenesis.
The present disclosure provides agents with novel mechanisms of action toward c-
Kit enzymes in the treatment of various types of diseases including cancer and cell proliferative
disorders, multiple sclerosis, asthma, mastocytosis, inflammatory disorders, allergic reactions,
fibrotic ers, auto-immune pathogenesis and metabolic disorders. tely the present
ion provides the medical ity with a novel pharmacological strategy for the
[FOLLOWED BY PAGE 5a]
treatment of diseases and disorders associated with c-Kit.
[0021A] ular features of the present disclosure are set out in the following numbered
aphs:
1. A compound of Formula (I):
or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or
er thereof,
wherein:
L is –C(O)NR5- or –NR5C(O)-;
A is ) cycloalkyl, (C6-C10) aryl, or 5- to 10-membered heteroaryl wherein the
cycloalkyl, aryl, or heteroaryl is optionally substituted with one or more R4;
R1 is H, (C1-C6) alkyl, -(CH2)qC(O)OH, or –C(O)N(R7)2;
R2 is ) alkyl, -C(O)R8, or –C(O)NR9R10;
each R3 is independently at each occurrence (C1-C6) alkyl, ) alkoxy,
(C1-C6) haloalkyl, (C1-C6) haloalkoxy, halogen, or OH;
each R4 is independently at each occurrence (C1-C6) alkyl, (C1-C6) alkoxy,
(C1-C6) haloalkyl, (C1-C6) haloalkoxy, halogen, -OH, CN, -(C(R6)2)p-heterocycloalkyl
wherein the heterocycloalkyl comprises a 4- to ered ring and 1 to 3 heteroatoms
selected from N, O, and S , or )2)p-heteroaryl wherein the heteroaryl comprises a 5- or
6-membered ring and 1 to 3 heteroatoms selected from N, O, and S, and wherein the
heterocycloalkyl or heteroaryl is optionally substituted with one or more substituents each
independently ed from
(C1-C6) alkyl, -NH2, (C1-C6) alkylamino, and (C1-C6) dialkylamino;
R5 is H, (C1-C6) alkyl, or (C1-C6) haloalkyl;
each R6 is independently H or (C1-C6) alkyl;
[FOLLOWED BY PAGE 5b]
each R7 is ndently H or (C1-C6) alkyl;
R8 is (C1-C6) alkyl, (C3-C7) cycloalkyl, ) alkenyl, (C1-C3) alkoxy, (C1-C6)
haloalkyl, ) haloalkoxy, or 4 to 7-membered heterocycloalkyl comprising 1 to 3
heteroatoms selected from N, O, and S;
R9 is H, (C1-C6) alkyl, (C1-C6) kyl, (C3-C7) cycloalkyl, or 4 to 7-membered
heterocycloalkyl comprising 1 to 3 heteroatoms selected from N, O, or S;
R10 is H, (C1-C6) alkyl, (C1-C6) haloalkyl, (C3-C7) cycloalkyl, or 4 to 7-membered
heterocycloalkyl comprising 1 to 3 heteroatoms selected from N, O, or S, wherein the
cycloalkyl or heterocycloalkyl is optionally substituted with one or more substituents each
independently selected from ) alkyl, -NH2, (C1-C6) alkylamino, (C1-C6) dialkylamino,
and -OH, and wherein the (C1-C6) alkyl is optionally substituted with one or more R11;
or R9 and R10 together with the nitrogen atom to which they are attached form a 4- to
7-membered heterocycloalkyl ring sing 1 to 3 heteroatom selected from N, O, and S,
optionally substituted with one or more substituent each independently selected from
(C 1-C6) alkyl, (C1-C6) hydroxyalkyl, -(CH2)q-NH 2, -(CH2)q-(C 1-C6) alkylamino,
-(CH 2)q-(C 1-C6) dialkylamino, -C(O)(C1-C6) alkyl, -OH, and 4- to 7-membered
heterocycloalkyl comprising 1 to 3 heteroatom selected from N, O, and S, and optionally
substituted with one or more (C1-C6) alkyl;
R11 is (C1-C6) alkoxy, -OH, -NH2, (C1-C6) alkylamino, (C1-C6) dialkylamino, 5- or 6-
membered heteroaryl comprising 1 to 3 heteroatoms selected from N, O, or S, or 4- to 7-
membered heterocycloalkyl comprising 1 to 3 heteroatoms selected from N, O, or S, wherein
the cycloalkyl is optionally substituted with one or more substituents each
ndently selected from (C1-C6) alkyl and OH; and
each n, p, and q is independently 0, 1 or 2; and
provided that when A is phenyl and R1 is H, then R2 is not H3.
2. The compound of paragraph 1, wherein L is a –C(O)NR5-.
3. The compound of paragraph 1, wherein L is a –NR5C(O)-.
4. The compound of any one of the preceding paragraphs, wherein R3 is (C1-C6)
alkyl or n.
. The compound of any one of the preceding paragraphs, wherein n is 1 and R3
is methyl or F.
[FOLLOWED BY PAGE 5c]
6. The compound of any one of the preceding paragraphs, wherein n is 1 and R3
is methyl.
7. The compound of any one of the preceding paragraphs, wherein A is (C6-C10)
aryl optionally tuted with one or more R4.
8. The compound of any one of the preceding paragraphs, wherein A is 6-
membered heteroaryl optionally substituted with one or more R4;
9. The compound of any one of the preceding paragraphs, wherein A is phenyl or
pyridinyl optionally substituted with one or more R4.
. The nd of any one of the preceding aphs, wherein A is phenyl or
pyridinyl substituted with one or more R4.
11. The compound of any one of the preceding paragraphs, wherein R5 is H.
12. The compound of any one of the preceding paragraphs, wherein n is 0.
13. The compound of any one of the preceding paragraphs, wherein n is 1.
14. The compound of any one of the preceding aphs, wherein n is 1 and R3
is ortho to the alkyne.
. The compound of any one of the preceding paragraphs, wherein R1 is H, -
CH3)2 or –CH2CH2C(O)OH.
16. The compound of any one of the preceding paragraphs, wherein R1 is H.
17. The compound of paragraph 1, having one of the ing formulae (Ia) or
(Ib):
(Ia), or
(Ib),
[FOLLOWED BY PAGE 5d]
or a pharmaceutically acceptable salt, e, solvate, prodrug, stereoisomer, or
tautomer thereof.
18. The compound of paragraph 1, having one of the following formulae (Ic) or
(Id) :
(Ic), or
(Id),
or a pharmaceutically acceptable salt, hydrate, e, prodrug, stereoisomer, or
tautomer thereof.
19. The compound of paragraph 1, having one of the following formulae (Ie) or
(If):
(Ie), or
[FOLLOWED BY PAGE 5e]
(If),
or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or
tautomer thereof.
. The compound of aph 19, wherein R5 is H.
21. The compound of paragraph 19 or 20, wherein one R4 is (C1-C6) haloalkyl and
the other R4 is (C1-C6) alkoxy, CN, or -(C(R6)2)p-heterocycloalkyl wherein the
heterocycloalkyl comprises a 4- to 7-membered ring and 1 to 3 heteroatoms selected from N,
O, and S.
22. The compound of any one of paragraphs 19 to 21, wherein at least one R4 is
CF3 and the other R4 is (C1-C6) alkoxy, CN, or -(C(R6)2)p-heterocycloalkyl wherein the
heterocycloalkyl ses a 4- to 7-membered ring and 1 to 3 heteroatoms selected from N,
O, and S.
23. The compound of any one of aphs 19 to 22, wherein at least one R4 is
CF3 and the other R4 is –OCH3, CN, or -(CH2)-pyrrolyl.
24. The compound of any one of paragraphs 19-23, wherein R1 is H and R2 is –
C(O)NR9R10.
. The compound of paragraph 24, wherein R9 is H and R10 is (C1-C6) alkyl.
26. The compound of paragraph 24, wherein R9 is H and R10 is (C1-C6) alkyl
tuted with one R11.
27. The compound of paragraph 26, wherein R11 is (C1-C6) alkoxy.
28. The compound of paragraph 27, wherein the ) alkoxy is –OCH3.
29. The compound of aph 24, wherein R9 is (C1-C6) alkyl and R10 is (C1-C6)
alkyl.
. The compound of paragraph 24, wherein R9 is ) alkyl and R10 is (C1-C6)
[FOLLOWED BY PAGE 5f]
alkyl tuted with one R11.
31. The compound of paragraph 30, wherein R11 is (C1-C6) alkoxy.
32. The compound of paragraph 31, wherein the (C1-C6) alkoxy is –OCH3.
33. The compound of aph 1, having one of the following formulae (Ig) or
(Ih):
(Ig), or
(Ih),
or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or
tautomer thereof.
34. The compound of paragraph 33, wherein R5 is H.
. The compound of paragraph 33 or 34, wherein R4 is (C1-C6) haloalkyl.
36. The compound of any one of paragraphs 33 to 35, wherein R4 is CF3.
37. The compound of any one of paragraphs 33 to 36, wherein n is 1 and R3 is
38. The compound of any one of paragraphs 33 to 37, wherein R1 is H and R2 is
(C1-C6) alkyl.
39. The compound of paragraph 38, n the (C1-C6) alkyl is selected from
[FOLLOWED BY PAGE 5g]
methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, iso-butyl, tert-butyl, n-pentyl, isopentyl
, entyl, neo-pentyl, sec-pentyl, 3-pentyl, n-hexane, 2-methyl pentane, yl
pentane, 2,2-dimethyl butane, and 2,3-dimethyl butane.
40. The compound of paragraph 39, wherein the (C1-C6) alkyl is ethyl.
41. The compound of aph 39, wherein the (C1-C6) alkyl is .
42. The compound of any one of aphs 33 to 37, n R1 is H and R2 is –
C(O)R 8.
43. The compound of paragraph 42, wherein R8 is (C1-C3) alkoxy.
44. The compound of paragraph 43, wherein the (C1-C3) alkoxy is OCH3.
45. The nd of any one of paragraphs 33 to 37, wherein R1 is H and R2 is –
C(O)NR 9R10 .
46. The compound of paragraph 45, n R9 is H and R10 is (C1-C6) alkyl.
47. The compound of paragraph 45, wherein R9 is H and R10 is (C1-C6) alkyl
substituted with one R11 .
48. The compound of paragraph 47, wherein R11 is (C1-C6) alkoxy.
49. The compound of paragraph 48, wherein the (C1-C6) alkoxy is –OCH3.
50. The compound of paragraph 47, wherein R11 is (C1-C6) dialkylamino.
51. The compound of paragraph 50, wherein the (C1-C6) dialkylamino is –
N(CH 3)2 or –N(CH2CH 3)2.
52. The compound of paragraph 47, wherein R11 is (C1-C6) alkylamino.
53. The compound of paragraph 52, n the ) alkylamino is –N(H)CH3.
54. The compound of paragraph 47, wherein R11 is –NH2.
55. The compound of paragraph 47, n R11 is 5- or 6-membered
heterocycloalkyl comprising 1 to 3 heteroatoms selected from N, O, or S, optionally
substituted with (C1-C6) alkyl or OH.
56. The compound of paragraph 47, wherein R11 is 6-membered heteroaryl
comprising 1 to 3 atoms selected from N, O, or S.
57. The compound of paragraph 47, wherein R11 is -OH.
58. The compound of paragraph 45, wherein R9 is (C1-C6) alkyl and R10 is (C1-C6)
alkyl.
59. The compound of paragraph 45, wherein R9 is (C1-C6) alkyl and R10 is (C1-C6)
alkyl substituted with one R11 .
60. The compound of paragraph 59, wherein R11 is (C1-C6) alkoxy.
[FOLLOWED BY PAGE 5h]
61. The nd of paragraph 60, wherein the (C1-C6) alkoxy is –OCH3.
62. The compound of paragraph 59, wherein R11 is -OH.
63. The compound of aph 59, wherein R11 is (C1-C6) dialkylamino.
64. The compound of aph 63, wherein the (C1-C6) dialkylamino is –
N(CH 3)2 or –N(CH2CH 3)2.
65. The compound of paragraph 59, wherein R11 is –NH2.
66. The compound of paragraph 59, wherein R11 is 5- or ered
cycloalkyl comprising 1 to 3 heteroatoms selected from N, O, or S, optionally
substituted with (C1-C6) alkyl or OH.
67. The compound of aph 59, wherein R11 is 6-membered heteroaryl
comprising 1 to 3 heteroatoms selected from N, O, or S.
68. The compound of paragraph 45, n R9 is H and R10 is (C3-C7) cycloalkyl
optionally substituted with –OH or -NH2.
69. The compound of paragraph 68, wherein the (C3-C7) cycloalkyl is cyclopropyl
or cyclohexyl optionally substituted with –OH or -NH2.
70. The compound of paragraph 45, wherein R9 is H and R10 is 4 to 6-membered
heterocycloalkyl comprising 1 to 3 heteroatoms selected from N, O, or S, optionally
substituted with methyl.
71. The compound of paragraph 45, wherein R9 is ) alkyl and R10 is 4 to 6-
membered heterocycloalkyl sing 1 to 3 heteroatoms selected from N, O, or S,
optionally substituted with methyl.
72. The compound of paragraph 45, wherein R9 and R10 together with the nitrogen
atom to which they are ed form a 4- to 6-membered heterocycloalkyl ring comprising 1
to 3 heteroatom selected from N, O, and S, optionally substituted with one or more
substituents each independently selected from (C1-C6) alkyl, (C1-C6) hydroxyalkyl, -(CH2)q-
(C 1-C6) dialkylamino, -C(O)(C1-C6) alkyl, OH, or 6-membered heterocycloalkyl comprising
1 to 3 heteroatom selected from N, O, and S, and optionally substituted with (C1-C6) alkyl.
73. The compound of any one of paragraphs 33 to 37, wherein R1 is –C(O)N(R7)2
and R2 is –C(O)NR9R10 .
74. The compound of paragraph 74, wherein R7 is (C1-C6) alkyl, R9 is )
alkyl and R10 is (C1-C6) alkyl.
75. The compound of any one of paragraphs 33 to 37, wherein R1 is -
(CH 2 is –C(O)R
2)qC(O)OH and R 8.
[FOLLOWED BY PAGE 5i]
76. The nd of paragraph 75, wherein R8 is (C2-C3) alkenyl.
77. The compound of any one of paragraphs 33 to 36, wherein n is 1 and R3 is F.
78. The compound of paragraph 77, wherein R1 is H and R2 is –C(O)NR9R10 .
79. The compound of paragraph 78, wherein R9 is H and R10 is (C1-C6) alkyl.
80. The compound of any one of paragraphs 33 to 36, wherein n is 0, R1 is H, and
R2 is –C(O)NR9R10 .
81. The compound of paragraph 78, wherein R9 is H and R10 is (C1-C6) alkyl.
82. The compound of aph 1, wherein the compound is selected from:
3-((2-(3,3-dimethylureido)thiazolyl)ethynyl)methyl-N-(4-(trifluoromethyl)pyridin
yl)benzamide;
4-methyl-N-(4-(trifluoromethyl)pyridinyl)((2-ureidothiazolyl)ethynyl)benzamide;
methyl (5-((2-methyl((4-(trifluoromethyl)pyridinyl)carbamoyl)phenyl)ethynyl)thiazol-
arbamate;
4-methyl((2-(3-methylureido)thiazolyl)ethynyl)-N-(4-(trifluoromethyl)pyridin
yl)benzamide;
3-((2-(3-(2-methoxyethyl)ureido)thiazolyl)ethynyl)methyl-N-(4-
(trifluoromethyl)pyridinyl)benzamide;
4-methyl((2-(3-(2-morpholinoethyl)ureido)thiazolyl)ethynyl)-N-(4-
(trifluoromethyl)pyridinyl)benzamide;
3-((2-(3-(2-methoxyethyl)methylureido)thiazolyl)ethynyl)methyl-N-(4-
(trifluoromethyl)pyridinyl)benzamide;
3-((2-(3-ethylmethylureido)thiazolyl)ethynyl)methyl-N-(4-(trifluoromethyl)pyridin-
2-yl)benzamide;
3-((2-(3-(2-(dimethylamino)ethyl)methylureido)thiazolyl)ethynyl)methyl-N-(4-
(trifluoromethyl)pyridinyl)benzamide;
(3-(2-hydroxyethyl)methylureido)thiazolyl)ethynyl)methyl-N-(4-
(trifluoromethyl)pyridinyl)benzamide;
(3-(2-(dimethylamino)ethyl)ureido)thiazolyl)ethynyl)methyl-N-(4-
(trifluoromethyl)pyridinyl)benzamide;
[FOLLOWED BY PAGE 5j]
4-methyl((2-(3-(2-(pyrrolidinyl)ethyl)ureido)thiazolyl)ethynyl)-N-(4-
(trifluoromethyl)pyridinyl)benzamide;
4-methyl((2-(3-((1-methylpiperidinyl)methyl)ureido)thiazolyl)ethynyl)-N-(4-
(trifluoromethyl)pyridinyl)benzamide;
4-methyl((2-(3-(2-(4-methylpiperazinyl)ethyl)ureido)thiazolyl)ethynyl)-N-(4-
(trifluoromethyl)pyridinyl)benzamide;
3-((2-(3-(2-hydroxymethylpropyl)ureido)thiazolyl)ethynyl)methyl-N-(4-
(trifluoromethyl)pyridinyl)benzamide;
4-methyl((2-(3-methyl(2-(4-methylpiperazinyl)ethyl)ureido)thiazolyl)ethynyl)-N-
ifluoromethyl)pyridinyl)benzamide;
3-((2-(3-cyclopropylureido)thiazolyl)ethynyl)methyl-N-(4-(trifluoromethyl)pyridin
yl)benzamide;
3-((2-(3-(2-(3-hydroxypyrrolidinyl)ethyl)ureido)thiazolyl)ethynyl)methyl-N-(4-
(trifluoromethyl)pyridinyl)benzamide;
4-methyl((2-(3-methyl(2-(pyrrolidinyl)ethyl)ureido)thiazolyl)ethynyl)-N-(4-
(trifluoromethyl)pyridinyl)benzamide;
4-methyl((2-(3-methyl((1-methylpyrrolidinyl)methyl)ureido)thiazolyl)ethynyl)-
N-(4-(trifluoromethyl)pyridinyl)benzamide;
(3-(2-hydroxymethylpropyl)methylureido)thiazolyl)ethynyl)methyl-N-(4-
(trifluoromethyl)pyridinyl)benzamide;
3-((2-(3-(4-hydroxycyclohexyl)methylureido)thiazolyl)ethynyl)methyl-N-(4-
(trifluoromethyl)pyridinyl)benzamide;
4-methyl-N-(5-((2-methyl((4-(trifluoromethyl)pyridin
yl)carbamoyl)phenyl)ethynyl)thiazolyl)piperazinecarboxamide;
3-hydroxymethyl-N-(5-((2-methyl((4-(trifluoromethyl)pyridin
yl)carbamoyl)phenyl)ethynyl)thiazolyl)azetidinecarboxamide;
4-methyl-N-(5-((2-methyl((4-(trifluoromethyl)pyridin
yl)carbamoyl)phenyl)ethynyl)thiazolyl)piperidinecarboxamide;
[FOLLOWED BY PAGE 5k]
yl((2-(3-(pyridinylmethyl)ureido)thiazolyl)ethynyl)-N-(4-
(trifluoromethyl)pyridinyl)benzamide;
4-(2-hydroxyethyl)-N-(5-((2-methyl((4-(trifluoromethyl)pyridin
yl)carbamoyl)phenyl)ethynyl)thiazolyl)piperazinecarboxamide;
4-methyl((2-(3-methyl(2-(methylamino)ethyl)ureido)thiazolyl)ethynyl)-N-(4-
(trifluoromethyl)pyridinyl)benzamide;
4-methyl((2-(3-methyl(1-methylpiperidinyl)ureido)thiazolyl)ethynyl)-N-(4-
(trifluoromethyl)pyridinyl)benzamide;
N-(5-((2-methyl((4-(trifluoromethyl)pyridinyl)carbamoyl)phenyl)ethynyl)thiazol
yl)piperazinecarboxamide;
3-((2-(3-(4-aminobutyl)ureido)thiazolyl)ethynyl)methyl-N-(4-(trifluoromethyl)pyridin-
2-yl)benzamide;
4-methyl((2-(3-methyl(1-methylpiperidinyl)ureido)thiazolyl)ethynyl)-N-(4-
(trifluoromethyl)pyridinyl)benzamide;
3-((2-(3-(4-aminocyclohexyl)methylureido)thiazolyl)ethynyl)methyl-N-(4-
(trifluoromethyl)pyridinyl)benzamide;
2-((dimethylamino)methyl)-N-(5-((2-methyl((4-(trifluoromethyl)pyridin
yl)carbamoyl)phenyl)ethynyl)thiazolyl)morpholinecarboxamide;
N-(5-((2-methyl((4-(trifluoromethyl)pyridinyl)carbamoyl)phenyl)ethynyl)thiazol
yl)morpholinecarboxamide;
3-((2-(3-(3-aminopropyl)ureido)thiazolyl)ethynyl)methyl-N-(4-
(trifluoromethyl)pyridinyl)benzamide;
4-acetyl-N-(5-((2-methyl((4-(trifluoromethyl)pyridin
yl)carbamoyl)phenyl)ethynyl)thiazolyl)piperazinecarboxamide;
3-((2-(3-(2-aminoethyl)ureido)thiazolyl)ethynyl)methyl-N-(4-(trifluoromethyl)pyridin-
2-yl)benzamide;
4-methyl((2-(3-methyl(1-methylazetidinyl)ureido)thiazolyl)ethynyl)-N-(4-
uoromethyl)pyridinyl)benzamide;
[FOLLOWED BY PAGE 5L]
3-(dimethylamino)-N-(5-((2-methyl((4-(trifluoromethyl)pyridin
yl)carbamoyl)phenyl)ethynyl)thiazolyl)pyrrolidinecarboxamide;
N-(5-((2-methyl((4-(trifluoromethyl)pyridinyl)carbamoyl)phenyl)ethynyl)thiazolyl)-
4-(4-methylpiperazinyl)piperidinecarboxamide;
2-fluoro((2-(3-methylureido)thiazolyl)ethynyl)-N-(4-(trifluoromethyl)pyridin
yl)benzamide;
2-fluoro-N-(4-(trifluoromethyl)pyridinyl)((2-ureidothiazolyl)ethynyl)benzamide;
(3-methylureido)thiazolyl)ethynyl)-N-(4-(trifluoromethyl)pyridinyl)benzamide;
4-fluoro((2-(3-methylureido)thiazolyl)ethynyl)-N-(4-(trifluoromethyl)pyridin
yl)benzamide;
3-((2-(3-(2-methoxyethyl)methylureido)thiazolyl)ethynyl)methyl-N-(4-(pyrrolidin-
1-ylmethyl)(trifluoromethyl)phenyl)benzamide;
N-(2-methoxy(trifluoromethyl)phenyl)((2-(3-(2-methoxyethyl)methylureido)thiazol-
-yl)ethynyl)methylbenzamide;
N-(4-cyano(trifluoromethyl)phenyl)((2-(3-(2-methoxyethyl)methylureido)thiazol
yl)ethynyl)methylbenzamide;
3-((2-(cyclopropanecarboxamido)thiazolyl)ethynyl)methyl-N-(4-
(trifluoromethyl)pyridinyl)benzamide;
3-((2-(cyclopropanecarboxamido)thiazolyl)ethynyl)methyl-N-(4-((4-methylpiperazin
hyl)(trifluoromethyl)phenyl)benzamide;
3-((2-acetamidothiazolyl)ethynyl)methyl-N-(4-(trifluoromethyl)pyridin
yl)benzamide;
4-methyl((2-pivalamidothiazolyl)ethynyl)-N-(4-(trifluoromethyl)pyridin
yl)benzamide;
N-(4-methyl((2-(3-methyl(1-methylpiperidinyl)ureido)thiazolyl)ethynyl)phenyl)-
4-(trifluoromethyl)picolinamide;
N-(3-((2-(3-(2-methoxyethyl)methylureido)thiazolyl)ethynyl)methylphenyl)
(trifluoromethyl)picolinamide;
[FOLLOWED BY PAGE 5m]
N-(4-methyl((2-(3-methyl(2-(4-methylpiperazinyl)ethyl)ureido)thiazol
yl)ethynyl)phenyl)(trifluoromethyl)picolinamide;
(2-(3,3-dimethylureido)thiazolyl)ethynyl)methylphenyl)
(trifluoromethoxy)benzamide;
N-(4-methyl((2-(3-methylureido)thiazolyl)ethynyl)phenyl)
(trifluoromethyl)picolinamide;
N-(3-((2-(3-(2-(dimethylamino)ethyl)methylureido)thiazolyl)ethynyl)methylphenyl)-
4-(trifluoromethyl)picolinamide;
N-(3-((2-(3-(2-(diethylamino)ethyl)methylureido)thiazolyl)ethynyl)methylphenyl)-
4-(trifluoromethyl)picolinamide;
N-(3-((2-(3-(2-hydroxyethyl)methylureido)thiazolyl)ethynyl)methylphenyl)
(trifluoromethyl)picolinamide;
N-(3-((2-(3-(2-methoxyethyl)methylureido)thiazolyl)ethynyl)phenyl)
(trifluoromethyl)picolinamide; and
N-(4-fluoro((2-(3-(2-methoxyethyl)methylureido)thiazolyl)ethynyl)phenyl)
(trifluoromethyl)picolinamide.
83. A pharmaceutical composition comprising a compound of any one of
paragraphs 1 to 82, or a pharmaceutically acceptable salt, solvate, prodrug, stereoisomer, or
tautomer thereof, and a pharmaceutically able diluent, excipient or carrier.
84. A method of treating a c-Kit-mediated disease or disorder, comprising
administering to a subject in need thereof a therapeutically effective amount of a compound
of any one of paragraphs 1 to 82, or a pharmaceutically acceptable salt, solvate, prodrug,
stereoisomer, or tautomer thereof.
85. The method of paragraph 84, n the ediated disease or disorder is
selected from cell erative disorder, a fibrotic disorder, and a metabolic disorder.
86. The method of paragraph 85, wherein said cell proliferative disorder is cancer.
87. The method of paragraph 86, wherein said cancer is selected from the group
consisting of leukemia, mast cell tumor, small cell lung cancer, testicular , cancer of
the intestinal tract, cancer of the central nervous system, cancer of the female genital
tract, sarcoma of neuroectodermal origin, and Schwann cell neoplasia ated with
[FOLLOWED BY PAGE 5n]
neurofibromatosis.
88. The method of paragraph 87, wherein said cancer is selected from the group
consisting of small cell lung carcinoma, acute myeloid ia (AML), neuroblastoma,
malignant melanomas, colorectal cancer,systemic mastocytosis (SM), and gastrointestinal
stromal tumors (GISTs).
89. The method of paragraph 84, wherein said ediated disease or er is
multiple sclerosis.
90. The method of paragraph 84, wherein said cKit-mediated disease or disorder is
asthma.
91. The method of paragraph 84, wherein said cKit-mediated disease or disorder is
an allergic reaction.
92. The method of paragraph 84, wherein said ediated disease or disorder
is inflammatory arthritis.
93. The method of paragraph 84, wherein said cKit-mediated disease or disorder
is mastocytosis.
94. A method of modulating c-Kit sing administering to a subject a
compound of any one of paragraphs 1 to 82.
95. A method of inhibiting c-Kit comprising administering to a subject a
compound of any one of paragraphs 1 to 82.
96. A method of treating or preventing a disease in which c-Kit plays a role,
sing administering to a subject in need thereof an effective amount of a compound of
any one of aphs 1 to 82.
[FOLLOWED BY PAGE 6]
Detailed Description of the Invention
The present invention relates to compounds and compositions that are capable of
inhibiting the activity of c-Kit. The invention features methods of treating, preventing or
ameliorating a disease or disorder in which c-Kit plays a role by administering to a patient in
need thereof a therapeutically effective amount of a compound of a (I), or a
pharrnaceutically acceptable salt, e, solvate, prodrug, stereoisomer, or tautomer f.
The s of the t invention can be used in the treatment of a variety of c-Kit
dependent diseases and disorders by inhibiting the activity of c-Kit enzymes. Inhibition of c-
Kit provides a novel approach to the treatment, prevention, or ration of diseases
including, but not limited to, cancer and metastasis.
In a first aspect of the invention, the nds of Formula (I) are described:
and pharrnaceutically acceptable salts, hydrates, solvates, prodrugs, stereoisomers, and
tautomers thereof, wherein A, L, R1, R2, R3, and n are as described herein above.
The details of the invention are set forth in the accompanying description below.
Although methods and materials similar or equivalent to those described herein can be used
in the practice or testing of the present invention, illustrative methods and materials are now
described. Other es, objects, and advantages of the invention will be nt from the
ption and from the . In the specification and the appended claims, the singular
forms also include the plural unless the context clearly dictates otherwise. Unless defined
otherwise, all technical and scientific terms used herein have the same meaning as commonly
understood by one of ordinary skill in the art to which this ion belongs. All patents and
publications cited in this specification are incorporated herein by reference in their entireties.
Definitions
The articles "a" and "an" are used in this disclosure to refer to one or more than
one (i.e., to at least one) of the grammatical object of the article. By way of example, "an
element" means one element or more than one element.
The term "and/or" is used in this disclosure to mean either "and" or "or" unless
indicated otherwise.
The term “optionally substituted” is understood to mean that a given chemical
moiety (e. g., an alkyl group) can (but is not required to) be bonded other substituents (e.g.,
heteroatoms). For instance, an alkyl group that is optionally substituted can be a fully
saturated alkyl chain (i.e., a pure hydrocarbon). Alternatively, the same optionally
substituted alkyl group can have substituents different from hydrogen. For instance, it can, at
any point along the chain be bounded to a n atom, a hydroxyl group, or any other
substituent described herein. Thus the term “optionally tuted” means that a given
chemical moiety has the ial to contain other functional groups, but does not necessarily
have any r functional groups. Suitable substituents used in the optional substitution of
the described groups e, without limitation, halogen, oxo, -OH, -CN, -COOH, -CH2CN,
-O-(C1-C6) alkyl, (C1-C6) alkyl, ) alkoxy, (C1-C6) haloalkyl, ) koxy, -O-
(C2-C6) alkenyl, -O-(C2-C6) alkynyl, (C2-C6) alkenyl,
(C2-C6) alkynyl, -OH, -OP(O)(OH)2, -OC(O)(C1-C6) alkyl, -C(O)(C1-C6) alkyl,
-OC(O)O(C1-C6) alkyl, -NH2, -NH((C1-C6) alkyl), -C6) alkyl)2, -NHC(O)(C1-C6) alkyl,
-C(O)NH(C1-C6) alkyl, (C1-C6) alkyl, H(C1-C6) alkyl, and S(O)N((C1-C6)
alkyl)2. The substituents can themselves be optionally substituted. “Optionally substituted”
as used herein also refers to substituted or unsubstituted whose meaning is described below.
As used herein, the term ituted” means that the specified group or moiety
bears one or more suitable substituents wherein the substituents may connect to the specified
group or moiety at one or more positions. For example, an aryl substituted with a cycloalkyl
may indicate that the cycloalkyl connects to one atom of the aryl with a bond or by fusing
with the aryl and sharing two or more common atoms.
Unless otherwise specifically defined, the term "aryl" refers to cyclic, aromatic
hydrocarbon groups that have 1 to 3 ic rings, including monocyclic or bicyclic groups
such as phenyl, biphenyl or naphthyl. Where ning two aromatic rings (bicyclic, etc.),
the aromatic rings of the aryl group may be joined at a single point (e.g., biphenyl), or fused
(e. g., naphthyl). The aryl group may be optionally substituted by one or more substituents,
e.g., l to 5 substituents, at any point of attachment. Exemplary substituents include, but are
not limited to, -H, -halogen, -O-(C1-C6) alkyl, (C1-C6) alkyl, -O-(C2-C6) alkenyl, -O-(C2-C6)
alkynyl,
(C2-C6) alkenyl, (C2-C6) alkynyl, -OH, -OP(O)(OH)2, (C1-C6) alkyl, -C(O)(C1-C6)
alkyl,
O(C1-C6) alkyl, NHZ, NH((C1-C6) alkyl), N((C1-C6) alkyl)2, -S(O)2-(C1-C6) alkyl,
-S(O)NH(C1-C6) alkyl, and S(O)N((C1-C6) alkyl)2. The substituents can themselves be
optionally substituted. Furthermore when containing two fused rings the aryl groups herein
defined may have an unsaturated or partially saturated ring fused with a fully saturated ring.
Exemplary ring systems of these aryl groups include, but are not d to, phenyl, biphenyl,
naphthyl, anthracenyl, phenalenyl, phenanthrenyl, l, indenyl, tetrahydronaphthalenyl,
tetrahydrobenzoannulenyl, and the like.
Unless otherwise specifically defined, "heteroaryl" means a lent
monocyclic aromatic radical of 5 to 24 ring atoms or a polycyclic aromatic radical,
containing one or more ring heteroatoms selected from N, O, or S, the ing ring atoms
being C. Heteroaryl as herein defined also means a bicyclic heteroaromatic group wherein
the atom is selected from N, O, or S. The aromatic radical is optionally substituted
independently with one or more substituents described herein. Examples include, but are not
limited to, furyl, thienyl, pyrrolyl, pyridyl, pyrazolyl, pyrimidinyl, imidazolyl, isoxazolyl,
oxazolyl, oxadiazolyl, pyrazinyl, indolyl, thiophenyl, quinolyl, benzopyranyl, isothiazolyl,
thiazolyl, azole, indazole, benzimidazolyl, thieno[3,2-b]thiophene, triazolyl, triazinyl,
imidazo[l,2-b]pyrazolyl, furo[2,3-c]pyridinyl, imidazo[l,2-a]pyridinyl, indazolyl,
o[2,3-c]pyridinyl, pyrrolo[3,2-c]pyridinyl, pyrazolo[3,4-c]pyridinyl, thieno[3,2-
c]pyridinyl, thieno[2,3-c]pyridinyl, thieno[2,3-b]pyridinyl, benzothiazolyl, indolyl, indolinyl,
indolinonyl, dihydrobenzothiophenyl, dihydrobenzofuranyl, benzofuran, chromanyl,
thiochromanyl, tetrahydroquinolinyl, dihydrobenzothiazine, obenzoxanyl, quinolinyl,
isoquinolinyl, l,6-naphthyridinyl, benzo[de]isoquinolinyl, [4,3-b][l,6]naphthyridinyl,
[2,3-b]pyrazinyl, quinazolinyl, tetrazolo[l,5-a]pyridinyl, [l,2,4]triazolo[4,3-
a]pyridinyl, isoindolyl, pyrrolo[2,3-b]pyridinyl, pyrrolo[3,4-b]pyridinyl, pyrrolo[3,2-
b]pyridinyl, imidazo[5,4-b]pyridinyl, pyrrolo[l,2-a]pyrimidinyl, tetrahydro pyrrolo[l,2-
a]pyrimidinyl, 3,4-dihydro-2H-lkz-pyrrolo[2,l-b]pyrimidine, dibenzo[b,d] thiophene,
pyridinone, furo[3,2-c]pyridinyl, furo[2,3-c]pyridinyl, lH-pyrido[3,4-b][l,4] thiazinyl,
xazolyl, benzoisoxazolyl, furo[2,3-b]pyridinyl, benzothiophenyl, phthyridinyl,
,2-b]pyridine, ]triazolo[l,5-a]pyridinyl, benzo [1,2,3]triazolyl, imidazo[l,2-
a]pyrimidinyl, [l,2,4]triazolo[4,3-b]pyridazinyl, benzo[c][l,2,5]thiadiazolyl,
benzo[c][l,2,5]oxadiazole, l,3-dihydro-2H-benzo[d]imidazolone, 3,4-dihydro-2H-
pyrazolo [l,5-b][l,2]oxazinyl, 4,5,6,7-tetrahydropyrazolo[l,5-a]pyridinyl, thiazolo[5,4-
d]thiazolyl, imidazo[2,l-b][l,3,4]thiadiazolyl, thieno[2,3-b]pyrrolyl, olyl, and
derivatives thereof. Furthermore when containing two fused rings the aryl groups herein
defined may have an unsaturated or partially saturated ring fused with a fully saturated ring.
Exemplary ring systems of these heteroaryl groups e indolinyl, indolinonyl,
dihydrobenzothiophenyl, dihydrobenzofuran, nyl, thiochromanyl,
tetrahydroquinolinyl, dihydrobenzothiazine, 3,4-dihydro-lH-isoquinolinyl, 2,3-
dihydrobenzofuran, indolinyl, indolyl, and dihydrobenzoxanyl.
n or “halo” refers to fluorine, chlorine, bromine, or iodine.
Alkyl refers to a straight or branched chain saturated hydrocarbon containing 1-12
carbon atoms. Examples of a (C1-C6) alkyl group include, but are not limited to, methyl,
ethyl, propyl, butyl, pentyl, hexyl, isopropyl, isobutyl, sec-butyl, tert-butyl, isopentyl,
neopentyl, and isohexyl.
“Alkoxy” refers to a straight or branched chain saturated hydrocarbon containing
1-12 carbon atoms containing a terminal “0” in the chain, i.e., yl). Examples of
alkoxy groups e, without limitation, methoxy, ethoxy, propoxy, butoxy, t-butoxy, or
pentoxy groups.
“Alkenyl” refers to a ht or branched chain unsaturated hydrocarbon
containing 2-12 carbon atoms. The “alkenyl” group contains at least one double bond in the
chain. The double bond of an alkenyl group can be unconjugated or conjugated to another
unsaturated group. Examples of alkenyl groups include ethenyl, propenyl, nyl, isobutenyl
, pentenyl, or hexenyl. An alkenyl group can be unsubstituted or substituted.
Alkenyl, as herein d, may be straight or branched.
“Alkynyl” refers to a straight or branched chain unsaturated hydrocarbon
containing 2-12 carbon atoms. The “alkynyl” group ns at least one triple bond in the
chain. Examples of l groups include ethynyl, propargyl, nyl, iso-butynyl,
pentynyl, or hexynyl. An l group can be unsubstituted or substituted.
“Cycloalkyl” means monocyclic saturated carbon rings containing 3-18 carbon
atoms. Examples of cycloalkyl groups include, without tions, cyclopropyl, cyclobutyl,
cyclopentyl, cyclohexyl, cycloheptanyl, cyclooctanyl, norboranyl, norborenyl,
bicyclo[2.2.2]octanyl, or bicyclo[2.2.2]octenyl.
WO 12136
“Heterocyclyl” or “heterocycloalkyl” monocyclic rings containing carbon and
heteroatoms taken from oxygen, nitrogen, or sulfur and wherein there is not lized TE
electrons (aromaticity) shared among the ring carbon or heteroatoms. The heterocycloalkyl
ring structure may be substituted by one or more substituents. The substituents can
themselves be ally substituted. Examples of heterocyclyl rings include, but are not
limited to, oxetanyl, azetadinyl, tetrahydrofuranyl, tetrahydropyranyl, pyrrolidinyl,
oxazolinyl, oxazolidinyl, thiazolinyl, thiazolidinyl, pyranyl, thiopyranyl, tetrahydropyranyl,
dioxalinyl, piperidinyl, morpholinyl, thiomorpholinyl, thiomorpholinyl S-oxide,
thiomorpholinyl S-dioxide, zinyl, azepinyl, oxepinyl, diazepinyl, tropanyl,
oxazolidinonyl, and homotropanyl.
The term “hydroxyalkyl” means an alkyl group as defined above, where the alkyl
group is substituted with one or more -OH groups. Examples of hydroxyalkyl groups include
HO-CH2-, HO-CHz-CHz- and CH3-CH(OH)-.
The term “haloalkyl” as used herein refers to an alkyl group, as defined herein,
which is substituted one or more halogen. Examples of haloalkyl groups include, but are not
limited to, trifiuoromethyl, difiuoromethyl, pentafiuoroethyl, trichloromethyl, etc.
The term “haloalkoxy” as used herein refers to an alkoxy group, as defined ,
which is tuted one or more halogen. Examples of haloalkyl groups include, but are not
limited to, trifiuoromethoxy, difiuoromethoxy, pentafiuoroethoxy, trichloromethoxy, etc.
The term “amine” as used herein refers to primary (R-NHz, R 7: H), secondary
(Rz-NH, R2 7: H) and tertiary (R3-N, R 7: H) amines. A substituted amine is intended to mean
an amine where at least one of the hydrogen atoms has been replaced by the substituent.
The term “amino” as used herein means a substituent containing at least one
nitrogen atom. Specifically, NHZ, -NH(alkyl) or mino, -N(alkyl)2 or dialkylamino,
, carbamide-, urea, and sulfamide tuents are ed in the term “amino”.
The term “alkylamino” as used herein refers to an amino or NH2 group where one
of the hydrogens has been replaced with an alkyl group, as defined herein above, i.e., -
NH(alkyl). Example of alkylamino groups include, but are not limited to, methylamino (1'. e.,
-NH(CH3)), ethylamino, propylamino, iso-propylamino, n-butylamino, sec-butylamino, tert-
butylamino, etc.
The term “dialkylamino” as used herein refers to an amino or NHZ group where
both of the hydrogens have been replaced with alkyl groups, as defined herein above, 1'. e., -
N(alkyl)2. The alkyl groups on the amino group can be the same or different alkyl .
e of alkylamino groups include, but are not limited to, dimethylamino (i.e., -
N(CH3)2), diethylamino, dipropylamino, diiso-propylamino, utylamino, di-sec-
butylamino, t-butylamino, methyl(ethyl)amino, methyl(butylamino), etc.
The term “oxo” as used herein refers to an “=0” group.
The term "solvate" refers to a complex of variable stoichiometry formed by a
solute and solvent. Such solvents for the purpose of the invention may not ere with the
biological activity of the solute. Examples of suitable solvents include, but are not limited to,
water, MeOH, EtOH, and AcOH. Solvates wherein water is the solvent molecule are
typically referred to as hydrates. Hydrates include compositions containing stoichiometric
amounts of water, as well as compositions containing le amounts of water.
The term "isomer" refers to compounds that have the same composition and
molecular weight but differ in physical and/or chemical properties. The structural difference
may be in constitution (geometric isomers) or in the ability to rotate the plane of polarized
light (stereoisomers). With regard to stereoisomers, the compounds of Formula (I) may have
one or more tric carbon atom and may occur as racemates, racemic mixtures and as
individual enantiomers or diastereomers.
The sure also includes pharmaceutical compositions comprising an effective
amount of a disclosed compound and a pharmaceutically acceptable carrier. Representative
"pharmaceutically acceptable salts" e, e.g., water-soluble and water-insoluble salts,
such as the acetate, amsonate (4,4-diaminostilbene-2,2-disulfonate), benzenesulfonate,
benzonate, bicarbonate, bisulfate, bitartrate, , bromide, butyrate, calcium, calcium
edetate, camsylate, carbonate, chloride, citrate, ariate, dihydrochloride, edetate,
edisylate, estolate, e, fumerate, f1unarate, gluceptate, gluconate, glutamate,
glycollylarsanilate, hexafluorophosphate, hexylresorcinate, hydrabamine, hydrobromide,
hydrochloride, hydroxynaphthoate, iodide, isothionate, lactate, lactobionate, e,
magnesium, malate, maleate, mandelate, mesylate, bromide, methylnitrate,
methylsulfate, mucate, napsylate, nitrate, N—methylglucamine ammonium salt, 3-hydroxy
naphthoate, oleate, oxalate, palmitate, pamoate (l,l-methene-bishydroxynaphthoate,
einbonate), pantothenate, phosphate/diphosphate, e, polygalacturonate, propionate, p-
toluenesulfonate, salicylate, stearate, subacetate, succinate, sulfate, sulfosalicylate, suramate,
tannate, te, teoclate, tosylate, triethiodide, and valerate salts.
A "patient" or “subject” is a , e. g., a human, mouse, rat, guinea pig, dog,
cat, horse, cow, pig, or non-human e, such as a monkey, nzee, baboon or
rhesus.
An "effective amount" when used in connection with a compound is an amount
effective for treating or preventing a e in a subject as described herein.
The term "carrier", as used in this disclosure, encompasses rs, excipients,
and diluents and means a material, composition or e, such as a liquid or solid flller,
diluent, excipient, solvent or encapsulating material, involved in carrying or transporting a
ceutical agent from one organ, or portion of the body, to another organ, or portion of
the body of a subject.
As used herein, ing” or “treat” describes the management and care of a
patient for the purpose of reversing, ting, or combating a disease, condition, or disorder
and es the administration of a compound of the present disclosure (1'.e., a nd of
Formula (I), or a pharmaceutically acceptable salt, prodrug, metabolite, polymorph or solvate
thereof, to reverse the disease, condition, or disorder, eliminate the disease, condition, or
disorder, or inhibit the process of the e, condition, or disorder.
A compound of the t disclosure (e.g., a compound of Formula (I), or a
pharmaceutically acceptable salt, prodrug, metabolite, polymorph or solvate thereof, can also
be used to prevent a disease, condition, or er or one or more symptoms of such disease,
condition, or disorder. As used herein, “preventing” or “prevent” describes reducing or
eliminating the onset of the symptoms or complications of the disease, condition, or disorder.
The term "disorder" is used in this disclosure to mean, and is used interchangeably
with, the terms disease, condition, or illness, unless otherwise indicated.
The term "administer", "administering", or "administration" as used in this
disclosure refers to either directly administering a disclosed compound or pharmaceutically
acceptable salt of the disclosed compound or a composition to a subject, or administering a
prodrug derivative or analog of the compound or pharmaceutically acceptable salt of the
compound or composition to the subject, which can form an equivalent amount of active
compound within the subject's body.
The term "prodrug," as used in this disclosure, means a compound which is
convertible in vivo by metabolic means (e.g., by hydrolysis) to a disclosed compound.
The present ion relates to compounds or pharmaceutically acceptable salts,
hydrates, solvates, prodrugs, stereoisomers, or tautomers thereof, capable of inhibiting c-Kit,
which are useful for the treatment of es and disorders associated with modulation of a
c-Kit enzyme. The invention further relates to compounds, or pharmaceutically acceptable
salts, hydrates, solvates, prodrugs, stereoisomers, or tautomers thereof, which are useful for
inhibiting c-Kit.
In one embodiment, the compounds of Formula (I) have the structure of Formula
(Ia):
and pharmaceutically acceptable salts, es, solvates, prodrugs, stereoisomers,
and tautomers thereof.
In another embodiment, the compounds of a (I) have the structure of
Formula (Ib):
R5 A (Ib),
and pharmaceutically acceptable salts, hydrates, solvates, prodrugs, stereoisomers,
and tautomers thereof.
In another embodiment, the nds of a (I) have the structure of
Formula (Ic):
RKNA Nl \ :
R2 \
A (Io),
and ceutically acceptable salts, hydrates, solvates, prodrugs, stereoisomers,
and tautomers thereof.
In another ment, the compounds of a (I) have the structure of
Formula (Id):
R1\N/T|\\ : 0
IL2 / 4<
R5 A (Id),
and pharmaceutically acceptable salts, hydrates, solvates, prodrugs, stereoisomers,
and tautomers thereof.
In another embodiment, the compounds of Formula (I) have the structure of
Formula (Ie):
WO 12136
and pharmaceutically acceptable salts, hydrates, solvates, prodrugs, stereoisomers,
and tautomers thereof.
In another embodiment, the compounds of Formula (I) have the structure of
Formula (If):
(If),
and pharmaceutically acceptable salts, hydrates, solvates, prodrugs, stereoisomers,
and tautomers thereof.
In another embodiment, the compounds of Formula (I) have the structure of
Formula (Ig):
— (1g),
and pharmaceutically acceptable salts, hydrates, solvates, gs, stereoisomers,
and ers thereof.
In another ment, the compounds of Formula (I) have the structure of
Formula (Ih):
/ \ R4
— (Ih),
and pharmaceutically acceptable salts, hydrates, solvates, prodrugs, stereoisomers,
and tautomers thereof.
In some embodiments of the Formulae above, A is (C6-C10) aryl. In another
ment, A is 5- or 6-membered heteroaryl. In yet r embodiment, A is 6-
membered aryl. In another embodiment, A is 6-membered heteroaryl. In yet r
embodiment, A is phenyl. In a further embodiment, A is pyridinyl.
In some embodiments of the Formulae above, L is —C(O)NR5—. In another
embodiment, L )NH—.
In some embodiments of the Formulae above, L is —NR5C(O)—. In another
embodiment, L is —NHC(O)—.
In some embodiments of the Formulae above, R1 is H, (C1-C6) alkyl, -
(CH2)qC(O)OH, or —C(O)N(R7)2. In another embodiment, R1 is (C1-C6) alkyl, -
(CH2)qC(O)OH, or —C(O)N(R7)2. In another embodiment, R1 is H, -(CH2)qC(O)OH, or —
C(O)N(R7)2. In yet another embodiment, R1 is H, (C1-C6) alkyl, or (R7)2. In another
embodiment, R1 is H, (C1-C6) alkyl, or -(CH2)qC(O)OH. In r embodiment, R1 is -
(CH2)qC(O)OH, or —C(O)N(R7)2. In yet another embodiment, R1 is H or ) alkyl. In
another embodiment, R1 is H or -(CH2)qC(O)OH. In yet another embodiment, R1 is H or —
C(O)N(R7)2. In another ment, R1 is H or (C1-C6) alkyl. In yet r embodiment,
R1 is H.
In some embodiments of the Formulae above, R2 is (C1-C6) alkyl, -C(O)Rg, or —
C(O)NR9R10. In another embodiment, R2 is (C1-C6) alkyl or -C(O)Rg. In yet another
embodiment, R2 is -C(O)Rg or —C(O)NR9R10. In another embodiment, R2 is (C1-C6) alkyl or
—C(O)NR9R10. In another embodiment, R2 is (C1-C6) alkyl. In yet another embodiment, R2 is
-C(O)Rg. In r embodiment, R2 is R9R10. In yet another embodiment, R2 is -
C(O)OCH3. In another embodiment, R2 is -C(O)CH3. In yet r embodiment, R2 is -
C(O)—l—butyl.
In some embodiments of the Formulae above, R9 is H, (C1-C6) alkyl, (C1-C6)
haloalkyl, (C3-C7) lkyl, or 4 to 7-membered heterocycloalkyl comprising 1 to 3
heteroatoms selected from N, O, or S. In another embodiment, R9 is H, (C1-C6) alkyl, (C1-C6)
haloalkyl, or (C3-C7) cycloalkyl. In yet another embodiment, R9 is H, (C1-C6) alkyl, or (C1-
C6) kyl. In another embodiment, R9 is H or (C1-C6) alkyl. In yet another embodiment,
R9 is (C1-C6) alkyl. In r embodiment, R9 is H, methyl, ethyl, n-propyl, iso-propyl, n-
butyl, sec-butyl, iso-butyl, tert-butyl, n-pentyl, iso-pentyl, tert-pentyl, neo-pentyl, sec-pentyl,
3-pentyl, n-hexane, 2-methyl pentane, 3-methyl pentane, 2,2-dimethyl , or 2,3-
dimethyl butane. In another embodiment, R9 is H. In yet another embodiment, R9 is methyl.
In some embodiments of the Formulae above, R10 is H, (C1-C6) alkyl, (C1-C6)
haloalkyl, (C3-C7) cycloalkyl, or 4 to 7-membered heterocycloalkyl comprising 1 to 3
atoms selected from N, O, or S, wherein the cycloalkyl or heterocycloalkyl is
optionally substituted with one or more substituents each ndently selected from (C1-
C6) alkyl, -NH2, ) alkylamino, ) dialkylamino, and -OH, and wherein the (C1-C6)
alkyl is optionally substituted with one or more RH. In another embodiment, R10 is H, (C1-
C6) alkyl, (C3-C7) lkyl, or 4 to 7-membered heterocycloalkyl comprising 1 to 3
heteroatoms selected from N, O, or S, wherein the cycloalkyl or heterocycloalkyl is
ally substituted with one or more substituents each independently selected from (C1-
C6) alkyl, -NH2, (C1-C6) alkylamino, (C1-C6) dialkylamino, and -OH, and wherein the (C1-C6)
alkyl is optionally substituted with one or more RH. In yet another embodiment, R10 is H,
(C1-C6) alkyl, or (C3-C7) cycloalkyl, n the cycloalkyl is optionally substituted with one
or more substituents each independently selected from (C1-C6) alkyl, -NH2, (C1-C6)
alkylamino, ) dialkylamino, and -OH, and wherein the (C1-C6) alkyl is optionally
substituted with one or more R”. In another embodiment, R10 is H or (C1-C6) alkyl, wherein
the (C1-C6) alkyl is optionally substituted with one or more R”. In yet another ment,
R10 is (C1-C6) alkyl is optionally substituted with one or more R”. In another embodiment,
R10 is methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, iso-butyl, tert-butyl, n-pentyl,
iso-pentyl, tert-pentyl, neo-pentyl, sec-pentyl, 3-pentyl, ne, yl pentane, 3-
methyl pentane, 2,2-dimethyl butane, or 2,3-dimethyl butane, wherein the methyl, ethyl, npropyl
, iso-propyl, n-butyl, sec-butyl, iso-butyl, tert-butyl, n-pentyl, iso-pentyl, tert-pentyl,
neo-pentyl, ntyl, 3-pentyl, n-hexane, 2-methyl pentane, 3-methyl e, 2,2-dimethyl
butane, or 2,3-dimethyl butane is optionally substituted with one or more R”. In yet another
ment, R10 is H. In another embodiment, R10 is methyl, ethyl, n-propyl, or n-butyl,
wherein the methyl, ethyl, n-propyl, or n-butyl is optionally substituted with one or more
In an embodiment, R10 is (C3-C7) cycloalkyl, wherein the lkyl is ally
tuted with one or more substituents each independently selected from (C1-C6) alkyl, -
NH2, (C1-C6) alkylamino, (C1-C6) dialkylamino, and —OH. In another embodiment, R10 is
cyclopropyl or exyl, wherein the cyclopropyl or cyclohexyl is optionally substituted
with one or more substituents each independently selected from (C1-C6) alkyl, -NH2, (C1-C6)
alkylamino, (C1-C6) dialkylamino, and —OH.
In an ment, R10 is 4 to 7-membered heterocycloalkyl comprising 1 to 3
heteroatoms selected from N, O, or S, wherein the heterocycloalkyl is optionally substituted
with one or more substituents each independently selected from (C1-C6) alkyl, -NH2, (C1-C6)
alkylamino, (C1-C6) dialkylamino, and —OH. In another embodiment, R10 is azetidinyl or
piperidinyl, wherein the azetidinyl or dinyl is ally substituted with one or more
substituents each independently selected from (C1-C6) alkyl, -NH2, (C1-C6) alkylamino, (C1-
C6) dialkylamino, and —OH.
In some embodiments of the Formulae above, R9 and R10 together with the
nitrogen atom to which they are attached form a 4- to ered heterocycloalkyl ring
comprising 1 to 3 heteroatom selected from N, O, and S, optionally substituted with one or
more substituent each independently selected from ) alkyl, (C1-C6) hydroxyalkyl, -
(CH2)q-NH2, -(CH2)q-(C1-C6) alkylamino, -(CH2)q-(C1-C6) dialkylamino, C1-C6) alkyl,
-OH, and 4- to ered heterocycloalkyl comprising 1 to 3 heteroatom selected from N,
O, and S, and optionally substituted with one or more (C1-C6) alkyl. In another embodiment,
R9 and R10 together with the nitrogen atom to which they are attached form azetidinyl,
morpholinyl, dinyl, or piperazinyl, ally substituted with one or more substituent
each independently selected from (C1-C6) alkyl, (C1-C6) hydroxyalkyl, -(CH2)q-NH2, -
(CH2)q-(C1-C6) mino, -(CH2)q-(C1-C6) dialkylamino, -C(O)(C1-C6) alkyl, -OH, and 4-
to 7-membered heterocycloalkyl comprising 1 to 3 heteroatom selected from N, O, and S, and
optionally substituted with one or more (C1-C6) alkyl. In yet another embodiment, R9 and R10
together with the nitrogen atom to which they are attached form azetidinyl, morpholinyl,
piperidinyl, or piperazinyl, optionally substituted with one or more substituent each
independently ed from (C1-C6) alkyl, (C1-C6) hydroxyalkyl, -(CH2)q-(C1-C6)
dialkylamino, -C(O)(C1-C6) alkyl, -OH, and 4- to 7-membered heterocycloalkyl comprising 1
to 3 heteroatom ed from N, O, and S, and ally substituted with one or more (C1-
C6) alkyl.
In some embodiments of the Formulae above, R11 is (C1-C6) alkoxy, -OH, -NH2,
(C1-C6) alkylamino, ) dialkylamino, 5- or 6- membered heteroaryl comprising 1 to 3
heteroatoms selected from N, O, or S, or 4- to 7-membered heterocycloalkyl comprising 1 to
3 heteroatoms selected from N, O, or S, n the heterocycloalkyl is optionally substituted
with one or more substituents each independently selected from (C1-C6) alkyl and OH. In
another embodiment, R“ is (C1-C6) alkoxy, (cl—c6) alkylamino, (cl—c6) dialkylamino, 5- or
6- membered aryl comprising 1 to 3 heteroatoms selected from N, O, or S, or 4- to 7-
membered heterocycloalkyl comprising 1 to 3 heteroatoms selected from N, O, or S, wherein
the heterocycloalkyl is optionally substituted with one or more substituents each
ndently selected from (C1-C6) alkyl and OH. In yet another embodiment, R11 is (C1-C6)
alkoxy, (C1-C6) alkylamino, or (C1-C6) dialkylamino. In another embodiment, R11 is 5- or 6-
membered heteroaryl comprising 1 to 3 heteroatoms selected from N, O, or S, or 4- to 7-
membered heterocycloalkyl comprising 1 to 3 heteroatoms selected from N, O, or S, wherein
the heterocycloalkyl is optionally substituted with one or more substituents each
independently selected from ) alkyl and OH. In yet another embodiment, R11 is OH.
In r embodiment, R11 is -OCH3. In yet r embodiment, R11 is -NH2, -NHCH3, -
N(CH3)2, or -N(CH2CH3)2. In yet another embodiment, R11 is pyrrolidinyl, piperidinyl,
piperazinyl, morpholinyl, or pyridinyl, wherein the pyrrolidinyl, piperidinyl, piperazinyl, or
morpholinyl is optionally substituted with one or more substituents each independently
ed from (C1-C6) alkyl and OH.
In some embodiments of the Formulae above, R3 is independently at each
ence (C1-C6) alkyl, (C1-C6) , (C1-C6) haloalkyl, (C1-C6) haloalkoxy, halogen, or
OH. In another embodiment, R3 is independently at each occurrence (C1-C6) alkyl, halogen,
or OH. In yet another embodiment, R3 is independently at each occurrence (C1-C6) alkyl or
halogen. In another embodiment, R3 is independently at each ence methyl, ethyl, n-
propyl, iso-propyl, n-butyl, sec-butyl, tyl, tert-butyl, yl, iso-pentyl, tert-pentyl,
neo-pentyl, sec-pentyl, 3-pentyl, n-hexane, 2-methyl pentane, 3-methyl pentane, 2,2-dimethyl
butane, or 2,3-dimethyl butane. In yet r embodiment, R3 is independently at each
occurrence fluoro, chloro, bromo, or iodo. In another ment, R3 is independently at
each occurrence methyl or fluoro. In another embodiment, R3 is . In another
embod1ment, R. 3 .
1s fluoro.
In some embodiments of the Formulae above, R4 is independently at each
ence (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, ) haloalkoxy, halogen, -
OH, CN, )2)p-heterocycloalkyl wherein the heterocycloalkyl comprises a 4- to 7-
membered ring and l to 3 heteroatoms ed from N, O, and S or -(C(R6)2)p-heteroaryl
wherein the aryl comprises a 5- or 6-membered ring and l to 3 heteroatoms selected
from N, O, and S, and n the heterocycloalkyl or heteroaryl is optionally substituted
with one or more substituents each independently selected from (C1-C6) alkyl, -NH2, (C1-C6)
alkylamino, and (C1-C6) dialkylamino. In another embodiment, R4 is independently at each
occurrence (C1-C6) , (C1-C6) kyl, (C1-C6) haloalkoxy, CN, or -(C(R6)2)p-
heterocycloalkyl wherein the heterocycloalkyl comprises a 4- to 7-membered ring and l to 3
heteroatoms selected from N, O, and S wherein the heterocycloalkyl is optionally
substituted with one or more substituents each independently selected from (C1-C6) alkyl, -
NH2, (C1-C6) alkylamino, and (C1-C6) lamino. In another embodiment, R4 is
independently at each occurrence (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, -
OH, CN, or -(C(R6)2)p-heterocycloalkyl wherein the heterocycloalkyl comprises a 5- or 6-
membered ring and l to 3 atoms selected from N, wherein the heterocycloalkyl is
optionally substituted with one or more substituents each ndently ed from (C1-
C6) alkyl. In another embodiment, R4 is —CF3. In yet another embodiment, R4 is —OCF3. In
another embodiment, R4 is —OCH3. In yet another embodiment, R4 is -(C(R6)2)p-
heterocycloalkyl n the heterocycloalkyl comprises pyrrolidinyl or piperazinyl, wherein
the pyrrolidinyl or piperazinyl is optionally substituted with one or more substituents each
independently selected from (C1-C6) alkyl.
In some ments of the Formulae above, R5 is H, (C1-C6) alkyl, or (C1-C6)
haloalkyl. In another embodiment, R5 is H or (C1-C6) alkyl. In yet another embodiment, R5 is
H or (C1-C6) haloalkyl. In another embodiment, R5 is (C1-C6) alkyl or (C1-C6) haloalkyl. In
another embodiment, R5 is (C1-C6) alkyl. In yet another embodiment, R5 is methyl, ethyl, n-
propyl, iso-propyl, n-butyl, sec-butyl, iso-butyl, tert-butyl, n-pentyl, iso-pentyl, tert-pentyl,
neo-pentyl, ntyl, 3-pentyl, n-hexane, 2-methyl pentane, 3-methyl pentane, 2,2-dimethyl
butane, or methyl butane. In another embodiment, R5 is (C1-C6) haloalkyl. In yet
another embodiment, R5 is H.
In some embodiments of the Formulae above, R6 is H or (C1-C6) alkyl. In another
embodiment, R6 is (C1-C6) alkyl. In yet another ment, R6 is H, methyl, ethyl, npropyl
, iso-propyl, n-butyl, sec-butyl, iso-butyl, tert-butyl, n-pentyl, ntyl, tert-pentyl,
neo-pentyl, sec-pentyl, 3-pentyl, n-hexane, yl pentane, 3-methyl pentane, 2,2-dimethyl
butane, or 2,3-dimethyl butane. In another embodiment, R6 is H. In yet another
embodiment, R6 is methyl.
In some embodiments of the Formulae above, R7 is H or (C1-C6) alkyl. In another
embodiment, R7 is (C1-C6) alkyl. In yet another embodiment, R7 is H, methyl, ethyl, n-
propyl, iso-propyl, n-butyl, sec-butyl, iso-butyl, tert-butyl, n-pentyl, iso-pentyl, tert-pentyl,
neo-pentyl, sec-pentyl, 3-pentyl, n-hexane, 2-methyl pentane, 3-methyl pentane, 2,2-dimethyl
, or 2,3-dimethyl butane. In another embodiment, R7 is H. In yet another
embodiment, R7 is methyl.
In some ments of the Formulae above, R8 is (C1-C6) alkyl, (C3-C7)
cycloalkyl, (C2-C6) l, (C1-C3) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, or 4 to 7-
membered cycloalkyl comprising 1 to 3 heteroatoms ed from N, O, and S. In
another embodiment, R8 is ) alkyl or (C1-C3) alkoxy. In yet another embodiment, R8 is
methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, iso-butyl, tert-butyl, n-pentyl, iso-
pentyl, tert-pentyl, neo-pentyl, sec-pentyl, 3-pentyl, ne, 2-methyl pentane, 3-methyl
pentane, 2,2-dimethyl , or 2,3-dimethyl butane. In another embodiment, R8 is methyl
or tert-butyl. In yet another embodiment, R8 is ) alkoxy. In another embodiment, R8 is
methoxy.
In some embodiments of the Formulae above, each n, p, and q is independently O,
l or 2. In another embodiment, n is O or 1. In yet another embodiment, n is O. In yet another
embodiment, n is 1. In another embodiment, p is O or 1. In yet another embodiment, p is O.
In another embodiment, p is 1. In another embodiment, q is O or 1. In yet another
embodiment, q is O. In another embodiment, q is l.
In some embodiments of the Formulae above, L is —C(O)NR5-.
In some embodiments of the Formulae above, L is —NR5C(O)-.
In some embodiments of the Formulae above, R3 is (C1-C6) alkyl or halogen.
In some ments of the Formulae above, 11 is l and R3 is methyl or F.
In some embodiments of the ae above, 11 is l and R3 is methyl.
In some embodiments of the Formulae above, A is (Cs-(:10) aryl optionally
substituted with one or more R4.
In some embodiments of the Formulae above, A is 6-membered heteroaryl
optionally substituted with one or more R4.
In some embodiments of the Formulae above, A is phenyl or pyridinyl optionally
substituted with one or more R4.
In some embodiments of the Formulae above, A is phenyl or pyridinyl substituted
with one or more R4.
In some embodiments of the Formulae above, R5 is H.
In some ments of the Formulae above, 11 is O.
In some embodiments of the Formulae above, 11 is l.
In some embodiments of the ae above, 11 is l and R3 is ortho to the .
In some embodiments of the Formulae above, R1 is H, -C(O)N(CH3)2 or —
CHZCH2C(O)OH.
In some embodiments of the Formulae above, R1 is H.
In some embodiments of the Formulae above, one R4 is (C1-C6) haloalkyl and the
other R4 is (C1-C6) alkoxy, CN, or -(C(R6)2)p-heterocycloalkyl n the heterocycloalkyl
ses a 4- to 7-membered ring and l to 3 heteroatoms selected from N, O, and S.
In some embodiments of the Formulae above, at least one R4 is CF3 and the other
R4 is (C1-C6) , CN, or -(C(R6)2)p-heterocycloalkyl wherein the heterocycloalkyl
comprises a 4- to 7-membered ring and l to 3 heteroatoms selected from N, O, and S.
In some embodiments of the Formulae above, at least one R4 is CF3 and the other
R4 is —OCH3, CN, or -(CH2)-pyrrolyl.
In another embodiment, R1 is H and R2 is —C(O)NR9R10.
In some embodiments of the Formulae above, R9 is H and R10 is (C1-C6) alkyl.
In some embodiments of the Formulae above, R9 is H and R10 is (C1-C6) alkyl
substituted with one R11.
In some embodiments of the Formulae above, R11 is (C1-C6) alkoxy.
In some embodiments of the ae above, the (C1-C6) alkoxy is —OCH3.
In some embodiments of the ae above, R9 is (C1-C6) alkyl and R10 is (C1-
C6) alkyl.
In some embodiments of the ae above, R9 is (C1-C6) alkyl and R10 is (C1-
C6) alkyl substituted with one R11.
In some embodiments of the Formulae above, R4 is (C1-C6) haloalkyl.
In some embodiments of the Formulae above, R4 is CF3.
In some embodiments of the Formulae above, 11 is l and R3 is methyl.
In some ments of the ae above, R1 is H and R2 is (C1-C6) alkyl.
In some embodiments of the Formulae above, (C1-C6) alkyl is selected from
methyl, ethyl, yl, iso-propyl, n-butyl, sec-butyl, iso-butyl, tert-butyl, n-pentyl, iso-
pentyl, tert-pentyl, neo-pentyl, sec-pentyl, 3-pentyl, n-hexane, 2-methyl pentane, 3-methyl
pentane, 2,2-dimethyl butane, and 2,3-dimethyl butane.
In some embodiments of the Formulae above, (C1-C6) alkyl is ethyl.
In some ments of the Formulae above, (C1-C6) alkyl is methyl.
In some embodiments of the Formulae above, R1 is H and R2 is —C(O)R8.
In r embodiment, R8 is (C1-C3) alkoxy.
In some embodiments of the Formulae above, ) alkoxy is OCH3.
In some embodiments of the Formulae above, R1 is H and R2 is —C(O)NR9R10.
In some embodiments of the Formulae above, R9 is H and R10 is (C1-C6) alkyl
substituted with one R”.
In some embodiments of the ae above, R11 is ) lamino.
In some embodiments of the Formulae above, (C1-C6) dialkylamino is —N(CH3)2
or —N(CH2CH3)2.
In some embodiments of the Formulae above, R11 is (C1-C6) alkylamino.
In some ments of the Formulae above, (C1-C6) alkylamino is —N(H)CH3.
In some embodiments of the Formulae above, R11 is —NH2.
In some embodiments of the Formulae above, R11 is 5- or 6-membered
heterocycloalkyl comprising 1 to 3 atoms selected from N, O, or S, optionally
substituted with (C1-C6) alkyl or OH.
In some embodiments of the Formulae above, R11 is 6-membered heteroaryl
comprising 1 to 3 heteroatoms selected from N, O, or S.
In some embodiments of the Formulae above, R11 is -OH.
In some embodiments of the Formulae above, R9 is H and R10 is (C3-C7)
cycloalkyl optionally substituted with —OH or -NH2..
In some embodiments of the Formulae above, (C3-C7) cycloalkyl is cyclopropyl or
cyclohexyl optionally substituted with —OH or -NH2.
In some embodiments of the Formulae above, R9 is H and R10 is 4 to 6-membered
heterocycloalkyl comprising 1 to 3 heteroatoms selected from N, O, or S, optionally
substituted with methyl
In some embodiments of the Formulae above, R9 is (C1-C6) alkyl and R10 is 4 to 6-
membered heterocycloalkyl comprising 1 to 3 heteroatoms selected from N, O, or S,
optionally substituted with methyl.
In some embodiments of the ae above, R9 and R10 together with the
nitrogen atom to which they are attached form a 4- to 6-membered heterocycloalkyl ring
comprising 1 to 3 heteroatom selected from N, O, and S, optionally substituted with one or
more substituents each independently ed from (C1-C6) alkyl, (C1-C6) yalkyl, -
(CH2)q-(C1-C6) dialkylamino, C1-C6) alkyl, OH, or 6-membered heterocycloalkyl
comprising 1 to 3 heteroatom selected from N, O, and S, and optionally substituted with (C1-
C6) alkyl.
In some embodiments of the Formulae above, (R1 is —C(O)N(R7)2 and R2 is
R9R10.
In some embodiments of the Formulae above, R1 is -(CH2)qC(O)OH and R2 is
—C(O)Rg.
In some embodiments of the Formulae above, R8 is ) alkenyl.
In some embodiments of the Formulae above, 11 is l and R3 is F.
In some embodiments of the Formulae above, R1 is H and R2 is R9R10.
In some embodiments of the Formulae above, 11 is O, R1 is H, and R2 is —
C(O)NR9R10.
In some ments of the Formulae above, when A is phenyl and R1 is H, then
R2 is not —C(O)CH3.
In some embodiments of the ae above, A is phenyl and R1 is H, an R2 is
(C1-C6) alkyl, -C(O)Rg, or R9R10, and R8 is (Cz—Cé) alkyl, (C3-C7) cycloalkyl, (Cz—Cé)
alkenyl, (C1-C3) alkoxy, (C1-C6) kyl, (C1-C6) haloalkoxy, or 4 to 7-membered
heterocycloalkyl comprising 1 to 3 heteroatoms selected from N, O, and S.
In some embodiments of the Formulae above, L is —C(O)NR5- or —NR5C(O)-, A is
(C3-C8) cycloalkyl, (Cs-Clo) aryl, or 5- to lO-membered heteroaryl wherein the cycloalkyl,
aryl, or heteroaryl is optionally substituted with one or more R4, R1 is H, (C1-C6) alkyl, -
C(O)OH, or —C(O)N(R7)2, R2 is ) alkyl, -C(O)Rg, or —C(O)NR9R10, each R3 is
independently at each occurrence (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6)
haloalkoxy, halogen, or OH, each R4 is independently at each occurrence (C1-C6) alkyl, (C1-
C6) , (C1-C6) haloalkyl, ) haloalkoxy, halogen, -OH, CN, -(C(R6)2)p-
heterocycloalkyl wherein the heterocycloalkyl ses a 4- to 7-membered ring and l to 3
heteroatoms selected from N, O, and S or
, -(C(R6)2)p-heteroaryl wherein the heteroaryl
comprises a 5- or 6-membered ring and l to 3 heteroatoms selected from N, O, and S, and
wherein the heterocycloalkyl or aryl is optionally substituted with one or more
substituents each independently selected from (C1-C6) alkyl, -NH2, (C1-C6) alkylamino, and
) dialkylamino, R5 is H, (C1-C6) alkyl, or (C1-C6) haloalkyl, each R6 is independently H
or (C1-C6) alkyl, each R7 is ndently H or (C1-C6) alkyl, R8 is (C1-C6) alkyl, (C3-C7)
cycloalkyl, (C2-C6) alkenyl, (C1-C3) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, or 4 to 7-
membered heterocycloalkyl comprising 1 to 3 heteroatoms selected from N, O, and S, R9 is
H, (C1-C6) alkyl, (C1-C6) haloalkyl, ) cycloalkyl, or 4 to 7-membered heterocycloalkyl
comprising 1 to 3 heteroatoms selected from N, O, or S, R10 is H, (C1-C6) alkyl, )
haloalkyl, (C3-C7) cycloalkyl, or 4 to ered heterocycloalkyl comprising 1 to 3
heteroatoms selected from N, O, or S, wherein the cycloalkyl or heterocycloalkyl is
optionally substituted with one or more substituents each independently ed from (C1-
C6) alkyl, -NH2, (C1-C6) alkylamino, (C1-C6) dialkylamino, and -OH, and wherein the (C1-C6)
alkyl is optionally tuted with one or more R”, or R9 and R10 together with the en
atom to which they are attached form a 4- to 7-membered heterocycloalkyl ring comprising 1
to 3 heteroatom selected from N, O, and S, optionally substituted with one or more
substituent each independently selected from (C1-C6) alkyl, (C1-C6) hydroxyalkyl, -(CH2)q-
NH2, -(CH2)q-(C1-C6) alkylamino, -(CH2)q-(C1-C6) dialkylamino, -C(O)(C1-C6) alkyl, -OH,
and 4- to 7-membered heterocycloalkyl comprising 1 to 3 heteroatom selected from N, O, and
S, and optionally substituted with one or more ) alkyl, R11 is (C1-C6) alkoxy, -OH, -
NHz, (C1-C6) alkylamino, (C1-C6) dialkylamino, 5- or 6- membered heteroaryl comprising 1
to 3 heteroatoms selected from N, O, or S, or 4- to 7-membered heterocycloalkyl comprising
1 to 3 heteroatoms selected from N, O, or S, wherein the heterocycloalkyl is optionally
substituted with one or more substituents each independently selected from (C1-C6) alkyl and
OH, and each n, p, and q is independently O, l or 2, and provided that when A is phenyl and
R1 is H, then R2 is not —C(O)CH3.
] In some embodiments of the Formulae above, L is —C(O)NR5-, A is (Cs-Clo) aryl
wherein the aryl is optionally substituted with one or more R4, R1 is H, R2 is (C1-C6) alkyl, -
C(O)Rg, or —C(O)NR9R10, R3 is ) alkyl, R4 is (cl—c6) haloalkyl, R5 is H, (C1—C6) alkyl,
or (C1-C6) haloalkyl, R8 is (C1-C6) alkyl, (C3-C7) cycloalkyl, (C2-C6) alkenyl, (C1-C3) alkoxy,
(C1-C6) haloalkyl, (C1-C6) haloalkoxy, or 4 to 7-membered heterocycloalkyl comprising 1 to
3 heteroatoms selected from N, O, and S, R9 is H, (C1-C6) alkyl, (C1-C6) haloalkyl, (C3-C7)
cycloalkyl, or 4 to 7-membered heterocycloalkyl sing 1 to 3 heteroatoms selected from
N, 0, or s, R10 is H, (C1-C6) alkyl, (C1-C6) haloalkyl, (C3-C7) cycloalkyl, or 4 to 7-membered
heterocycloalkyl sing 1 to 3 heteroatoms selected from N, O, or S, wherein the
lkyl or cycloalkyl is ally substituted with one or more substituents each
independently selected from (C1-C6) alkyl, -NH2, (C1-C6) mino, (C1-C6) dialkylamino,
and -OH, and wherein the (C1-C6) alkyl is optionally substituted with one or more R”, or R9
and R10 together with the nitrogen atom to which they are attached form a 4- to 7-membered
heterocycloalkyl ring sing 1 to 3 heteroatom selected from N, O, and S, optionally
substituted with one or more tuent each independently selected from (C1-C6) alkyl, (C1-
C6) hydroxyalkyl, q-NH2, -(CH2)q-(C1-C6) alkylamino, -(CH2)q-(C1-C6) dialkylamino, -
C(O)(C1-C6) alkyl, -OH, and 4- to 7-membered heterocycloalkyl comprising 1 to 3
heteroatom ed from N, O, and S, and optionally substituted with one or more (C1-C6)
alkyl, R“ is (C1-C6) alkoxy, -OH, -NH2, (C1-C6) alkylamino, (C1-C6) dialkylamino, 5— or 6-
ed heteroaryl comprising 1 to 3 heteroatoms selected from N, O, or S, or 4- to 7-
membered heterocycloalkyl comprising 1 to 3 heteroatoms selected from N, O, or S, wherein
the heterocycloalkyl is optionally substituted with one or more substituents each
independently selected from (C1-C6) alkyl and OH, and n is 1.
In some embodiments of the Formulae above, L is —C(O)NR5-, A is 5- to 10-
membered heteroaryl wherein the heteroaryl is optionally substituted with one or more R4, R1
is H, R2 is (C1-C6) alkyl, -C(O)Rg, or —C(O)NR9R10, R3 is (C1-C6) alkyl, R4 is (C1-C6)
haloalkyl, R5 is H, (C1-C6) alkyl, or (C1-C6) haloalkyl, R8 is (C1-C6) alkyl, (C3-C7) cycloalkyl,
(C2-C6) alkenyl, (C1-C3) alkoxy, (C1-C6) kyl, ) haloalkoxy, or 4 to 7-membered
heterocycloalkyl comprising 1 to 3 heteroatoms selected from N, O, and S, R9 is H, )
alkyl, (C1-C6) haloalkyl, (C3-C7) cycloalkyl, or 4 to 7-membered heterocycloalkyl comprising
1 to 3 heteroatoms selected from N, O, or S, R10 is H, (C1-C6) alkyl, (C1-C6) haloalkyl, (C3-
C7) cycloalkyl, or 4 to 7-membered heterocycloalkyl comprising 1 to 3 heteroatoms selected
from N, O, or S, wherein the cycloalkyl or heterocycloalkyl is optionally substituted with one
or more substituents each ndently selected from (C1-C6) alkyl, -NH2, (C1-C6)
alkylamino, (C1-C6) dialkylamino, and -OH, and wherein the (C1-C6) alkyl is optionally
substituted with one or more R”, or R9 and R10 together with the nitrogen atom to which they
are attached form a 4- to 7-membered cycloalkyl ring sing 1 to 3 heteroatom
selected from N, O, and S, optionally substituted with one or more substituent each
independently selected from (C1-C6) alkyl, (C1-C6) hydroxyalkyl, -(CH2)q-NH2, -(CH2)q-(C1-
C6) alkylamino, -(CH2)q-(C1-C6) dialkylamino, -C(O)(C1-C6) alkyl, -OH, and 4- to 7-
membered heterocycloalkyl comprising 1 to 3 heteroatom selected from N, O, and S, and
optionally substituted with one or more (C1-C6) alkyl, R11 is ) alkoxy, -OH, -NH2, (C1-
C6) alkylamino, (C1-C6) dialkylamino, 5- or 6- membered heteroaryl comprising 1 to 3
atoms selected from N, O, or S, or 4- to 7-membered heterocycloalkyl comprising 1 to
3 atoms selected from N, O, or S, wherein the heterocycloalkyl is optionally tuted
with one or more substituents each independently selected from (C1-C6) alkyl and OH, and n
is 1.
In r embodiment, L is —C(O)NR5- wherein R5 is is
7 H, A pyridinyl
optionally substituted with one or more R4, wherein R4 is —CF3, R1 is H, R2 is (C1-C6) alkyl, -
C(O)Rg, or —C(O)NR9R10, R3 is methyl, R8 is (C1-C6) alkyl, (C3-C7) cycloalkyl, )
l, (C1-C3) alkoxy, (C1-C6) haloalkyl, (C1-C6) koxy, or 4 to 7-membered
heterocycloalkyl comprising 1 to 3 heteroatoms selected from N, O, and S, R9 is H, (C1-C6)
alkyl, (C1-C6) haloalkyl, (C3-C7) cycloalkyl, or 4 to 7-membered heterocycloalkyl comprising
1 to 3 heteroatoms selected from N, O, or S, R10 is H, (C1-C6) alkyl, (C1-C6) haloalkyl, (C3-
C7) cycloalkyl, or 4 to 7-membered heterocycloalkyl comprising 1 to 3 heteroatoms selected
from N, O, or S, wherein the cycloalkyl or heterocycloalkyl is optionally tuted with one
or more substituents each independently selected from (C1-C6) alkyl, -NH2, (C1-C6)
alkylamino, (C1-C6) dialkylamino, and -OH, and wherein the (C1-C6) alkyl is ally
tuted with one or more R”, or R9 and R10 together with the nitrogen atom to which they
are attached form a 4- to 7-membered heterocycloalkyl ring comprising 1 to 3 heteroatom
selected from N, O, and S, optionally substituted with one or more substituent each
independently selected from (C1-C6) alkyl, (C1-C6) hydroxyalkyl, q-NH2, -(CH2)q-(C1-
C6) alkylamino, -(CH2)q-(C1-C6) lamino, -C(O)(C1-C6) alkyl, -OH, and 4- to 7-
membered heterocycloalkyl comprising 1 to 3 heteroatom selected from N, O, and S, and
optionally substituted with one or more (C1-C6) alkyl, R11 is (C1-C6) alkoxy, -OH, -NH2, (C1-
WO 12136
C6) alkylamino, (C1-C6) dialkylamino, 5- or 6- membered heteroaryl comprising 1 to 3
heteroatoms selected from N, O, or S, or 4- to 7-membered heterocycloalkyl comprising 1 to
3 heteroatoms selected from N, O, or S, wherein the heterocycloalkyl is optionally substituted
with one or more substituents each independently selected from (C1-C6) alkyl and OH, and n
is 1.
In another embodiment, L is —C(O)NR5- wherein R5 is
7 H, A is pyridinyl
optionally substituted with one or more R4, wherein R4 is —CF3, R1 is H, R2 is g, R3 is
methyl, R8 is (C1-C6) alkyl, (C3-C7) cycloalkyl, ) alkenyl, (C1-C3) alkoxy, (C1-C6)
haloalkyl, (C1-C6) haloalkoxy, or 4 to 7-membered heterocycloalkyl comprising 1 to 3
heteroatoms selected from N, O, and S, and n is 1.
In another embodiment, L is —C(O)NR5- wherein R5 is is
7 H, A pyridinyl
optionally substituted with one or more R4, wherein R4 is —CF3, R1 is H, R2 is -C(O)Rg, R3 is
methyl, R8 is (C1-C6) alkyl, (C3-C7) cycloalkyl, or (C1-C3) alkoxy, and n is 1. In another
embodiment, R8 is methoxy. In another embodiment, R8 is . In another ment,
R8 is l—butyl. In another embodiment, R8 is ropyl.
] In another embodiment, L is —C(O)NR5-, wherein R5 is H, A is pyridinyl
ally substituted with one or more R4, wherein R4 is —CF3, R1 is H, R3 is methyl, R2 is —
C(O)NR9R10, wherein R9 is H and R10 is H, (C1-C6) alkyl, or (C3-C7) lkyl, wherein the
(C1-C6) alkyl is optionally substituted with one or more R”, wherein R11 is (C1-C6) alkoxy, -
OH, -NH2, (C1-C6) alkylamino, (C1-C6) lamino, 5- or 6- membered aryl
comprising 1 to 3 heteroatoms selected from N, O, or S, or 4- to 7-membered
heterocycloalkyl comprising 1 to 3 heteroatoms selected from N, O, or S, wherein the
heterocycloalkyl is optionally substituted with one or more substituents each independently
ed from (C1-C6) alkyl and OH, and n is 1.
In another embodiment, L is —C(O)NR5- wherein R5 is is
7 H, A pyridinyl
substituted with one or more R4, wherein R4 is —CF3, R1 is H, R3 is methyl, R2 is —
C(O)NR9R10 n R9 is H and R10 is H,
, methyl, ethyl, propyl, n-butyl, isobutyl, or
ropyl, wherein the , ethyl, propyl, n-butyl, or isobutyl is optionally substituted
with one or more R“, n R“ is (C1-C6) , -OH, -NH2, (C1-C6) alkylamino, (C1-C6)
dialkylamino, 5- or 6- membered heteroaryl comprising 1 to 3 heteroatoms selected from N,
O, or S, or 4- to 7-membered heterocycloalkyl comprising 1 to 3 heteroatoms selected from
N, O, or S, wherein the heterocycloalkyl is optionally substituted with one or more
substituents each independently selected from (C1-C6) alkyl and OH, and n is 1. In another
embodiment, R10 is H. In another embodiment, R10 is cyclopropyl,.
In another embodiment, L is —C(O)NR5-, n R5 is H, A is pyridinyl
optionally substituted with one or more R4, wherein R4 is —CF3, R1 is H, R3 is , R2 is —
C(O)NR9R10, wherein R9 is H and R10 is , ethyl, , n-butyl, or isobutyl, wherein
the methyl, ethyl, propyl, n-butyl, or isobutyl is substituted with one or more R”, wherein R11
is (C1-C6) , -OH, -NH2, (C1-C6) dialkylamino, 5- or 6- membered heteroaryl
comprising 1 to 3 heteroatoms selected from N, O, or S, or 4- to ered
heterocycloalkyl comprising 1 to 3 heteroatoms selected from N, O, or S, wherein the
heterocycloalkyl is optionally substituted with one or more substituents each independently
ed from (C1-C6) alkyl and OH, and n is 1.
In another embodiment, L is —C(O)NR5-, wherein R5 is H, A is pyridinyl
optionally substituted with one or more R4, wherein R4 is —CF3, R1 is H, R3 is methyl, R2 is —
C(O)NR9R10, n R9 is H and R10 is , wherein the methyl is optionally substituted
with one or more R”, wherein R11 is 5- or 6- membered heteroaryl comprising 1 to 3
atoms selected from N, O, or S, or 4- to 7-membered heterocycloalkyl comprising 1 to
3 heteroatoms selected from N, O, or S, wherein the heterocycloalkyl is optionally substituted
with one or more substituents each independently ed from ) alkyl and OH, and n
is 1. In another embodiment, R10 is . In another embodiment, R10 is methyl, wherein
the methyl is substituted with R11 wherein R11 is N-methylpiperidinyl. In another
embodiment, R10 is methyl, wherein the methyl is substituted with R11, wherein R11 is
pyridinyl.
In another embodiment, L is —C(O)NR5-, wherein R5 is H, A is pyridinyl
optionally substituted with one or more R4, wherein R4 is —CF3, R1 is H, R3 is methyl, R2 is —
C(O)NR9R10, wherein R9 is H and R10 is ethyl, wherein the ethyl is substituted with one or
more R”, wherein R11 is ) alkoxy, -NH2, (C1-C6) dialkylamino, or 4- to 7-membered
heterocycloalkyl comprising 1 to 3 heteroatoms selected from N, O, or S, wherein the
heterocycloalkyl is optionally substituted with one or more substituents each independently
selected from (C1-C6) alkyl and OH, and n is 1. In another embodiment, R10 is ethyl, wherein
the ethyl is tuted with R11 wherein R11 is methoxy. In another embodiment, R10 is
ethyl, wherein the ethyl is substituted with R11, wherein R11 is ylamino. In another
embodiment, R10 is ethyl, wherein the ethyl is substituted with one or more R”, wherein R11
is —NH2, and n is 1.
In another embodiment, L is —C(O)NR5-, wherein R5 is H, A is pyridinyl
optionally substituted with one or more R4, wherein R4 is —CF3, R1 is H, R3 is methyl, R2 is —
C(O)NR9R10, wherein R9 is H and R10 is ethyl, wherein the ethyl is substituted with one or
more R”, wherein R11 is 4- to 7-membered heterocycloalkyl comprising 1 to 3 heteroatoms
selected from N, O, or S, wherein the heterocycloalkyl is optionally tuted with one or
more substituents each independently selected from (C1-C6) alkyl and OH, and n is 1. In
another embodiment, R10 is ethyl, wherein the ethyl is substituted with R11, and n R11
is morpholinyl. In another embodiment, R10 is ethyl, wherein the ethyl is substituted with
R11, and wherein R11 is pyrrolidinyl. In another embodiment, R10 is ethyl, wherein the ethyl
is substituted with R11, and wherein R11 is N-methylpiperazinyl. In another embodiment, R10
is ethyl, wherein the ethyl is substituted with R11, and wherein R11 is 3-hydroxypyrrolidinyl.
In another embodiment, L is —C(O)NR5-, wherein R5 is H, A is pyridinyl
substituted with one or more R4, wherein R4 is —CF3, R1 is H, R3 is methyl, R2 is —
C(O)NR9R10 wherein R9 is H and R10 is H,
7 methyl, ethyl, propyl, l, isobutyl, or
cyclopropyl, wherein the methyl, ethyl, propyl, n-butyl, or isobutyl is optionally substituted
with one or more R”, wherein R11 is —OH or -NH2, and n is 1. In another embodiment, R10 is
isobutyl, wherein the isobutyl is substituted with R11, wherein R11 is —OH. In another
ment, R10 is n-butyl, wherein the n-butyl is substituted with R11, wherein R11 is -NH2.
In another embodiment, R10 is n-propyl, wherein the n-propyl is substituted with R11, wherein
R11 is -NH2.
In another embodiment, L is —C(O)NR5-, wherein R5 is H, A is pyridinyl
optionally substituted with one or more R4, wherein R4 is —CF3, R1 is H, R3 is methyl, R2 is —
C(O)NR9R10, wherein R9 is methyl and R10 is H, ) alkyl, (C1-C6) haloalkyl, )
cycloalkyl, or 4 to 7-membered heterocycloalkyl comprising 1 to 3 heteroatoms selected from
N, O, or S, wherein the cycloalkyl or cycloalkyl is optionally substituted with one or
more substituents each independently selected from (C1-C6) alkyl, -NH2, (C1-C6) alkylamino,
(C1-C6) dialkylamino, and -OH, and wherein the (C1-C6) alkyl is optionally substituted with
one or more R11 wherein R11 is (C1-C6) alkoxy, -OH, -NH2,
7 (C1-C6) alkylamino, (C1-C6)
dialkylamino, 5- or 6- ed heteroaryl comprising 1 to 3 heteroatoms selected from N,
O, or S, or 4- to ered heterocycloalkyl comprising 1 to 3 atoms selected from
N, O, or S, n the heterocycloalkyl is optionally substituted with one or more
substituents each independently selected from (C1-C6) alkyl and OH, and n is 1.
In another embodiment, L is —C(O)NR5- wherein R5 is H, A is
7 pyridinyl
substituted with one or more R4, wherein R4 is —CF3, R1 is H, R3 is methyl, R2 is —
C(O)NR9R10 wherein R9 is methyl and R10 is , ethyl, , n-butyl, or isobutyl,
n the , ethyl, propyl, n-butyl, or yl is optionally substituted with one or
more R”, wherein R11 is (C1-C6) alkoxy, -OH, -NH2, (C1-C6) alkylamino, (C1-C6)
dialkylamino, 5- or 6- membered heteroaryl comprising 1 to 3 heteroatoms selected from N,
O, or S, or 4- to 7-membered heterocycloalkyl comprising 1 to 3 heteroatoms selected from
N, O, or S, wherein the heterocycloalkyl is optionally substituted with one or more
substituents each independently selected from (C1-C6) alkyl and OH, and n is 1.
In another embodiment, L is —C(O)NR5-, wherein R5 is H, A is pyridinyl
substituted with one or more R4, wherein R4 is —CF3, R1 is H, R3 is methyl, R2 is —
C(O)NR9R10, wherein R9 is methyl and R10 is methyl, ethyl, or yl, wherein the ,
ethyl, or isobutyl is optionally substituted with one or more R”, wherein R11 is (C1-C6)
alkoxy, -OH, -NH2, ) mino, (C1-C6) dialkylamino, 5- or 6- ed heteroaryl
comprising 1 to 3 heteroatoms selected from N, O, or S, or 4- to 7-membered
heterocycloalkyl sing 1 to 3 heteroatoms ed from N, O, or S, wherein the
heterocycloalkyl is optionally tuted with one or more substituents each independently
selected from (C1-C6) alkyl and OH, and n is 1. In another embodiment, R10 is methyl,
wherein the methyl is substituted with R11, wherein R11 is 2-methylpyrrolidinyl. In another
embodiment, R10 is isobutyl, wherein the isobutyl is substituted with R11, wherein R11 is -OH.
In another embodiment, R10 is methyl. In another embodiment, R10 is ethyl.
In r embodiment, L is —C(O)NR5-, wherein R5 is H, A is pyridinyl
substituted with one or more R4, wherein R4 is —CF3, R1 is H, R3 is methyl, R2 is —
C(O)NR9R10, wherein R9 is methyl and R10 is ethyl, n the ethyl is substituted with one
or more R11 wherein R“ is
7 (C1-C6) alkoxy, -OH, -NH2, (C1-C6) alkylamino, (C1-C6)
dialkylamino, 5- or 6- membered heteroaryl comprising 1 to 3 heteroatoms selected from N,
O, or S, or 4- to 7-membered heterocycloalkyl comprising 1 to 3 heteroatoms selected from
N, O, or S, wherein the heterocycloalkyl is optionally substituted with one or more
substituents each independently selected from (C1-C6) alkyl and OH, and n is 1.
In another ment, L is —C(O)NR5-, wherein R5 is H, A is pyridinyl
substituted with one or more R4, n R4 is —CF3, R1 is H, R3 is methyl, R2 is —
C(O)NR9R10, wherein R9 is methyl and R10 is ethyl, wherein the ethyl is substituted with one
or more RH, wherein R11 is (C1-C6) alkoxy, -OH, ) alkylamino, (C1-C6) dialkylamino,
or S, or 4- to 7-membered heterocycloalkyl comprising 1 to 3 atoms selected from N,
O, or S, wherein the heterocycloalkyl is ally substituted with one or more substituents
each independently selected from (C1-C6) alkyl and OH, and n is 1. In another embodiment,
R11 is y. In another embodiment, R11 is dimethylamino. In another embodiment, R11
is -OH. In another embodiment, R11 is —NHCH3. In another embodiment, R11 is N-
methylpiperazinyl. In another embodiment, R11 is pyrrolidinyl.
In another embodiment, L is —C(O)NR5- n R5 is H, A is pyridinyl
ally substituted with one or more R4, wherein R4 is —CF3, R1 is H, R3 is methyl, R2 is —
C(O)NR9R10 wherein R9 is methyl and R10 is
7 (C3-C7) cycloalkyl, or 4 to 7-membered
heterocycloalkyl comprising 1 to 3 heteroatoms selected from N, O, or S, wherein the
cycloalkyl or heterocycloalkyl is optionally substituted with one or more substituents each
independently selected from (C1-C6) alkyl, -NH2, (C1-C6) mino, (C1-C6) dialkylamino,
and -OH, and wherein the (C1-C6) alkyl is optionally substituted with one or more R”,
n R“ is (C1-C6) alkoxy, -OH, -NH2, (C1-C6) mino, (C1-C6) dialkylamino, 5— or 6-
membered heteroaryl comprising 1 to 3 heteroatoms selected from N, O, or S, or 4- to 7-
membered heterocycloalkyl comprising 1 to 3 heteroatoms selected from N, O, or S, wherein
the heterocycloalkyl is optionally substituted with one or more substituents each
independently ed from ) alkyl and OH, and n is 1.
In another embodiment, L is —C(O)NR5- wherein R5 is H, A is pyridinyl
optionally substituted with one or more R4, wherein R4 is —CF3, R1 is H, R3 is methyl, R2 is —
C(O)NR9R10, wherein R9 is methyl and R10 is (C3-C7) cycloalkyl, wherein the cycloalkyl is
optionally substituted with one or more substituents each independently selected from (C1-
C6) alkyl, -NH2, (C1-C6) alkylamino, (C1-C6) dialkylamino, and -OH, and n is 1.
In another embodiment, L is —C(O)NR5- wherein R5 is H, A is pyridinyl
optionally substituted with one or more R4, wherein R4 is —CF3, R1 is H, R3 is methyl, R2 is —
C(O)NR9R10 wherein R9 is methyl and R10 is cyclohexyl, wherein the cyclohexyl is
ally tuted with one or more substituents each independently ed from (C1-
C6) alkyl, -NH2, (C1-C6) alkylamino, (C1-C6) dialkylamino, and -OH, and n is 1. In another
embodiment, R10 is cyclohexyl, wherein the cyclohexyl is substituted with -OH. In another
embodiment, R10 is cyclohexyl, wherein the cyclohexyl is substituted with -NH2.
In another embodiment, L is —C(O)NR5- wherein R5 is H, A is pyridinyl
optionally substituted with one or more R4, wherein R4 is —CF3, R1 is H, R3 is methyl, R2 is —
9R10, wherein R9 is methyl and R10 is 4 to 7-membered heterocycloalkyl comprising
1 to 3 heteroatoms ed from N, O, or S, wherein the heterocycloalkyl is optionally
substituted with one or more substituents each independently ed from (C1-C6) alkyl, -
NH2, (C1-C6) alkylamino, ) dialkylamino, and -OH, and n is 1.
In another embodiment, L is —C(O)NR5- wherein R5 is H, A is pyridinyl
optionally substituted with one or more R4, wherein R4 is —CF3, R1 is H, R3 is methyl, R2 is —
C(O)NR9R10 wherein R9 is methyl and R10 is piperidinyl, n the piperidinyl is
optionally substituted with one or more substituents each independently selected from (C1-
C6) alkyl, -NH2, (C1-C6) alkylamino, (C1-C6) dialkylamino, and —OH, and n is 1. In another
embodiment, R10 is piperidinyl, wherein the piperidinyl is substituted with methyl. In another
embodiment, R10 is azetidinyl, wherein the azetidinyl is substituted with methyl.
In another ment, L is —C(O)NR5-, wherein R5 is H, A is pyridinyl
optionally substituted with one or more R4, n R4 is —CF3, R1 is H, R2 is —C(O)NR9R10,
R3 is , R9 and R10 together with the nitrogen atom to which they are attached form a 4-
to 7-membered heterocycloalkyl ring comprising 1 to 3 heteroatom selected from N, O, and
S, ally substituted with one or more substituent each independently selected from (C1-
C6) alkyl, (C1-C6) hydroxyalkyl, -(CH2)q-NH2, -(CH2)q-(C1-C6) alkylamino, -(CH2)q-(C1-C6)
dialkylamino, -C(O)(C1-C6) alkyl, -OH, and 4- to 7-membered heterocycloalkyl comprising 1
to 3 heteroatom selected from N, O, and S, and optionally substituted with one or more (C1-
C6) alkyl, and n is 1. In another embodiment, R9 and R10 together with the nitrogen atom to
which they are attached form an azetidine ring, wherein the azetidine ring is substituted with
methyl. In r embodiment, R9 and R10 together with the en atom to which they
are attached form a pyrrolidine ring, wherein the pyrrolidine ring is substituted with
dimethylamino.
In another embodiment, L is —C(O)NR5-, wherein R5 is H, A is pyridinyl
optionally substituted with one or more R4, wherein R4 is —CF3, R1 is H, R2 is R9R10,
R3 is methyl, R9 and R10 together with the nitrogen atom to which they are attached form a
piperazine ring, optionally substituted with one or more substituent each independently
selected from (C1-C6) alkyl, (C1-C6) hydroxyalkyl, -(CH2)q-NH2, -(CH2)q-(C1-C6)
alkylamino, -(CH2)q-(C1-C6) dialkylamino, -C(O)(C1-C6) alkyl, -OH, and 4- to 7-membered
heterocycloalkyl comprising 1 to 3 heteroatom selected from N, O, and S, and optionally
substituted with one or more ) alkyl, and n is 1. In another embodiment, R9 and R10
together with the en atom to which they are attached form a piperazine ring. In another
embodiment, R9 and R10 together with the en atom to which they are ed form a
zine ring, wherein the piperazine ring is substituted with methyl. In another
embodiment, R9 and R10 together with the nitrogen atom to which they are attached form a
piperazine ring, wherein the piperazine ring is substituted with hydroxyethyl. In another
embodiment, R9 and R10 together with the nitrogen atom to which they are attached form a
piperazine ring, n the piperazine ring is substituted with C(O)CH3.
In another embodiment, L is —C(O)NR5-, wherein R5 is H, A is pyridinyl
optionally substituted with one or more R4, wherein R4 is —CF3, R1 is H, R2 is R9R10,
R3 is methyl, R9 and R10 er with the nitrogen atom to which they are attached form a
piperidine ring, optionally substituted with one or more substituent each independently
selected from (C1-C6) alkyl, (C1-C6) hydroxyalkyl, -(CH2)q-NH2, -(CH2)q-(C1-C6)
mino, -(CH2)q-(C1-C6) dialkylamino, -C(O)(C1-C6) alkyl, -OH, and 4- to 7-membered
heterocycloalkyl sing 1 to 3 heteroatom selected from N, O, and S, and ally
substituted with one or more (C1-C6) alkyl, and n is 1. In another embodiment, R9 and R10
together with the en atom to which they are attached form a piperidine ring, n the
piperidine ring is substituted with methyl. In another embodiment, R9 and R10 together with
the nitrogen atom to which they are ed form a piperidine ring, n the piperidine
ring is substituted with N-methylpiperazine.
In another embodiment, L is —C(O)NR5-, wherein R5 is H, A is pyridinyl
optionally substituted with one or more R4, wherein R4 is —CF3, R1 is H, R2 is —C(O)NR9R10,
R3 is methyl, R9 and R10 together with the nitrogen atom to which they are attached form a
morpholine ring, optionally substituted with one or more substituent each independently
ed from (C1-C6) alkyl, (C1-C6) hydroxyalkyl, -(CH2)q-NH2, -(CH2)q-(C1-C6)
alkylamino, -(CH2)q-(C1-C6) dialkylamino, -C(O)(C1-C6) alkyl, -OH, and 4- to 7-membered
cycloalkyl comprising 1 to 3 atom selected from N, O, and S, and optionally
substituted with one or more (C1-C6) alkyl, and n is 1. In another embodiment, R9 and R10
together with the nitrogen atom to which they are attached form a morpholine ring. In
another embodiment, R9 and R10 together with the nitrogen atom to which they are attached
form a morpholine ring, wherein the morpholine ring is substituted with -(CH2)q-(C1-C6)
dialkylamino, wherein q is l and the -(CH2)q-(C1-C6) dialkylamino is —CH2N(CH3)2.
In another embodiment, L is —C(O)NR5- wherein R5 is H, A is
7 pyridinyl
optionally substituted with one or more R4, wherein R4 is —CF3, R1 is H, R2 is (C1-C6) alkyl, -
C(O)Rg, or —C(O)NR9R10, R3 is fluoro, R8 is (C1-C6) alkyl, (C3-C7) cycloalkyl, (Cz—Cé)
alkenyl, (C1-C3) , (C1-C6) haloalkyl, (C1-C6) haloalkoxy, or 4 to 7-membered
heterocycloalkyl comprising 1 to 3 heteroatoms selected from N, O, and S, R9 is H, (C1-C6)
alkyl, (C1-C6) kyl, (C3-C7) cycloalkyl, or 4 to 7-membered heterocycloalkyl comprising
1 to 3 heteroatoms selected from N, O, or S, R10 is H, (C1-C6) alkyl, (C1-C6) haloalkyl, (C3-
C7) cycloalkyl, or 4 to 7-membered heterocycloalkyl sing 1 to 3 heteroatoms selected
from N, O, or S, wherein the lkyl or cycloalkyl is optionally substituted with one
or more substituents each independently selected from (C1-C6) alkyl, -NH2, (C1-C6)
alkylamino, (C1-C6) dialkylamino, and -OH, and wherein the ) alkyl is optionally
substituted with one or more R”, or R9 and R10 together with the nitrogen atom to which they
are attached form a 4- to 7-membered heterocycloalkyl ring comprising 1 to 3 heteroatom
ed from N, O, and S, optionally tuted with one or more substituent each
independently selected from (C1-C6) alkyl, (C1-C6) hydroxyalkyl, -(CH2)q-NH2, -(CH2)q-(C1-
C6) alkylamino, -(CH2)q-(C1-C6) dialkylamino, -C(O)(C1-C6) alkyl, -OH, and 4- to 7-
membered heterocycloalkyl comprising 1 to 3 atom selected from N, O, and S, and
optionally substituted with one or more (C1-C6) alkyl, R11 is (C1-C6) alkoxy, -OH, -NH2, (C1-
C6) alkylamino, (C1-C6) lamino, 5- or 6- membered aryl comprising 1 to 3
heteroatoms selected from N, O, or S, or 4- to 7-membered cycloalkyl comprising 1 to
3 heteroatoms selected from N, O, or S, wherein the heterocycloalkyl is optionally substituted
with one or more substituents each independently selected from (C1-C6) alkyl and OH, and n
is 1.
In another embodiment, L is —C(O)NR5-, wherein R5 is H, A is nyl
optionally substituted with one or more R4, wherein R4 is —CF3, R1 is H, R3 is fluoro, R2 is —
C(O)NR9R10, wherein R9 is H and R10 is H or (C1-C6) alkyl, wherein the (C1-C6) alkyl is
optionally substituted with one or more R”, wherein R11 is (C1-C6) alkoxy, -OH, -NH2, (C1-
C6) alkylamino, (C1-C6) dialkylamino, 5- or 6- membered heteroaryl comprising 1 to 3
heteroatoms selected from N, O, or S, or 4- to 7-membered heterocycloalkyl comprising 1 to
3 heteroatoms selected from N, O, or S, wherein the heterocycloalkyl is optionally substituted
with one or more substituents each independently selected from (C1-C6) alkyl and OH, and n
is 1.
In another embodiment, L is —C(O)NR5-, n R5 is H, A is pyridinyl
optionally substituted with one or more R4, wherein R4 is —CF3, R1 is H, R3 is fluoro, R2 is —
C(O)NR9R10, wherein R9 is H and R10 is H or (C1-C6) alkyl, and n is 1. In another
embodiment, R10 is H. In r embodiment, R10 is methyl.
In another embodiment, L is —C(O)NR5-, wherein R5 is H, A is pyridinyl
optionally substituted with one or more R4, wherein R4 is —CF3, R1 is H, R2 is ) alkyl, -
C(O)Rg, or —C(O)NR9R10, R8 is ) alkyl, ) lkyl, (oz—c6) alkenyl, (C1-C3)
alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, or 4 to 7-membered heterocycloalkyl
comprising 1 to 3 heteroatoms selected from N, O, and S, R9 is H, (C1-C6) alkyl, (C1-C6)
haloalkyl, (C3-C7) cycloalkyl, or 4 to ered heterocycloalkyl comprising 1 to 3
heteroatoms selected from N, O, or S, R10 is H, (C1-C6) alkyl, ) haloalkyl, (C3-C7)
cycloalkyl, or 4 to 7-membered heterocycloalkyl comprising 1 to 3 heteroatoms selected from
N, O, or S, wherein the cycloalkyl or cycloalkyl is optionally substituted with one or
more substituents each independently selected from (C1-C6) alkyl, -NH2, (C1-C6) alkylamino,
(C1-C6) dialkylamino, and -OH, and wherein the ) alkyl is optionally substituted with
one or more R”, or R9 and R10 together with the nitrogen atom to which they are attached
form a 4- to 7-membered heterocycloalkyl ring comprising 1 to 3 heteroatom selected from
N, O, and S, optionally substituted with one or more substituent each ndently selected
from (C1-C6) alkyl, (C1-C6) hydroxyalkyl, -(CH2)q-NH2, -(CH2)q-(C1-C6) mino, -
(CH2)q-(C1-C6) dialkylamino, -C(O)(C1-C6) alkyl, -OH, and 4- to 7-membered
heterocycloalkyl comprising 1 to 3 heteroatom selected from N, O, and S, and ally
substituted with one or more (C1-C6) alkyl, R11 is (C1-C6) alkoxy, -OH, -NH2, (C1-C6)
alkylamino, (C1-C6) dialkylamino, 5- or 6- membered heteroaryl comprising 1 to 3
heteroatoms ed from N, O, or S, or 4- to 7-membered heterocycloalkyl comprising 1 to
3 heteroatoms selected from N, O, or S, wherein the heterocycloalkyl is optionally substituted
with one or more substituents each independently selected from (C1-C6) alkyl and OH, and n
is 0.
In another embodiment, L is —C(O)NR5-, n R5 is H, A is pyridinyl
ally substituted with one or more R4, wherein R4 is —CF3, R1 is H, R2 is —C(O)NR9R10,
wherein R9 is H and R10 is H or (C1-C6) alkyl, wherein the (C1-C6) alkyl is optionally
substituted with one or more R”, wherein R11 is (C1-C6) alkoxy, -OH, -NH2, (C1-C6)
mino, (C1-C6) dialkylamino, 5- or 6- membered aryl comprising 1 to 3
heteroatoms selected from N, O, or S, or 4- to 7-membered cycloalkyl comprising 1 to
3 heteroatoms selected from N, O, or S, n the heterocycloalkyl is optionally substituted
with one or more substituents each independently selected from (C1-C6) alkyl and OH, and n
is 0.
In another embodiment, L is —C(O)NR5-, wherein R5 is H, A is pyridinyl
optionally substituted with one or more R4, wherein R4 is —CF3, R1 is H, R2 is —C(O)NR9R10,
wherein R9 is H and R10 is (C1-C6) alkyl, and n is O. In another embodiment, L is —C(O)NR5-
wherein R5 is H, A is pyridinyl optionally substituted with one or more R4, wherein R4 is —
CF3, R1 is H, R2 is —C(O)NR9R10, wherein R9 is H and R10 is methyl, and n is 0.
In another embodiment, L is —C(O)NR5-, wherein R5 is H, A is phenyl optionally
substituted with one or more R4, wherein R4 is (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6)
kyl, (C1-C6) haloalkoxy, halogen, -OH, CN, -(C(R6)2)p-heterocycloalkyl wherein the
heterocycloalkyl ses a 4- to 7-membered ring and l to 3 heteroatoms selected from N,
O, and S or -(C(R6)2)p-heteroaryl wherein the heteroaryl comprises a 5- or 6-membered ring
and l to 3 atoms selected from N, O, and S, and wherein the heterocycloalkyl or
heteroaryl is optionally substituted with one or more tuents each independently selected
from (C1-C6) alkyl, -NH2, (C1-C6) mino, and (C1-C6) dialkylamino, R1 is H, R2 is (c1—
C6) alkyl, -C(O)Rg, or R9R10, R3 is methyl, R8 is (C1-C6) alkyl, ) cycloalkyl,
(C2-C6) alkenyl, (C1-C3) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, or 4 to 7-membered
heterocycloalkyl comprising 1 to 3 heteroatoms selected from N, O, and S, R9 is H, (C1-C6)
alkyl, (C1-C6) haloalkyl, ) cycloalkyl, or 4 to 7-membered heterocycloalkyl comprising
1 to 3 heteroatoms selected from N, O, or S, R10 is H, (C1-C6) alkyl, (C1-C6) haloalkyl, (C3-
C7) cycloalkyl, or 4 to 7-membered heterocycloalkyl comprising 1 to 3 heteroatoms selected
from N, O, or S, wherein the cycloalkyl or heterocycloalkyl is optionally substituted with one
or more substituents each independently selected from (C1-C6) alkyl, -NH2, (C1-C6)
alkylamino, ) dialkylamino, and -OH, and wherein the (C1-C6) alkyl is optionally
tuted with one or more R”, or R9 and R10 together with the nitrogen atom to which they
are attached form a 4- to 7-membered heterocycloalkyl ring comprising 1 to 3 heteroatom
selected from N, O, and S, optionally substituted with one or more substituent each
independently selected from (C1-C6) alkyl, (C1-C6) hydroxyalkyl, -(CH2)q-NH2, -(CH2)q-(C1-
C6) alkylamino, -(CH2)q-(C1-C6) dialkylamino, -C(O)(C1-C6) alkyl, -OH, and 4- to 7-
membered heterocycloalkyl comprising 1 to 3 heteroatom selected from N, O, and S, and
ally substituted with one or more (C1-C6) alkyl, R11 is (C1-C6) alkoxy, -OH, -NH2, (C1-
C6) alkylamino, ) dialkylamino, 5- or 6- membered aryl comprising 1 to 3
heteroatoms selected from N, O, or S, or 4- to ered heterocycloalkyl comprising 1 to
3 heteroatoms ed from N, O, or S, wherein the cycloalkyl is optionally substituted
with one or more substituents each independently selected from (C1-C6) alkyl and OH, and n
is 1.
In another embodiment, L is —C(O)NR5-, wherein R5 is H, A is phenyl ally
substituted with one or more R4, wherein R4 is (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6)
haloalkyl, (C1-C6) haloalkoxy, halogen, -OH, CN, -(C(R6)2)p-heterocycloalkyl wherein the
heterocycloalkyl comprises a 4- to 7-membered ring and l to 3 heteroatoms selected from N,
O, and S or -(C(R6)2)p-heteroaryl n the heteroaryl comprises a 5- or 6-membered ring
and l to 3 heteroatoms selected from N, O, and S, and wherein the heterocycloalkyl or
heteroaryl is optionally substituted with one or more substituents each independently ed
from (C1-C6) alkyl, -NH2, (C1-C6) alkylamino, and (C1-C6) dialkylamino, R1 is H, R2 is —
C(O)Rg, R3 is methyl, R8 is (C1-C6) alkyl, (C3-C7) lkyl, (C2-C6) alkenyl, (C1-C3)
alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, or 4 to 7-membered heterocycloalkyl
comprising 1 to 3 heteroatoms selected from N, O, and S, and n is 1.
In another embodiment, L is —C(O)NR5-, wherein R5 is H, A is phenyl optionally
substituted with one or more R4, n R4 is selected from —CF3 and —CH2-N-
methylpiperazinyl, R1 is H, R2 is g, R3 is methyl, R8 is (C1-C6) alkyl, (C3-C7)
cycloalkyl, or (C1-C3) alkoxy, and n is 1.
In another embodiment, L is —C(O)NR5-, n R5 is H, A is phenyl ally
substituted with one or more R4, wherein R4 is selected from —CF3 and —CH2-N-
methylpiperazinyl, R1 is H, R2 is -C(O)Rg, R3 is methyl, R8 is (C3-C7) cycloalkyl, and n is 1.
In another embodiment, R8 is cyclopropyl.
In another embodiment, L is —C(O)NR5-, wherein R5 is H, A is phenyl optionally
substituted with one or more R4, wherein R4 is (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6)
haloalkyl, (C1-C6) haloalkoxy, halogen, -OH, CN, -(C(R6)2)p-heterocycloalkyl n the
cycloalkyl ses a 4- to 7-membered ring and 1 to 3 heteroatoms selected from N,
O, and S or -(C(R6)2)p-heteroaryl wherein the heteroaryl comprises a 5- or 6-membered ring
and 1 to 3 heteroatoms selected from N, O, and S, and wherein the heterocycloalkyl or
heteroaryl is optionally substituted with one or more substituents each independently selected
from (C1-C6) alkyl, -NH2, (C1-C6) alkylamino, and (C1-C6) dialkylamino, R1 is H, R3 is
methyl, R2 is R9R10, wherein R9 is H, (C1-C6) alkyl, ) haloalkyl, )
cycloalkyl, or 4 to 7-membered heterocycloalkyl comprising 1 to 3 heteroatoms selected from
N, 0, or s, R10 is H, (C1-C6) alkyl, (C1-C6)haloa1ky1, (C3-C7) cycloalkyl, or 4 to 7-membered
heterocycloalkyl comprising 1 to 3 heteroatoms selected from N, O, or S, wherein the
cycloalkyl or heterocycloalkyl is optionally substituted with one or more substituents each
independently selected from (C1-C6) alkyl, -NH2, (C1-C6) alkylamino, ) dialkylamino,
and -OH, and wherein the (C1-C6) alkyl is optionally substituted with one or more R”,
wherein R“ is (C1-C6) alkoxy, -OH, -NH2, (C1-C6) alkylamino, (C1-C6) dialkylamino, 5— or 6-
ed heteroaryl comprising 1 to 3 heteroatoms selected from N, O, or S, or 4- to 7-
membered cycloalkyl comprising 1 to 3 heteroatoms selected from N, O, or S, wherein
the heterocycloalkyl is optionally substituted with one or more substituents each
independently selected from (C1-C6) alkyl and OH, and n is 1.
In another embodiment, L is —C(O)NR5-, wherein R5 is H, A is phenyl ally
substituted with one or more R4, wherein R4 is (C1-C6) alkyl, ) alkoxy, (C1-C6)
haloalkyl, (C1-C6) haloalkoxy, halogen, -OH, CN, -(C(R6)2)p-heterocycloalkyl wherein the
heterocycloalkyl comprises a 4- to 7-membered ring and 1 to 3 heteroatoms selected from N,
O, and S or -(C(R6)2)p-heteroaryl wherein the heteroaryl ses a 5- or 6-membered ring
and 1 to 3 heteroatoms selected from N, O, and S, and wherein the heterocycloalkyl or
heteroaryl is optionally substituted with one or more substituents each independently selected
from (C1-C6) alkyl, -NH2, (C1-C6) alkylamino, and (C1-C6) dialkylamino, R1 is H, R3 is
methyl, R2 is —C(O)NR9R10, wherein R9 is methyl and R10 is (C1-C6) alkyl, wherein the (C1-
C6) alkyl is optionally substituted with one or more R”, wherein R11 is (C1-C6) alkoxy, -OH,
-NH2, (C1-C6) alkylamino, (C1-C6) lamino, 5- or 6- membered heteroaryl comprising 1
to 3 heteroatoms selected from N, O, or S, or 4- to 7-membered heterocycloalkyl comprising
1 to 3 heteroatoms selected from N, O, or S, wherein the heterocycloalkyl is optionally
substituted with one or more substituents each independently ed from (C1-C6) alkyl and
OH, and n is 1.
In r embodiment, L is —C(O)NR5-, wherein R5 is H, A is phenyl optionally
substituted with one or more R4, n R4 is selected from —CF3, CN, methoxy, and -
(C(R6)2)p-heterocycloalkyl, wherein p is 1 and -(C(R6)2)p-heterocycloalkyl is CH2-
pyrrolidinyl, R1 is H, R3 is methyl, R2 is —C(O)NR9R10, wherein R9 is methyl and R10 is (C1-
C6) alkyl, wherein the (C1-C6) alkyl is optionally substituted with one or more R”, wherein
R“ is ) alkoxy, -OH, -NH2, (C1-C6) alkylamino, (C1-C6) dialkylamino, 5— or 6-
membered heteroaryl comprising 1 to 3 atoms selected from N, O, or S, or 4- to 7-
membered cycloalkyl comprising 1 to 3 heteroatoms selected from N, O, or S, wherein
the heterocycloalkyl is optionally substituted with one or more substituents each
independently ed from (C1-C6) alkyl and OH, and n is 1.
In another embodiment, L is —C(O)NR5-, wherein R5 is H, A is phenyl optionally
substituted with one or more R4, wherein R4 is selected from —CF3, CN, methoxy, and -
(C(R6)2)p-heterocycloalkyl, n p is 1 and -(C(R6)2)p-heterocycloalkyl is CH2-
pyrrolidinyl, R1 is H, R3 is methyl, R2 is R9R10, wherein R9 is methyl and R10 is ethyl,
wherein the ethyl is optionally tuted with one or more R”, wherein R11 is methoxy, and
n is 1. In another embodiment, R4 is selected from —CF3 and yrrolidinyl. In another
embodiment, R4 is selected from —CF3 and methoxy. In another embodiment, R4 is selected
from —CF3 and —CN.
In another embodiment, L is — NR5C(O)-, wherein R5 is H, A is phenyl optionally
substituted with one or more R4, wherein R4 is —OCF3, R1 is H, R3 is methyl, R2 is —
C(O)NR9R10, wherein R9 is methyl and R10 is methyl, and n is 1.
In r embodiment, L is —NR5C(O)-, wherein R5 is H, A is pyridinyl
optionally substituted with one or more R4, wherein R4 is —CF3, R1 is H, R2 is (C1-C6) alkyl, -
C(O)Rg, or —C(O)NR9R10, R3 is methyl, R8 is ) alkyl, (C3-C7) cycloalkyl, (C2-C6)
alkenyl, (C1-C3) alkoxy, ) haloalkyl, (C1-C6) haloalkoxy, or 4 to 7-membered
heterocycloalkyl comprising 1 to 3 heteroatoms selected from N, O, and S, R9 is H, )
alkyl, (C1-C6) haloalkyl, (C3-C7) cycloalkyl, or 4 to 7-membered heterocycloalkyl comprising
l to 3 heteroatoms selected from N, O, or S, R10 is H, (C1-C6) alkyl, (C1-C6) haloalkyl, (C3-
C7) lkyl, or 4 to 7-membered heterocycloalkyl comprising 1 to 3 heteroatoms selected
from N, O, or S, wherein the cycloalkyl or heterocycloalkyl is optionally substituted with one
or more substituents each ndently selected from (C1-C6) alkyl, -NH2, (C1-C6)
alkylamino, (C1-C6) dialkylamino, and -OH, and wherein the (C1-C6) alkyl is optionally
substituted with one or more R”, or R9 and R10 together with the nitrogen atom to which they
are attached form a 4- to 7-membered heterocycloalkyl ring sing 1 to 3 atom
selected from N, O, and S, optionally substituted with one or more substituent each
independently ed from (C1-C6) alkyl, (C1-C6) hydroxyalkyl, -(CH2)q-NH2, -(CH2)q-(C1-
C6) alkylamino, -(CH2)q-(C1-C6) dialkylamino, C1-C6) alkyl, -OH, and 4- to 7-
membered heterocycloalkyl comprising 1 to 3 heteroatom selected from N, O, and S, and
optionally substituted with one or more (C1-C6) alkyl, R11 is (C1-C6) alkoxy, -OH, -NH2, (C1-
C6) alkylamino, (C1-C6) dialkylamino, 5- or 6- membered heteroaryl comprising 1 to 3
atoms selected from N, O, or S, or 4- to 7-membered heterocycloalkyl comprising 1 to
3 heteroatoms selected from N, O, or S, wherein the heterocycloalkyl is optionally substituted
with one or more substituents each independently selected from (C1-C6) alkyl and OH, and n
is 1.
In another embodiment, L is —NR5C(O)-, wherein R5 is H, A is pyridinyl
optionally tuted with one or more R4, wherein R4 is —CF3, R1 is H, R3 is methyl, R2 is —
C(O)NR9R10, wherein R9 is methyl and R10 is H, (C1-C6) alkyl, ) haloalkyl, (C3-C7)
cycloalkyl, or 4 to 7-membered heterocycloalkyl comprising 1 to 3 heteroatoms selected from
N, O, or S, wherein the cycloalkyl or heterocycloalkyl is optionally substituted with one or
more substituents each independently selected from (C1-C6) alkyl, -NH2, (C1-C6) alkylamino,
(C1-C6) dialkylamino, and -OH, and wherein the (C1-C6) alkyl is optionally substituted with
one or more R11 wherein R11 is (C1-C6) alkoxy, -OH, -NH2, (C1-C6) alkylamino, (C1-C6)
lamino, 5- or 6- membered heteroaryl sing 1 to 3 heteroatoms selected from N,
O, or S, or 4- to 7-membered heterocycloalkyl comprising 1 to 3 heteroatoms ed from
N, O, or S, wherein the heterocycloalkyl is optionally substituted with one or more
substituents each independently selected from ) alkyl and OH, and n is 1. In another
embodiment, R10 is H.
In another embodiment, L is —NR5C(O)-, wherein R5 is H, A is pyridinyl
optionally substituted with one or more R4, wherein R4 is —CF3, R1 is H, R3 is , R2 is —
C(O)NR9R10, wherein R9 is methyl and R10 is 4 to 7-membered heterocycloalkyl sing
1 to 3 heteroatoms selected from N, O, or S, wherein the heterocycloalkyl is optionally
substituted with one or more substituents each independently selected from (C1-C6) alkyl, -
NH2, (C1-C6) alkylamino, (C1-C6) dialkylamino, and -OH, and n is 1. In another
embodiment, R10 is N-methylpiperidinyl.
In r embodiment, L is O)-, wherein R5 is H, A is pyridinyl
substituted with one or more R4, wherein R4 is —CF3, R1 is H, R3 is methyl, R2 is —
C(O)NR9R10, wherein R9 is H and R10 is H, methyl, ethyl, propyl, n-butyl, isobutyl, or
cyclopropyl, wherein the methyl, ethyl, propyl, n-butyl, or isobutyl is optionally substituted
with one or more R“, wherein R“ is (C1-C6) alkoxy, -OH, -NH2, (C1-C6) alkylamino, (C1-C6)
dialkylamino, 5- or 6- membered heteroaryl comprising 1 to 3 heteroatoms selected from N,
O, or S, or 4- to 7-membered heterocycloalkyl comprising 1 to 3 atoms selected from
N, O, or S, wherein the heterocycloalkyl is optionally tuted with one or more
substituents each independently selected from (C1-C6) alkyl and OH, and n is 1.
In another embodiment, L is —NR5C(O)-, n R5 is H, A is pyridinyl
substituted with one or more R4, wherein R4 is —CF3, R1 is H, R3 is methyl, R2 is —
C(O)NR9R10, wherein R9 is H and R10 is ethyl, wherein ethyl is optionally substituted with
one or more R”, wherein R11 is (C1-C6) alkoxy, -OH, -NH2, (C1-C6) alkylamino, (C1-C6)
dialkylamino, 5- or 6- membered heteroaryl sing 1 to 3 heteroatoms selected from N,
O, or S, or 4- to 7-membered heterocycloalkyl sing 1 to 3 heteroatoms selected from
N, O, or S, wherein the cycloalkyl is optionally substituted with one or more
substituents each independently ed from (C1-C6) alkyl and OH, and n is 1. In another
embodiment, R11 is y. In r embodiment, R11 is N-piperazinyl. In another
embodiment, R11 is -OH.
In another embodiment, L is —NR5C(O)-, wherein R5 is H, A is pyridinyl
substituted with one or more R4, wherein R4 is —CF3, R1 is H, R3 is methyl, R2 is —
C(O)NR9R10, wherein R9 is H and R10 is ethyl, wherein ethyl is optionally substituted with
one or more RH, n R11 is (C1-C6) dialkylamino, and n is 1. In another embodiment,
R11 is dimethylamino. In another embodiment, R11 is diethylamino.
In another ment, L is —NR5C(O)-, n R5 is H, A is pyridinyl
substituted with one or more R4, wherein R4 is —CF3, R1 is H, R3 is (C1-C6) alkyl, (C1-C6)
alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, halogen, or OH,, R2 is —C(O)NR9R10, n
R9 is H and R10 is ethyl, wherein the ethyl is optionally substituted with one or more R”,
wherein R11 is methoxy, and n is O or 1.
In another embodiment, L is —NR5C(O)-, wherein R5 is H, A is pyridinyl
substituted with one or more R4, wherein R4 is —CF3, R1 is H, R3 is fluoro, R2 is —
C(O)NR9R10, wherein R9 is H and R10 is ethyl, wherein the ethyl is optionally substituted
with one or more RH, wherein R11 is methoxy, and n is 1.
] In r embodiment, L is —NR5C(O)-, wherein R5 is H, A is pyridinyl
substituted with one or more R4, wherein R4 is —CF3, R1 is H, R2 is —C(O)NR9R10, wherein R9
is H and R10 is ethyl, wherein the ethyl is optionally substituted with one or more R”,
wherein R11 is methoxy, and n is 0.
miting illustrative compounds of the invention include:
3 -((2-(3 ,3 -dimethylureido)thiazol-S -yl)ethynyl)methyl-N-(4-(trifluoromethyl)pyridin
yl)benzamide (I— 1),
4-methyl-N-(4-(trifluoromethyl)pyridinyl)-3 -((2-ureidothiazol-5 -yl)ethynyl)benzamide (1-
methyl (5 -((2-methyl -5 -((4-(trifluoromethyl)pyri dinyl)carbamoyl)phenyl)ethynyl)thiazol -
2-yl)carbamate (1-3),
4-methyl-3 -((2-(3 -methylureido)thiazol-5 -yl)ethynyl)-N-(4-(trifluoromethyl)pyridin
yl)benzamide (1-4),
3 -((2-(3 -(2-methoxyethyl)ureido)thiazol -5 -yl)ethynyl)methyl -N-(4-
(trifluoromethyl)pyridinyl)benzamide (1-5),
4-methyl-3 3 -(2-morpholinoethyl)ureido)thiazol-S -yl)ethynyl)-N-(4-
(trifluoromethyl)pyridinyl)benzamide (1-6),
3 -((2-(3 -(2-methoxyethyl)-3 -methylureido)thiazol -5 -yl)ethynyl)methyl-N-(4-
(trifluoromethyl)pyridinyl)benzamide (1-7),
3 -((2-(3 -3 -methylureido)thiazol-5 -yl)ethynyl)methyl-N-(4-(trifluoromethyl)pyridin-
2-yl)benzamide (1-8),
3 -((2-(3 -(2-(dimethylamino)ethyl)-3 -methylureido)thiazol-5 -yl)ethynyl)methyl-N-(4-
(trifluoromethyl)pyridinyl)benzamide (1-9),
3 -((2-(3 -(2-hydroxyethyl)-3 lureido)thiazol -5 -yl)ethynyl)methyl-N-(4-
(trifluoromethyl)pyridinyl)benzamide (I— 1 0),
3 -((2-(3 -(2-(dimethylamino)ethyl)ureido)thiazol -5 hynyl)methyl-N-(4-
(trifluoromethyl)pyridinyl)benzamide (I— 1 1),
4-methyl-3 -((2-(3 -(2-(pyrrolidin- l hyl)ureido)thiazol-5 -yl)ethynyl)-N-(4-
(trifluoromethyl)pyridin-Z-yl)benzamide (1-12);
4-methyl-3 -((2-(3 -(( l -methylpiperidinyl)methyl)ureido)thiazol-S -yl)ethynyl)-N-(4-
(trifluoromethyl)pyridinyl)benzamide (I— 13);
4-methyl-3 -((2-(3 -(2-(4-methylpiperazin- l -yl)ethyl)ureido)thiazol-5 -yl)ethynyl)-N-(4-
(trifluoromethyl)pyridinyl)benzamide (I— 1 4);
3 -((2-(3 -(2-hydroxymethylpropyl)ureido)thiazol -5 -yl)ethynyl)methyl-N-(4-
(trifluoromethyl)pyridinyl)benzamide (I— 1 5);
4-methyl-3 -((2-(3 -methyl -3 -(2-(4-methylpiperazin- l -yl)ethyl)ureido)thiazol-S -yl)ethynyl)-N-
(4-(trifluoromethyl)pyridinyl)benzamide (I— 1 6);
3 -((2-(3 propylureido)thiazol-5 -yl)ethynyl)methyl-N-(4-(trifluoromethyl)pyridin
yl)benzamide (I— 1 7);
3 -((2-(3 -(2-(3 -hydroxypyrrolidin- l -yl)ethyl)ureido)thiazol -5 -yl)ethynyl)methyl-N-(4-
(trifluoromethyl)pyridinyl)benzamide (I— 1 8);
4-methyl-3 -((2-(3 -methyl -3 -(2-(pyrrolidin- l -yl)ethyl)ureido)thiazol -5 -yl)ethynyl)-N-(4-
oromethyl)pyridinyl)benzamide (1-1 9);
4-methyl-3 -((2-(3 -methyl -3 -((l -methylpyrrolidinyl)methyl)ureido)thiazol -5 -yl)ethynyl )-
N—(4-(trifluoromethyl)pyridin-Z-yl)benzamide (1-20);
3 -((2-(3 droxymethylpropyl)-3 -methylureido)thiazol -5 -yl)ethynyl)methyl-N-(4-
(trifluoromethyl)pyridinyl)benzamide (1-2 1);
3 -((2-(3 -(4-hydroxycyclohexyl)-3 -methylureido)thiazol-5 -yl)ethynyl)methyl-N-(4-
(trifluoromethyl)pyridinyl)benzamide (1-22);
yl-N—(5-((2-methyl((4-(trifluoromethyl)pyridin
yl)carbamoyl)phenyl)ethynyl)thiazolyl)piperazine- l xamide (1-23);
3 -hydroxy-3 -methyl-N—(5-((2-methyl-5 -((4-(trifluoromethyl)pyridin
yl)carbamoyl)phenyl)ethynyl)thiazolyl)azetidine- l -carboxamide (1-24);
4-methyl-N—(5-((2-methyl((4-(trifluoromethyl)pyridin
yl)carbamoyl)phenyl)ethynyl)thiazolyl)piperidine- l xamide (1-25);
4-methy1-3 -((2-(3 -(pyridiny1methyl)ureido)thiazol-5 -y1)ethyny1)—N—(4-
(trifluoromethyl)pyridin-Z-yl)benzamide (1-26);
4-(2-hydroxyethyl)-N—(5-((2-methy1((4-(trifluoromethyl)pyridin
yl)carbamoyl)pheny1)ethyny1)thiazoly1)piperazine-1 -carboxamide (1-27);
4-methy1-3 -((2-(3 -methy1-3 ethy1amino)ethy1)ureido)thiazol-5 -y1)ethyny1)-N—(4-
(trifluoromethyl)pyridin-Z-yl)benzamide (1-28);
4-methy1-3 -((2-(3 -methy1-3 -(1-methy1piperidiny1)ureido)thiazoly1)ethyny1)—N—(4-
(trifluoromethyl)pyridin-Z-yl)benzamide (1-29);
(2-methy1((4-(trifluoromethy1)pyridiny1)carbamoyl)pheny1)ethyny1)thiazol
y1)piperazinecarboxamide (1-30);
3 -((2-(3 -(4-aminobuty1)ureido)thiazol-S -y1)ethyny1)methy1-N-(4-(trifluoromethyl)pyridin-
2-y1)benzamide (1-31);
4-methy1-3 -((2-(3 -methy1-3 -(1 -methy1piperidin-3 -y1)ureido)thiazol-5 -y1)ethyny1)—N—(4-
(trifluoromethyl)pyridin-Z-yl)benzamide (1-32);
3 3 -(4-aminocyclohexy1)-3 -methy1ureido)thiazoly1)ethyny1)methy1-N—(4-
(trifluoromethyl)pyridin-Z-yl)benzamide (1-33);
2-((dimethylamino)methyl)—N—(5-((2-methyl ((4-(trifluoromethy1)pyridin
yl)carbamoy1)phenyl)ethynyl)thiazoly1)morpholinecarboxamide ;
N—(5-((2-methy1((4-(trifluoromethy1)pyridiny1)carbamoyl)pheny1)ethyny1)thiazol
yl)morpholinecarboxamide ;
3 -((2-(3 -(3 -aminopropy1)ureido)thiazoly1)ethyny1)—4-methy1-N-(4-
(trifluoromethyl)pyridin-Z-yl)benzamide ;
4-acetyl-N—(5-((2-methyl((4-(trifluoromethyl)pyridin
yl)carbamoy1)pheny1)ethyny1)thiazoly1)piperazine-1 -carboxamide ;
3 -((2-(3 -(2-aminoethy1)ureido)thiazoly1)ethynyl)—4-methy1-N-(4-(trifluoromethyl)pyridin-
2-y1)benzamide (1-38);
4-methy1-3 -((2-(3 -methy1-3 -(1 -methy1azetidin-3 -y1)ureido)thiazol-5 -y1)ethyny1)-N—(4-
(trifluoromethyl)pyridin-Z-yl)benzamide (1-39);
3 -(dimethy1 amino)—N—(5-((2-methy1((4-(trifluoromethy1)pyridin
yl)carbamoyl)pheny1)ethyny1)thiazoly1)pyrrolidine-1 -carboxamide (1-40);
N—(5-((2-methy1((4-(trifluoromethy1)pyridiny1)carbamoyl)phenyl)ethynyl)thiazoly1)-
4-(4-methy1piperazin-1 -y1)piperidinecarboxamide (1-41);
2-fluoro—5 -((2-(3 -methylureido)thiazol-5 -y1)ethyny1)-N-(4-(trifluoromethy1)pyridin
zamide ;
2-fluoro—N—(4-(trifluoromethy1)pyridinyl)((2-ureidothiazoly1)ethyny1)benzamide (I-
43)‘7
3-((2-(3 -methy1ureido)thiazoly1)ethynyl)-N—(4-(trifluoromethy1)pyridinyl)benzamide
(1-44);
4-fluoro—3 -((2-(3 -methy1ureido)thiazol-5 -y1)ethyny1)-N-(4-(trifluoromethy1)pyridin
yl)benzamide (1-45);
3 3 -(2-methoxyethy1)-3 -methy1ureido)thiazol-5 -y1)ethyny1)methy1-N-(4-(pyrrolidin-
1-y1methy1)—3 -(trifluoromethy1)pheny1)benzamide (1-46);
N—(2-methoxy-3 -(trifluoromethyl)pheny1)-3 -((2-(3 thoxyethy1)—3 1ureido)thiazol-
-y1)ethyny1)methylbenzamide (1-47);
N—(4-cyano-3 -(trifluoromethyl)pheny1)-3 -((2-(3 -(2-methoxyethy1)-3 -methy1ureido)thiazol -5 -
yl)ethyny1)methylbenzamide (1-48);
3-((2-(cyclopropanecarboxamido)thiazoly1)ethyny1)—4-methy1-N-(4-
(trifluoromethyl)pyridin-Z-yl)benzamide (1-49);
3 -((2-(cyc1opropanecarboxamido)thiazoly1)ethyny1)—4-methy1-N-(4-((4-methy1piperazin
yl)methy1)—3-(trifluoromethy1)pheny1)benzamide (1-50);
3-((2-acetamidothiazoly1)ethyny1)methyl-N-(4-(trifluoromethy1)pyridinyl)benzamide
(1-51);
4-methy1-3 -((2-piva1ami dothiazol-S -y1)ethyny1)—N—(4-(trifluoromethy1)pyridin-Z-
yl)benzamide (1-52);
ethy1-3 -((2-(3 -methy1-3 -(1-methy1piperidiny1)ureido)thiazoly1)ethyny1)pheny1)—
4-(trifluoromethyl)picolinamide (1-53);
N—(3 -((2-(3 -(2-methoxyethyl)—3 -methylureido)thiazolyl)ethynyl)methylphenyl)
(trifluoromethyl)picolinamide (1-54),
N—(4-methyl-3 -((2-(3 -methyl-3 -(2-(4-methylpiperazin- l -yl)ethyl)ureido)thiazol
yl)ethynyl)phenyl)(trifluoromethyl)picolinamide (1-55),
N—(3 -((2-(3 ,3 -dimethylureido)thiazol-5 -yl)ethynyl)methylphenyl)-3 -
(trifluoromethoxy)benzamide (1-56),
N—(4-methyl-3 -((2-(3 -methylureido)thiazol-5 hynyl)phenyl)
(trifluoromethyl)picolinamide (1-57),
N—(3 -((2-(3 -(2-(dimethyl amino)ethyl)-3 -methylureido)thiazol-5 hynyl)methylphenyl)-
4-(trifluoromethyl)picolinamide (1-58),
N—(3 -((2-(3 -(2-(diethylamino)ethyl)-3 -methylureido)thiazolyl)ethynyl)methylphenyl)-
4-(trifluoromethyl)picolinamide (1-59),
N—(3 -((2-(3 droxyethyl)-3 -methylureido)thiazol-5 -yl)ethynyl)methylphenyl)
(trifluoromethyl)picolinamide (1-60),
N—(3 3 -(2-methoxyethyl)—3 -methylureido)thiazolyl)ethynyl)phenyl)
(trifluoromethyl)picolinamide (1-61), and
uoro-3 -((2-(3 -(2-methoxyethyl)-3 -methylureido)thiazolyl)ethynyl)phenyl)
(trifluoromethyl)picolinamide .
In another embodiment of the invention, the compounds of Formula (I) are
enantiomers. In some embodiments the compounds are the antiomer. In other
embodiments the compounds are the (R)-enantiomer. In yet other ments, the
nds of Formula (I) may be (+) or (-) enantiomers.
It should be understood that all isomeric forms are included within the present
invention, including mixtures thereof. If the compound contains a double bond, the
substituent may be in the E or Z configuration. If the compound contains a disubstituted
cycloalkyl, the cycloalkyl substituent may have a cis- or trans configuration. All tautomeric
forms are also intended to be included.
Compounds of the invention, and pharmaceutically acceptable salts, hydrates,
solvates, isomers and prodrugs thereof may eXist in their tautomeric form (for example,
as an amide or imino ether). All such tautomeric forms are contemplated herein as part of the
present invention.
] The compounds of the invention may contain asymmetric or chiral centers, and,
therefore, exist in different stereoisomeric forms. It is intended that all stereoisomeric forms
of the compounds of the invention as well as mixtures thereof, including racemic mixtures,
form part of the present invention. In addition, the present invention es all geometric
and positional isomers. For example, if a compound of the invention incorporates a double
bond or a fused ring, both the cis- and trans-forms, as well as mixtures, are embraced within
the scope of the invention. Each compound herein disclosed includes all the enantiomers that
conform to the general structure of the compound. The compounds may be in a racemic or
enantiomerically pure form, or any other form in terms of stereochemistry. The assay results
may reflect the data collected for the racemic form, the enantiomerically pure form, or any
other form in terms of stereochemistry.
reomeric mixtures can be separated into their dual diastereomers on
the basis of their physical chemical differences by methods well known to those skilled in the
art, such as, for example, by chromatography and/or fractional crystallization. Enantiomers
can be separated by ting the enantiomeric e into a reomeric mixture by
reaction with an appropriate optically active compound (e. g., chiral auxiliary such as a chiral
alcohol or Mosher's acid chloride), separating the reomers and converting (e.g.,
hydrolyzing) the individual diastereomers to the ponding pure omers. Also,
some of the compounds of the invention may be atropisomers (e.g., substituted biaryls) and
are considered as part of this invention. Enantiomers can also be separated by use of a chiral
HPLC .
It is also possible that the compounds of the invention may exist in different
tautomeric forms, and all such forms are embraced within the scope of the invention. Also,
for example, all keto-enol and imine-enamine forms of the nds are included in the
invention.
All stereoisomers (for example, geometric isomers, optical isomers and the like)
of the present compounds (including those of the salts, solvates, esters and prodrugs of the
compounds as well as the salts, solvates and esters of the prodrugs), such as those which may
exist due to asymmetric carbons on various substituents, including enantiomeric forms
(which may exist even in the e of asymmetric carbons), rotameric forms, atropisomers,
WO 12136 2017/066291
and diastereomeric forms, are contemplated within the scope of this invention, as are
positional isomers (such as, for example, 4-pyridyl and 3-pyridyl). (For example, if a
compound of Formula (I) incorporates a double bond or a fused ring, both the cis- and trans-
forms, as well as mixtures, are embraced within the scope of the invention. Also, for
e, all keto-enol and imine-enamine forms of the compounds are included in the
invention.) Individual stereoisomers of the compounds of the invention may, for example, be
substantially free of other isomers, or may be admixed, for example, as racemates or with all
other, or other selected, stereoisomers. The chiral centers of the present invention can have
the S or R configuration as defined by the IUPAC 1974 Recommendations. The use of the
terms “salt77 (L solvate77 (L 77 (4
7 7 ester, prodrug” and the like, is intended to y apply to the
salt, solvate, ester and prodrug of enantiomers, stereoisomers, rotamers, tautomers, positional
isomers, racemates or prodrugs of the inventive compounds.
The compounds of Formula (I) may form salts which are also within the scope of
this invention. Reference to a compound of the Formula herein is understood to include
reference to salts f, unless otherwise indicated.
The present invention relates to compounds which are modulators of c-Kit. In one
embodiment, the compounds of the present invention are inhibitors of c-Kit.
The invention is directed to compounds as described herein and ceutically
acceptable salts, es, solvates, gs, stereoisomers, or tautomers f, and
pharmaceutical compositions comprising one or more compounds as described herein, or
pharmaceutically acceptable salts, hydrates, solvates, prodrugs, stereoisomers, or tautomers
thereof.
Method of Synthesizing the Compounds
The compounds of the present ion may be made by a variety of methods,
ing standard chemistry. Suitable synthetic routes are depicted in the Schemes given
below.
The compounds of Formula (I) may be prepared by methods known in the art of
organic synthesis as set forth in part by the following synthetic s. In the schemes
described below, it is well understood that protecting groups for sensitive or reactive groups
are employed where ary in accordance with general principles or chemistry. Protecting
groups are manipulated according to standard s of organic synthesis (T. W. Greene
and P. G. M. Wuts, "Protective Groups in Organic Synthesis", Third edition, Wiley, New
York 1999). These groups are d at a convenient stage of the compound synthesis
using methods that are readily apparent to those skilled in the art. The selection processes, as
well as the reaction conditions and order of their execution, shall be consistent with the
preparation of nds of Formula (I).
Those skilled in the art will recognize if a stereocenter exists in the compounds of
Formula (1). Accordingly, the present invention includes both possible stereoisomers (unless
ed in the synthesis) and includes not only c compounds but the individual
enantiomers and/or diastereomers as well. When a compound is desired as a single
enantiomer or diastereomer, it may be obtained by stereospecific synthesis or by resolution of
the final product or any convenient intermediate. Resolution of the final product, an
ediate, or a starting material may be affected by any suitable method known in the art.
See, for example, "Stereochemistry of Organic Compounds" by E. L. Eliel, S. H. Wilen,
and L. N. Mander (Wiley-lnterscience, 1994).
The compounds described herein may be made from commercially available
starting materials or synthesized using known organic, inorganic, and/or enzymatic processes.
Preparation of compounds
The compounds of the present invention can be prepared in a number of ways well
known to those d in the art of organic synthesis. By way of example, compounds of the
present invention can be sized using the methods described below, er with
synthetic methods known in the art of synthetic organic chemistry, or variations n as
appreciated by those skilled in the art. Preferred methods e but are not limited to those
methods described below. Starting materials are either commercially ble or made by
known procedures in the reported literature or as illustrated. Compounds of the present
invention can be synthesized by following the steps outlined in General Scheme 1 which
comprise the assembling of (thiazolyl)-carbamates or -ureas. Starting materials are either
commercially ble or made by known procedures in the reported literature or as
illustrated.
General Scheme 1
(Boc)n
HN’ n = 1,2
Boc —N
Boc‘N s)—/
_N Pd(PPh3)4, Cul
s / (i-Pr)2NEt, DMF H
H / R5
| I
3/\ \A
1a-1 1b-1 (R )n O
RZ-N'
_, —,
(R3)n o
wherein L is _C(O)NR5_
wherein A, Rl-R3, and R5 and n are defined as in a (I).
The general manner of preparing target compounds of Formula (I) wherein L is
—C(O)NR5- by using intermediates 121-1 and 1b-1, is outlined above in General Scheme 1.
Coupling of 121-1 to 1b—1 in the presence of a palladium (0) catalyst and a base, e.g.,
ropylethylamine (DIPEA), in a solvent (e.g., ylformamide (DMF),
dimethylsulfoxide (DMSO), etc.) optionally at elevated temperature provides intermediate
1c—1. Deprotection in the presence of a strong acid (e.g., trifluoroacetic acid) and a solvent
(e. g., dichloromethane (DCM)). Derivatization before or after the coupling step provides the
desired product of Formula (I).
Compounds of Formula (I) can exist as enantiomeric or reomeric
stereoisomers. Enantiomerically pure compounds of Formula (I) can be prepared using
enantiomerically pure chiral ng blocks. Alternatively, racemic mixtures of the final
compounds or a racemic mixture of an advanced intermediate can be ted to chiral
purification as described herein below to r the desired enantiomerically pure
intermediates or final compounds. In the instances where an advanced intermediate is
d into its individual enantiomers, each individual enantiomer can be carried on
separately to r the final enantiomerically pure nds of Formula (I).
It should be understood that in the description and formula shown above, the
various groups Rl-RH, L, A, n, p, and q and other variables are as defined above, except
where otherwise indicated. Furthermore, for synthetic es, the compounds of General
Scheme 1 are merely entative with elected radicals to illustrate the general synthetic
methodology of the compounds of Formula (I) as defined .
Methods of Using the Disclosed Compounds
Another aspect of the invention relates to a method of ng a disease or
disorder associated with modulation of c-Kit. The method comprises administering to a
patient in need of a treatment for a disease or disorder associated with modulation of c-Kit an
effective amount the compositions and compounds of Formula (I).
Another aspect of the invention relates to a method of ting a disease or
disorder ated with tion of c-Kit. The method comprises administering to a
t in need of a treatment for a disease or disorder associated with modulation of c-Kit an
effective amount the compositions and compounds of Formula (I).
Another aspect of the invention relates to a method of treating a c-Kit-mediated
disease or disorder. The method comprises administering to a patient in need of a treatment
of a disease or disorder associated with modulation of c-Kit an effective amount the
compositions and compounds of Formula (I).
r aspect of the invention relates to a method of preventing a c-Kit-mediated
disease or disorder. The method comprises administering to a patient in need of a treatment
for diseases or disorders associated with modulation of c-Kit an effective amount the
compositions and compounds of Formula (I).
] In another aspect, the present invention is directed to a method of inhibiting c-Kit.
The method involves administering to a patient in need thereof an effective amount of a
nd of Formula (I).
Another aspect of the present invention relates to a method of treating a e or
disorder in a patient associated with the inhibition of c-Kit, the method comprising
administering to a patient in need thereof an effective amount of a compound of Formula (I).
In one embodiment, the disease or disorder is selected from the group consisting of cancer
and cell proliferative disorders, multiple sclerosis, asthma, ytosis, inflammatory
disorders, allergic reactions, fibrotic disorders, and metabolic ers.
Another aspect of the present invention s to a method of preventing a e
or er in a patient associated with the inhibition of c-Kit, the method comprising
administering to a patient in need thereof an ive amount of a compound of Formula (I).
The t invention also relates to the use of an inhibitor of c-Kit for the
preparation of a medicament used in the treatment, prevention, inhibition or elimination of a
disease or disorder mediated by c-Kit, wherein the ment comprises a compound of
Formula (I).
In another aspect, the present invention relates to a method for the manufacture of
a medicament for treating, preventing, inhibiting, or eliminating a disease or disorder
mediated by c-Kit, wherein the medicament comprises a nd of Formula (I).
Another aspect of the present invention s to a compound of Formula (I) for
use in the manufacture of a medicament for treating a disease or disorder associated with
inhibiting c-Kit.
In another aspect, the t invention relates to the use of a compound of
Formula (I) in the treatment of a disease or disorder associated with inhibiting c-Kit.
In another aspect, the present invention relates to the use of a compound of
Formula (I) in the prevention of a disease or disorder associated with inhibiting c-Kit.
In some embodiments of the methods above, the disease or er is selected
from the group consisting of cancer, metastasis, inflammation and auto-immune
pathogenesis.
In some embodiments of the methods above, the disease or disorder is selected
from the group ting of cell proliferative disorder, a f1brotic disorder, and a lic
disorder.
In an embodiment of the methods above, the disease or disorder is multiple
sclerosis.
In an embodiment of the methods above, the disease or disorder is asthma. In
another embodiment of the methods above, the disease or disorder is mastocytosis.
In an embodiment of the methods above, the disease or disorder is an allergic
reaction.
In an embodiment of the methods above, the disease or disorder is inflammatory
arthritis.
Another aspect of the invention relates to a method of treating cancer. The
method comprises administering to a patient in need thereof an effective amount of a
compound of Formula (I).
In some embodiments, the cancer is selected from liposarcoma, neuroblastoma,
glioblastoma, bladder cancer, adrenocortical cancer, multiple myeloma, colorectal cancer,
non-small cell lung cancer, oropharyngeal cancer, penis cancer, anal cancer, thyroid cancer,
vaginal cancer, gastric cancer, rectal cancer, thyroid cancer, Hodgkin ma and diffuse
large B-cell ma.
In some ments, the cancer is selected from ia, mast cell tumor,
small cell lung , testicular cancer, cancer of the gastrointestinal tract, cancer of the
l nervous system, cancer of the female genital tract, sarcoma of neuroectodermal origin,
and Schwann cell neoplasia associated with neurof1bromatosis.
In some ments, the cancer is selected from small cell lung carcinoma,
acute myeloid leukemia (AML), thymic oma, desmoid tumor, neuroblastoma,
malignant melanomas, colorectal cancer, systemic mastocytosis (SM), and gastrointestinal
stromal tumors (GISTs).
Another aspect of the invention relates to a method of inducing cell cycle arrest,
sis in tumor cells, and/or enhanced tumor-specific T cell immunity. The method
comprises contacting the cells with an effective amount of a compound of Formula (I).
In one embodiment, the t invention relates to the use of an inhibitor of c-Kit
for the preparation of a medicament used in treatment, prevention, inhibition or elimination
of a disease or disorder associated with associated with cancer and metastasis.
In some embodiments, administration of a nd of Formula (I) or a
pharmaceutical composition comprising a compound of the present invention and a
pharmaceutically acceptable carrier s a change in the cell cycle or cell viability.
r aspect of the invention relates to a method of treating inflammation. The
method comprises administering to a patient in need thereof an ive amount of a
nd of a (I).
Another aspect of the invention relates to a method of treating auto-immune
pathogenesis. The method comprises administering to a patient in need thereof an effective
amount of a compound of Formula (I).
Another aspect of the invention is directed to ceutical compositions
comprising a compound of Formula (I) and a pharmaceutically able carrier. The
pharmaceutical acceptable carrier may further include an excipient, diluent, or surfactant.
In one embodiment, are provided methods of treating a disease or disorder
ated with modulation of c-Kit including, , metastasis, inflammation and auto-
immune pathogenesis, comprising administering to a patient suffering from at least one of
said diseases or disorder a nd of Formula (I).
In one embodiment, are provided methods of treating a disease or disorder
associated with modulation of c-Kit including, cancer and metastasis, comprising
administering to a patient suffering from at least one of said diseases or er a compound
of Formula (I).
One therapeutic use of the compounds or itions of the present invention
which inhibit c-Kit is to provide treatment to patients or subjects suffering from cancer,
asis, inflammation and auto-immune pathogenesis.
Another therapeutic use of the compounds or compositions of the present
invention which inhibit c-Kit is to provide treatment to patients or subjects suffering from
cancer and metastasis.
The disclosed compounds of the invention can be administered in effective
s to treat or prevent a er and/or prevent the development thereof in subjects.
Administration of the disclosed compounds can be accomplished via any mode of
administration for therapeutic agents. These modes include systemic or local administration
such as oral, nasal, parenteral, transdermal, aneous, vaginal, buccal, rectal or topical
administration modes.
Depending on the intended mode of administration, the disclosed compositions
can be in solid, semi-solid or liquid dosage form, such as, for example, injectables, tablets,
suppositories, pills, elease capsules, elixirs, tinctures, emulsions, syrups, powders,
liquids, suspensions, or the like, sometimes in unit dosages and consistent with conventional
pharmaceutical practices. Likewise, they can also be administered in enous (both bolus
and infusion), intraperitoneal, aneous or intramuscular form, and all using forms well
known to those skilled in the pharmaceutical arts.
Illustrative pharmaceutical compositions are tablets and n capsules
comprising a Compound of the Invention and a pharmaceutically acceptable carrier, such as
a) a diluent, e.g., purified water, ceride oils, such as hydrogenated or partially
hydrogenated ble oil, or mixtures thereof, corn oil, olive oil, sunflower oil, safflower
oil, fish oils, such as EPA or DHA, or their esters or triglycerides or es thereof, omega-
3 fatty acids or derivatives thereof, lactose, se, sucrose, mannitol, sorbitol, cellulose,
sodium, saccharin, glucose and/or glycine, b) a lubricant, e.g., silica, talcum, stearic acid, its
magnesium or calcium salt, sodium oleate, sodium stearate, magnesium stearate, sodium
benzoate, sodium acetate, sodium chloride and/or polyethylene glycol, for tablets also, c) a
binder, e.g., magnesium aluminum silicate, starch paste, gelatin, anth, methylcellulose,
sodium carboxymethylcellulose, magnesium ate, natural sugars such as glucose or
beta-lactose, corn sweeteners, natural and synthetic gums such as acacia, tragacanth or
sodium alginate, waxes and/or nylpyrrolidone, if desired, d) a egrant, e.g.,
starches, agar, methyl cellulose, bentonite, xanthan gum, algic acid or its sodium salt, or
effervescent mixtures, e) absorbent, colorant, flavorant and sweetener, f) an emulsifier or
dispersing agent, such as Tween 80, Labrasol, HPMC, DOSS, caproyl 909, labrafac, labrafil,
peceol, transcutol, capmul MCM, capmul PG-12, captex 355, re, vitamin E TGPS or
other acceptable emulsifier, and/or g) an agent that enhances absorption of the compound
such as cyclodextrin, hydroxypropyl-cyclodextrin, PEG400, PEG200.
Liquid, particularly injectable, itions can, for example, be prepared by
dissolution, dispersion, etc. For example, the disclosed compound is dissolved in or mixed
with a pharmaceutically acceptable solvent such as, for example, water, saline, aqueous
dextrose, glycerol, ethanol, and the like, to y form an injectable isotonic solution or
suspension. Proteins such as albumin, chylomicron particles, or serum proteins can be used
to solubilize the disclosed compounds.
The disclosed compounds can be also ated as a suppository that can be
ed from fatty emulsions or sions, using polyalkylene glycols such as propylene
glycol, as the carrier.
The disclosed compounds can also be stered in the form of liposome
ry systems, such as small unilamellar vesicles, large ellar vesicles and
multilamellar vesicles. Liposomes can be formed from a variety of phospholipids, containing
cholesterol, stearylamine or atidylcholines. In some embodiments, a film of lipid
ents is hydrated with an s solution of drug to a form lipid layer encapsulating
the drug, as described in US. Pat. No. 564 which is hereby incorporated by reference
in its entirety.
Disclosed compounds can also be red by the use of monoclonal antibodies
as individual carriers to which the disclosed compounds are coupled. The sed
compounds can also be coupled with soluble polymers as targetable drug carriers. Such
polymers can include polyvinylpyrrolidone, pyran copolymer,
polyhydroxypropylmethacrylamide-phenol, polyhydroxyethylaspanamidephenol, or
hyleneoxidepolylysine substituted with palmitoyl residues. Furthermore, the Disclosed
nds can be coupled to a class of biodegradable polymers useful in achieving
lled release of a drug, for example, polylactic acid, polyepsilon caprolactone,
polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydropyrans,
polycyanoacrylates and cross-linked or amphipathic block copolymers of hydrogels. In one
embodiment, disclosed compounds are not ntly bound to a polymer, e.g., a
polycarboxylic acid polymer, or a polyacrylate.
Parental injectable administration is generally used for subcutaneous,
intramuscular or intravenous injections and infusions. Injectables can be prepared in
conventional forms, either as liquid solutions or suspensions or solid forms suitable for
dissolving in liquid prior to injection.
Another aspect of the invention is directed to pharmaceutical compositions
comprising a compound of Formula (I) and a pharmaceutically acceptable carrier. The
pharmaceutical acceptable carrier may further include an excipient, diluent, or surfactant.
Compositions can be prepared according to conventional mixing, granulating or
coating methods, respectively, and the present pharmaceutical compositions can n from
about 0.1% to about 99%, from about 5% to about 90%, or from about 1% to about 20% of
the disclosed compound by weight or volume.
The dosage regimen utilizing the disclosed compound is selected in accordance
with a variety of factors including type, species, age, weight, seX and medical condition of the
t; the severity of the condition to be treated; the route of administration; the renal or
hepatic function of the patient; and the particular disclosed compound employed. A
physician or veterinarian of ordinary skill in the art can readily determine and prescribe the
effective amount of the drug required to prevent, counter or arrest the progress of the
condition.
Effective dosage s of the disclosed nds, when used for the
indicated s, range from about 0.5 mg to about 5000 mg of the disclosed compound as
needed to treat the condition. Compositions for in vivo or in vitro use can contain about 0.5,
, 20, 50, 75, 100, 150, 250, 500, 750, 1000, 1250, 2500, 3500, or 5000 mg of the disclosed
compound, or, in a range of from one amount to another amount in the list of doses. In one
embodiment, the compositions are in the form of a tablet that can be scored.
Examples
The disclosure is r illustrated by the following examples and synthesis
schemes, which are not to be construed as limiting this disclosure in scope or spirit to the
specific procedures herein described. It is to be understood that the examples are provided to
illustrate n embodiments and that no limitation to the scope of the disclosure is ed
thereby. It is to be further understood that resort may be had to s other embodiments,
modifications, and equivalents thereof which may suggest lves to those skilled in the
art without departing from the spirit of the present disclosure and/or scope of the appended
claims.
Analytical s, Materials, and Instrumentation
Unless otherwise noted, reagents and solvents were used as received from
commercial suppliers. Proton nuclear magnetic resonance (NMR) spectra were obtained on
Bruker spectrometers at 400 MHz. Spectra are given in ppm (6) and coupling constants, J,
are reported in Hertz. Tetramethylsilane (TMS) was used as an internal standard. Mass
spectra were collected using a Waters ZQ Single Quad Mass Spectrometer (ion trap
electrospray tion (ESI)). Purity and low resolution mass spectral data were measured
using Waters Acquity i-class ultra-performance liquid tography (UPLC) system with
Acquity Photo Diode Array Detector, Acquity Evaporative Light Scattering Detector (ELSD)
and Waters ZQ Mass Spectrometer. Data was ed using Waters MassLynX 4.1 re
and purity characterized by UV wavelength 220 nm, evaporative light scattering detection
(ELSD) and electrospray positive ion (ESI). (Column: Acquity UPLC BEH C18 1.7 pm 2.1
X 50 mm; Flow rate 0.6 mL/min; Solvent A 0.l%: 10 mM Ammonium
e/Acetonitrile/Formic Acid), Solvent B (95/5/0.09%: Acetonitrile/Water/Formic
Acid); nt: 5-100% B from 0 to 2 mins, hold 100% B to 2.2 mins and 5% B at 2.21
mins. Abbreviations used in the following examples and ere herein are:
br broad
CDI 1,1’ -carbonyldiimidazole
DCM dichloromethane
DIPEA MN—diisopropylethylamine
DMAP 4-(dimethylamino)pyridine
DMF N,N—dimethylformamide
DMSO dimethyl sulfoxide
EI electron ionization
ESI electrospray ionization
Et ethyl
Et3N triethylamine
EtOAc ethyl e
EtOH ethanol
GCMS gas chromatography—mass spectrometry
h hour(s)
HATU 2-(7-Aza- lH-benzotriazole- l -yl)- l , 1,3 , 3 -tetramethyluronium
hexafluorophosphate
HPLC high-performance liquid chromatography
LCMS liquid chromatography—mass spectrometry
m multiplet
Me methyl
MeOH methanol
MHz megahertz
min minutes
MS molecular sieves
NMR nuclear magnetic resonance
ppm parts per million
PSI Pounds per square inch
s singlet
TBAF tetra-n-butylammonium e
TFA trifluoroacetic acid
THF tetrahydrofuran
Methods for the Synthesis of Compounds of Formula (1)
Method A
Example 1: 3-((2-(3,3-dimethylureido)thiazol-S-yl)ethynyl)methyl-N-(4-
(trifluoromethyl)pyridinyl)benzamide (I-1)
HZN N
' |
800i2 N
F3 N\
I) /
o 0 ii)
1a 1b 1c
3°C H — TMS
HBr BocHN iaoc
H2N >—_N Pd(PPh3)2CI2. Cul ‘N
8):!“ (Boc)20 (Boc)20 >—N (i_pr)2NEt, DMF >—N
/ Ill) fr N)
r )
r H
1a' 1b' 1d
16' MS
(Boc)n
HN’ n =1,2
BOG Boc intermediate 1c
Boc—N' $>=N
HN /
TBAF —N
S / Ffd(PP[\rli|3£)t4.DC|\:lilF
(I-Pr)2 .
+ S / H
VI) T
H H H
1e 1e' 1f /
H2N o
f“ H96
/ 8):“!
H CDI/DCM (CH3)2N"I /
'X) X) H X = NH, 0
viii)
N N
\ H
0 | N
/ N\
Steps 1' and ii. 3-iodomethyl-N-(4-(trifluoromethyl)pyridinyl)benzamide (1c)
15.72 g (0.06 mol, 1.0 eq) of methylbenzoic acid (121) in 60 m1 of thionyl
chloride was d for 1 h. The reaction mixture was evaporated by rotary evaporation to
give a brown solid, 1b, which was further dried under high vacuum for 1 h. The solid 1b was
then dissolved in 36 ml of THF and carried onto the next step without ation.
To a flask under N2 atmosphere and with stirring was added DMAP (366 mg, 3.0
mmol, 0.05 eq), DIPEA (12.6 ml, 9.36 g, 72 mmol, 1.2 eq), o
(trifluoromethyl)pyridine (9.9 g, 61.2 mmol, 1.02 eq) and THF (120 ml). To this solution was
then slowly added solution of an acid chloride (1b, freshly prepared as above) using a funnel
under a N2 atmosphere and the reaction mixture was stirred at rt overnight. Water (60 ml)
was added, followed by EtOAc (150 ml). The organic layer was ted, and the aqueous
layer was ted with EtOAc (2x100 ml). The combined organic layers were dried,
filtered, and concentrated in vacuo. The resulting crude product was purified by flash column
tography on silica gel ng with EtOAc/Heptane 20%) to give intermediate 1c as a
white solid.
Steps iii to vi. -S-ethynylthiazol-Z-amine (Id)
Di-tert-butyl dicarbonate [(Boc)20, 100.7 g, 0.461 mol, 1.2 eq] was added to a
flask containing a mixture of 2-aminobromothiazole monohydrobromide (1a', 100 g,
0.385 mol, 1.0 eq) and 4-(dimethylamino)pyridine (DMAP, 1.18 g, 9.7 mmol, 0.025 eq) in
900 mL of THF and 135 mL of Et3N and cooled to 0 0C using an ice bath. The on
mixture was d at r.t. overnight and then concentrated in vacuo. The residue was stirred
in EtOAc/Heptane (1:10, 250 ml) at rt overnight and then filtered. The filtrate was washed
with brine, dried, filtered, and concentrated in vacuo to furnish intermediate 1b' as a yellow
solid (91% yield).
Di-tert-butyl dicarbonate [(Boc)20, 90.4 g, 0.414 mol, 1.2 eq] was added to a flask
containing a mixture of intermediate lb' (97.9 g, 0.351 mol, 1.0 eq) and 4-
(dimethylamino)pyridine (DMAP, 1.07 g, 8.7 mmol, 0.025 eq) in 880 ml of THF and 121 ml
of Et3N and cooled to 0 0C using an ice bath. The reaction mixture was stirred at rt overnight.
Water (200 ml) and DCM were added and the resulting mixture was d at rt for 30 min.
The organic layer was separated and the aqueous layer was extracted with DCM (2 x 150 ml).
The combined organic layers were washed with brine, dried over Na2S04, filtered and
concentrated in vacuo. The crude residue was purified with a short silica gel column (eluting
with EtOAc/Heptane 1:20) to give intermediate lc' as an off-white solid (113 g, 85% yield).
A mixture of the di-Boc material lb' (48.5 g, 0.128 mol, 1.0 eq),
trimethylsilylacetylene (21.8 ml, 15.1 g, 154 mmol, 1.29 eq), Pd(PPh3)2Clz (4.7 g), CuI (1.5
g), and Et3N (50 ml) in 200 ml of DMF was heated at 70 0C in a sealed tube under an N2
atmosphere and the resulting mixture was stirred for 1.5 h. After concentrating the reaction
mixture in vacuo, sat. aq. N212CO3 and DCM were added to the crude residue. The c
layer was separated and the combined organic layers were concentrated in vacuo.
Purification by flash column chromatography on silica gel (eluting with EtOAc/Heptane
1:10) gave intermediate 1d as a brown solid (37 g, 78% yield).
TBAF (1.0 M in THF, 108 ml) was slowly dropped to a solution of 1d (37 g, 0.1
mol) in 108 ml of DCM at rt. The resulting mixture was d at rt for 1 h and then water
and DCM were added. The organic layer was separated and the combined organic layers
were concentrated in vacuo. Purification by flash column chromatography on silica gel
(eluting with EtOAc/Heptane 10% to 30%) ed a mixture of intermediates 1e (di—Boc-
-ethynylthiazolamine, 24.5 g, 75% yield) and le' (Bocethynylthiazolamine, 2.1 g,
9% yield).
Steps vii to x. 3-((2-(3,3-dimethylureid0)thiaz01yl)ethynyl)—4-methyl-N-(4-
(triflu0r0methyl)pyridinyl)benzamide (I-1)
] A mixture of 1e and le' (24.5 g, 75.5 mmol, 1.0 eq), intermediate 1c (31.4 g, 77.3
mmol, 1.02 eq), Pd(PPh3)4 (7.2 g), CuI (2.05 g), and DIPEA (72.5 ml) in 153 ml ofDMF was
heated at 100 0C under an atmosphere of N2 and stirred for 3 h. After g to r.t., the
mixture was evaporated in vacuo. Water and DCM were added with ng. The organic
layer was separated and the aqueous layer was extracted with DCM (2 x 100 ml). The
ed organic layers were washed with brine, dried, filtered, and concentrated in vacuo to
furnish a yellow solid (1f, 50 g).
The yellow solid 1f obtained above was dissolved in 200 ml of DCM and 200 ml
of TFA was then added. The resulting mixture was stirred at rt for 1 h and then concentrated
in vacuo. DCM and sat. aq. Na2CO3 were added with stirring and cooling using an ice bath
until a pH of 9 — 10 was obtained. The organic layer was separated and the aqueous layer was
ted with DCM (2 x 100 ml). The combined organic layers were washed with brine,
dried, filtered, and concentrated to give a yellow solid, which was purified by flash column
chromatography on silica gel (MeOH/DCM 1:20) hing intermediate 1g as a yellow
solid (20 g, 62% yield for two steps). 1H NMR (CD3OD): 5 2.33 (3H, s), 7.03 (1H, s), 7.21
(1H, d), 7.24 (1H, d), 7.67 (1H, d), 7.85 (1H, d), 8.39 (2H, d). ESI—MS m/z: 401.1 [M-1]'.
A solution of intermediate 1g (80 mg) and l,l’-carbonyldiimidazole (CD1, 80 mg)
in DCM (4 ml) was stirred at 50 oC overnight and then cooled to r.t. To the resulting
suspension was added dimethylamine (2.0 M in THF, 5 eq.). The mixture was stirred at rt for
2 h, and then d. The filtrate was concentrated and then purified by prep HPLC to
furnish the title compound I-1 (52% yield).
The compounds in Table 1 were synthesized as described in Method A above
using the corresponding ridinyl- or iodophenylbenzamides and di-Boc-S-
ethynylthiazolamine in step Vii, and the corresponding l or amine in step X.
TABLE 1:
1H NMR (400
Amine/alcohol in
MHz) ppm; ESI—
step x.
MS m/z
(CDgOD): 8.45 —
8.51 (m, 2 H), 7.98
(d, J: 2.01 Hz, 1
H), 7.78 (dd, J :
7.97, 1.94 Hz, 1
H), 7.46 (s, 1 H),
7.33 (d, J: 8.44
Hz, 1 H), 7.30 (d,
J : 5.30 Hz, 1 H),
2.95 (s, 6 H), 2.44
(s, 3 H), [M+H]+
(CDgOD): 8.61 (d,
J : 4.69 Hz, 2 H),
8.12 (d, J: 521
Hz, 1 H), 7.92 (dd,
J : 7.55 Hz, 1 H),
7.58 (s, 1 H), 7.42
— 7.51 (m, 2 H),
2.58 (s, 3 H),
[M+H]+ 446.
(CDgOD): 8.61 (d,
J : 3.68 Hz, 2 H),
8.13 (d, J: 201
Hz, 1 H), 7.94 (d,
J: 1.88 Hz, 1 H),
7.61 (s, 1 H), 7.47
(s, 1 H), 7.43 (d, J
: 4.86 Hz, 1 H),
3.87 (s, 3 H) 2.58
(s, 3 H), [M+H]+
WO 12136
. . . H NMR (400
Amlne/alcohol 1n
Compound Structure 33;]? MHz) ppm; ESI—
step x. 0
MS m/z
(CD3OD)I 8.44 (br
s, 2 H), 7.95 (d, J
: 1.76 Hz, 1 H),
7.75 (dd, J: 8.03,
2.01 Hz, 1 H), 7.39
(s, 1 H), 7.32 (d, J
: 8.44 Hz, 1 H),
7.26 (d, J: 5.30
Hz, 1 H), 2.68 (s, 3
H), 2.41 (s, 3 H),
[M+H]+ 460.
(CD3OD)I 8.60 (s,
2 H), 8.12 (d,J:
2.01 Hz, 1 H), 7.87
— 7.93 (m, 1 H),
7.57 (s, 1 H), 7.48
(d, J: 8.03 Hz, 1
CH30CH2CH2NH2 39 H), 7.43 (d, J :
.65 Hz, 1 H), 3.55
(d, J : 7.98 Hz,
2H), 3.46 (d, J :
7.99 Hz, 2 H), 3.41
(s, 3H), 2.58 (s, 3
H), [M+H]+ 504.
(CD3OD)I 8.61 (s,
1 H), 8.11 (d,J:
2.01 Hz, 1 H), 7.92
(dd, J : 8.20 Hz, 1
H), 7.66 (s, 1 H),
7.59 (s, 1 H), 7.41
fNN — 7.49 (m, 2 H),
\2 4.09 (br s, 2 H),
3.81 (br. s., 2 H),
3.71 (t, J: 5.77
Hz, 4 H), 3.38 (t, J
: 5.70, 2 H), 3.23
(br s, 2 H), 2.57 (s,
3 H), [M+H]+ 559.
(CDC13): 9.58 (br
s, 1H), 8.76 (br s.,
1 H), 8.61 (s, 1 H),
8.40 (d, J: 5.14
\o/\/N\ 63 Hz, 1 H), 7.93 (d,
J: 1.88 Hz, 1 H),
7.72 (dd, J: 7.97,
1.94 Hz, 1 H), 7.51
(s, 1 H), 7.30 (d, J
1H NMR (400
Amlne/alcohol 1n
Compound ure MHz) ppm; ESI—
step x.
: 8.03 Hz, 1 H),
7.22 (d, J: 5, 19
Hz, 1H), 3.51 —
3.59 (m, 2 H), 3.42
— 3.49 (m, 2 H),
3.39 (s, 3 H), 3.00
(s, 3 H), 2.47 (s, 3
H), [M+H]+ 518.
(CDC13): 9.01 (s, 1
H), 8.60 (s, 1 H),
8.40 (d, J: 5.02
Hz, 1 H), 7.94 (d,
J: 1.76 Hz, 1 H),
7.74 (dd, J: 7.97,
1.94 Hz, 1 H), 7.52
(s, 1 H), 7.31 (d, J
CH3CH2NHCH3 : 8.16 Hz, 1 H),
7.23 (d, J: 5.36
Hz, 1 H), 3.30 —
3.46 (q, J: 7.96
Hz, 2 H), 2.95 (s, 3
H), 2.47 (s, 3 H),
1.14 (t, J: 7.96
Hz, 3 H), [M+H]+
(CDC13): 8.85 (s, 1
H), 8.71 (s, 1 H),
8.49 (d, J: 5.14
Hz, 1 H), 8.03 (d,
J: 2.01 Hz, 1 H),
7.81 (dd, J: 7.91,
2.01 Hz, 1 H), 7.59
(s, 1 H), 7.39 (d, J
: 8.03 Hz, 1 H),
7.29 (d, J: 5.46
Hz, 1 H), 3.32 —
3.46 (m, 2 H), 3.07
(s, 3 H), 2.61 —
2.74 (m, 2 H), 2.56
(s, 3 H), 2.47 (s, 6
H), [M+H]+ 531.
1H NMR (400
Amlne/alcohol 1n
MHz) ppm; ESI—
step x.
(CDC13): 8.59 —
8.63 (m, 2 H), 8.41
(d, J: 2.01 Hz, 1
H), 7.74 (dd, J :
7.78, 2.01 Hz, 1
H), 7.48 (s, 1 H),
7.31 (d, J: 7.99
HO(CH2)2NHCH3 38 Hz, 1H), 7.22 (d, J
: 5.42 Hz, 1 H),
3.88 (t, J: 7.89
HZ, 2 H), 3.49 (t, J
: 7.99 Hz, 2 H),
3.04 (s, 3 H), 2.49
(s, 3 H), [M+H]+
(DMSO-dg): 11.30
(s, 1H), 10.82 (s,
1H), 8.66 (d, J :
.14 Hz, 1 H), 8.49
(s, 1 H), 8.19 (d, J
: 2.01 Hz, 1 H),
7.96 (dd, J: 8.03,
\ NH2
N/\/ 23 2.01 Hz, 1 H), 7.62
(s, 1 H), 7.44 —
7.50 (m, 2 H), 3.10
(d, J: 5.65 Hz, 2
H), 2.53 (s, 3 H),
2.38 — 2.47 (m, 2
H), 2.17 — 2.30 (m,
6 H), [M+H]+ 517.
(CDgOD): 12.04 —
12.16 (m, 2 H),
9.50 (d, J: 5.14
Hz, 1 H), 9.34 (s, 1
H), 9.00 (d, J :
1.76 Hz, 1 H), 8.78
(dd, J: 6.16 Hz, 1
H), 8.54 (s, 1 H),
8.29 — 8.38 (m, 2
H), 7.86 (br s, 1
H), 4.30 — 4.37 (m,
4 H), 3.85 (br s, 2
H), 2.82 (br s, 2
H), 2.69 (br s, 2
H), [M+H]+ 543.
1H NMR (400
Amine/alcohol in
Compound Structure MHz) ppm; ESI—
step x.
MS m/z
(DMSO-dg): 11.30
(s, 1 H), 10.70 (s,
1 H), 8.69 (d, J:
.14 Hz, 1H), 8.53
(s, 1 H), 8.21 (s, 1
H), 7.96 (dd, J :
7.97, 1.82 Hz, 1
H), 7.70 (s, 1 H),
7.58 (d, J: 2.08
Hz, 1H), 7.51 (d, J
: 7.99 Hz, 1 H),
6.67 (br s, 1 H),
3.06 (t, J: 8.01
Hz, 2 H), 2.77 (d,
J : 8.00, 2 H),
2.15 (s, 3 H), 1.81
(t, d=8.06 Hz, 2
H), 1.61 (d, J:
8.05 Hz, 2 H), 1.40
(m, 1 H), 1.11 —
1.24 (In, 2 H),
[M+H]+ 557.
dg): 11.30
(s, 1 H), 10.92 ( s,
1 H), 8.69 (d, J:
.14 Hz, 1 H), 8.53
(s, 1 H), 8.20 (d, J
: 2.01 Hz, 1 H),
7.96 (dd, J: 7.97,
1.94 Hz, 1 H), 7.70
(s, 1 H), 7.54 (dd,
J : 5.02,1.00 Hz,
1 H), 7.49 (d, J :
8.03 Hz, 1 H), 6.58
(s, 1 H), 3.20 —
3.29 (m, 4 H), 2.28
— 2.37 (m, 8 H),
2.17 (s, 3 H) ,
[M+H]+ 572.
1H NMR (400
Amlne/alcohol 1n
nd Structure MHz) ppm; ESI—
step x.
(DMSO-dg)2
11.30 (s, 1 H),
.72 (s, 1 H),
8.69 (d, J: 5.14
Hz, 1 H), 8.53 (s, 1
H), 8.20 (d, J :
2.01 Hz, 1 H), 7.96
(dd, J: 8.03,1.88
Hz, 1 H), 7.70 (s, 1
H), 7.64 (d, J :
2.02 Hz, 1 H), 7.48
(d, J : 7.98 Hz, 1
H), 6.66 (s, 1 H),
3.10 (d,J: 5.65
Hz, 2H), 1.11 (s, 6
H), [M+H]+ 518.
(CD3OD)I 8.60 (s,
2H), 8.11 (d,J:
2.01 Hz, 1 H), 7.91
(dd, J: 8.03, 2.01
Hz, 1 H), 7.60 (s, 1
H), 7.47 (d, J :
7.62 Hz, 1 H), 7.43
(d, J : 5.27 Hz, 1
H), 3.52 (m, 2 H),
3.06 (s, 3 H) 2.63 —
2.82 (m, 8 H), 2.58
(s, 3 H), 2.37 (s, 3
H), [M+H]+ 586.
(CD30D): 8.59 —
8.63 (m, 2 H), 8.12
(d, J: 2.01 Hz, 1
H), 7.92 (dd, J :
7.78, 2.01 Hz, 1
H), 7.58 (s, 1 H),
7.42 — 7.50 (m, 2
H), 2.63- 2.69 (m,
1 H), 2.58 (s, 3 H),
0.78 — 0.83 (m, 2
H), 0.58 (dd, J:
3.51, 2.01 Hz, 2
H), [M+H]+ 486.
1H NMR (400
Amine/alcohol in
Compound ure MHz) ppm; ESI—
step x.
MS m/z
(DMSO-dg): 11.31
(s, 1H), 10.85 (s.,
1 H), 8.69 (d, J:
.14 Hz, 1 H), 8.53
(s, 1 H), 8.19 (s,1
H), 7.92 - 7.98 (m,
1 H), 7.69 (s, 1 H),
7.47 - 7.56 (m, 2
H), 6.66 (s, 1 H),
4.72 (br s, 2 H),
4.23 (br s, 2 H),
2.78 (br s, 2 H),
2.62 - 2.72 (m, 2
H), 2.40 (br s, 3
H), 2.34 (d, J :
1.76 Hz, 2 H), 2.19
(In, 1 H), 1.58 (br
s, 2 H), [M+H]+
(DMSO-dg): 11.30
(s, 1 H), 8.69 (d, J
: 5.14 Hz, 1 H),
8.53 (s, 1 H), 8.19
(d,J: 1.88 Hz,1
H), 7.95 (dd, J :
7.91,1.88 Hz,1
H), 7.70 (s, 1 H),
7.54 (d, J: 5.07
Hz, 1 H), 7.49 (d,
J: 8.16 Hz, 1 H),
3.46 (t, J: 5.33
Hz, 2 H), 2.97 (s, 3
H), 2.75 (s, 2 H),
2.67 (br s, 4 H),
1.81 (br s, 4 H),
[M+H]+ 557.
1H NMR (400
Amlne/alcohol 1n
Compound Structure MHz) ppm; ESI—
step x.
(DMSO-dg): 11.30
(s, 1 H), 8.69 (d, J
: 5.14 Hz, 1 H),
8.53 (s, 1 H), 8.19
(d,J: 1.88 Hz,1
H), 7.95 (dd, J :
7.97,1.94 Hz,1
H), 7.70 (s, 1 H),
7.55 (d, J: 5.23
Hz, 1 H), 7.49 (d,
J: 8.16 Hz, 1 H),
3.60 (br s, 1H),
3.06 (br s, 2H)
2.98 (s, 3 H), 1.94
(br s, 2H), 1.79 (br
s, 2 H), 1.63 (br s,
2 H), [M+H]+ 557.
(DMSO-dg) 11.30
(s, 1 H), 8.69 (d, J
: 5.14 Hz, 1 H),
8.53 (s, 1 H), 8.20
(d,J: 1.88 Hz,1
H), 7.96 (dd, J :
.94 Hz,1
H), 7.73 (s, 1 H),
7.47 - 7.56 (m, 2
H), 3.34 (s, 2 H),
3.04 (br s, 3 H),
1.08 - 1.26 (m, 6
H), [M+H]+ 532.
(DMSO-dg) 11.31
(s, 1 H), 11.20 (s,
1H), 8.69 (d, J :
.14 Hz, 1 H), 8.54
(s, 1 H), 8.20 (d, J
: 2.01 Hz, 1 H),
7.96 (dd, J: 7.91,
1.88 Hz, 1 H), 7.75
(s, 1 H), 7.48 -
7.56 (m, 2 H), 4.55
(d, J: 4.64 Hz, 1
H), 3.28 (s, 1 H),
2.83 (s, 3 H), 1.87
(d, J: 11.54 Hz, 2
H), 1.55 (d, J:
7.03 Hz, 4 H), 1.30
(dd, J: 11.29,
. . . H NMR (400
C1310pd Amlne/alcohol 1n
Compound Structure MHz) ppm; ESI—
(CD3OD)I 8.60 (s,
2 H), 8.10 (d, J:
1.88 Hz, 1 H), 7.92
(dd, J: 7.97, 1.94
Hz, 1 H), 7.56 (s, 1
H), 7.41 - 7.49 (m,
2 H), 4.53 (br s, 2
H), 3.57 (br s, 2
H), 3.15 (br s, 2
H), 2.97 (s, 3 H),
2.57 (s, 3 H),
[M+H]+ 529.
(CD3OD)I 8.59 (s,
1 H), 8.58 (s, 1 H),
,J:1.88
Hz, 1 H), 7.91 (dd,
J : 7.97, 1.95 Hz,
1 H), 7.59 (s, 1 H),
7.42 — 7.48 (m, 2
H), 4.01 (s, 4 H),
2.56 (s, 3 H), 1.52
(s, 3 H), [M+H]+
(CDgOD): 8.48 —
8.56 (m, 2 H), 8.02
(d, J: 2.01 Hz, 1
H), 7.83 (dd, J :
8.03, 2.01 Hz, 1
H), 7.45 (s, 2 H),
7.30 — 7.43 (m, 2
H), 3.77 — 3.87 (m,
1 H), 3.46 — 3.57
(m, 2 H), 3.02 —
3.23 (m, 2 H), 2.85
(s, 3H), 2.48 (s, 3
H), 2.19 (d, J:
14.93 Hz, 2 H),
1.73(m, 2 H),
[M+H]+ 543.
1H NMR (400
Amine/alcohol in
Compound ure MHz) ppm; ESI—
step x.
MS m/z
(CDgOD): 8.60 (d,
J : 4.81 Hz, 2 H),
8.51 (d, J: 5.03
Hz, 2 H), 8.12 (d,
J: 2.01 Hz, 1 H),
7.92 (dd, J: 8.03,
2.01 Hz, 1 H), 7.59
(s, 1 H), 7.48 (d, J
: 8.03 Hz, 1 H),
7.41 — 7.44 (m, 3
H), 4.53 — 4.55 (m,
2 H), 2.57 (s, 3 H),
[M+H]+ 537.
(CDgOD): 8.59 —
8.63 (m, 2 H), 8.11
(d, J: 2.01 Hz, 1
H), 7.92 (dd, J :
7.97, 1.94 Hz, 1
H), 7.57 (s, 1 H),
7.47 (d, J: 7.73
Hz, 1 H), 7.42 —
7.44 (m, 1 H), 3.69
— 3.91 (m, 6 H),
2.99 (br s, 6 H)
2.57 (s, 3 H),
[M+H]+ 559.
(CDgOD): 8.61 (d,
J : 4.52 Hz, 2 H),
8.10 (d,J: 1.76
Hz, 1 H), 7.92 (dd,
J: 8.03, 2.01 Hz,
1 H), 7.60 (s, 1 H),
7.48 (d, J: 7.75
Hz, 1 H), 7.42 —
7.45 (m, 1 H), 3.77
(t, J: 5.52 Hz, 2
H), 3.27 (t, J :
.52 Hz, 2H), 3.15
(s, 3 H), 2.77 (s, 3
H), 2.57 (s, 3 H),
[M+H]+ 517.
1H NMR (400
Amlne/alcohol 1n
Compound Structure MHz) ppm; ESI—
step x.
): 8.37 —
8.41 (m, 2 H), 7.89
(d, J: 2.01 Hz, 1
H), 7.69 (dd, J :
8.03, 2.01 Hz, 1
H), 7.37 (s, 1 H),
7.25 (d, J: 7.75
Hz, 1 H), 7.21 (d,
J : 5.20 Hz, 1 H),
3.93 — 4.02 (m, 1
H), 2.73 — 2.80 (m,
H), 2.36 (s, 3 H),
2.10 (s, 3 H), 1.93
— 2.05 (m, 2 H),
1.60 — 1.74 (m, 2
H), 1.37 — 1.54 (m,
2 H), [M+H]+ 557.
(CD30D): 8.60 (d,
J : 4.70 Hz, 1 H),
8.59 (s, 1 H), 8.10
(d, J: 2.01 Hz, 1
H), 7.91 (dd, J :
8.03, 2.01 Hz, 1
H), 7.55 (s, 1 H),
7.46 (d, J: 8.35
Hz, 1 H), 7.42 (d,
J: 5.31 Hz, 1 H),
3.85 — 3.95 (m, 4
H), 3.33 (s, 3H),
3.28 — 3.31 (m, 4
H), 2.56 (s, 3 H),
[M+H]+ 515.
(CD3OD)I 8.61 (s,
1 H), 8.60 (s, 1 H),
8.11 (d,J: 2.01
Hz, 1 H), 7.92 (dd,
J : 8.03,1.88 Hz,
1 H), 7.58 (s, 1 H),
7.47 (d, J: 7.75
Hz, 1 H), 7.43 (d,
J : 5.16 Hz, 1 H),
3.00 (t, J: 7.28
Hz, 2 H), 2.57 (s, 3
H), 1.62 — 1.78 (m,
4 H), [M+H]+ 517.
1H NMR (400
Amine/alcohol in
Compound Structure MHz) ppm; ESI—
step x.
MS m/z
(CDgOD): 8.58 —
8.63 (s, 2 H), 8.11
(d, J: 2.01 Hz, 1
H), 7.92 (dd, J :
7.91,1.88 Hz, 1
H), 7.60 (s, 1 H),
7.39 — 7.52 (m, 2
H), 4.51 (m, 1 H),
3.50 (m, 2 H), 3.20
(t,J: 11.92 Hz, 2
H), 3.05 (s, 3 H),
2.93 (s, 3 H), 2.57
(s, 3 H), 2.15 (d, J
: 8.28 Hz, 1 H),
1.81 — 2.02 (m, 3
H), [M+H]+ 557.
(CD30D): 8.50 —
8.54 (m, 2 H), 8.03
(d, J: 2.01 Hz, 1
H), 7.83 (dd, J :
8.03, 2.01 Hz, 1
H), 7.53 (s, 1 H),
7.34 — 7.42 (m, 2
H), 4.06 — 4.15 (m,
1 H), 3.01 — 3.23
(m, 1 H), 2.94 (s, 3
H), 2.49 (s, 3 H),
2.08 (d, J: 12.55
Hz, 2 H), 1.72 —
1.90 (m, 4 H),
1.53— 1.65 (m, 2
H), [M+H]+ 557.
1H NMR (400
alcohol in
Compound Structure MHz) ppm; ESI—
step x.
MS m/z
(DMSO-dg) 11.71
(hrs, 1 H), 11.30
(s, 1 H), 8.69 (d, J
: 5.14 Hz, 1 H),
8.52 — 8.58 (m, 1
H), 8.20 (d, J :
1.88 Hz, 1 H), 7.96
(dd, J: 8.03,1.88
Hz, 1 H), 7.76 (s, 1
H), 7.64 (s, 1 H),
7.43 — 7.57 (m, 2
H), 6.99 — 7.05 (br
s, 1H), 4.16 (d,J
: 12.92 Hz, 1 H),
4.04 (d, J: 12.92
Hz, 1 H), 3.86 (dd,
J: 11.61, 2.20
Hz, 1 H), 3.34 —
3.57 (m, 3 H), 2.92
—3.14 (m, 1 H),
2.68 (dd, J:
13.05, 10.67 Hz, 1
H), 2.28 — 2.39 (m,
2 H), [M+H]+ 585.
(CD30D): 8.57 —
8.64 (m, 2 H), 8.11
(d, J: 2.01 Hz, 1
H), 7.91 (dd, J :
8.03, 2.01 Hz, 1
H), 7.59 (s, 1 H),
7.42 — 7.45 (m, 2
H), 3.68 — 3.77 (m,
4 H), 3.55 — 3.64
(m, 4 H), 2.57 (s, 3
H), [M+H]+ 516.
1H NMR (400
Amine/alcohol in
step x. MHzg/[gpnnllizESI
)I 8.60 (s,
1 H), 8.59 (s, 1 H),
8.10 (d, J: 2.01
Hz, 1 H), 7.91 (dd,
J : 7.91, 1.88 Hz,
1 H), 7.58 (s, 1 H),
7.46 (d, J: 7.76
Hz, 1 H), 7.43 (d,
J : 5.27 Hz, 1 H),
3.40 (t, J: 6.65
Hz, 2 H), 3.03 (t, J
: 7.28 Hz, 2 H),
2.56 (s, 3 H) 1.85 —
2.01 (In, 2 H),
[M+H]+503.
(CDgOD): 8.58 —
8.64 (m, 2 H), 8.12
(d, J: 1.76 Hz, 1
H), 7.92 (dd, J :
6.71 Hz, 1 H), 7.60
(s, 1 H), 7.43 —
7.50 (m, 2 H), 3.61
— 3.71 (m, 8 H),
2.58 (s, 3 H), 2.16
(s, 3 H), [M+H]+
(CD3OD)I 8.60 (s,
1 H), 8.59 (s, 1 H),
8.09 (d, J: 2.01
Hz, 1 H), 7.91 (dd,
J : 7.97, 1.94 Hz,
1 H), 7.58 (s, 1 H),
7.46 (d, J: 8.31
Hz, 1 H), 7.42 (d,
J : 5.28 Hz, 1 H),
3.57 (t, J: 5.83
Hz, 2 H), 3.14 (t, J
: 5.77 Hz, 2 H),
2.56 (s, 3 H),
[M+H]+ 489.
1H NMR (400
Amine/alcohol in
Compound Structure MHz) ppm; ESI—
step x.
MS m/z
(CD3OD)I 8.58 (s,
2 H), 8.09 (d, J:
1.76 Hz, 1H),
7.90 (dd, J: 8.03,
2.01 Hz, 1 H),
7.62 (s, 1 H), 7.34
— 7.53 (m, 2 H),
4.26 — 4.40 (m, 1
H), 4.09 — 4.21 (m,
1 H), 4.03 (dd, J :
.79, 6.02 Hz, 1
H), 3.39 — 3.52 (m,
2 H), 2.99 (s, 3 H),
2.84 (s, 3 H), 2.55
(s, 3 H), [M+H]+
(CD3OD)I 8.60 (s,
2 H), 8.10 (d,J:
2.01 Hz, 1 H), 7.91
(dd, J: 8.03, 2.01
Hz, 1 H), 7.55 —
7.66 (m, 1 H), 7.47
(d, J : 7.70 Hz, 1
H), 7.43 (d, J :
.28 Hz, 1 H), 3.97
— 4.09 (m, 2 H),
3.84 (ddd, J:
.54, 8.78, 3.51
Hz, 1 H), 3.57 —
3.74 (m, 2 H), 3.00
(s, 6 H), 2.47 —
2.65 (m, 4 H), 2.18
- 2.41 (m, 1H),
[M+H]+ 543.
1H NMR (400
Amine/alcohol in
Compound Structure MHz) ppm; ESI—
step x.
(CD3OD)I 8.60 (s,
1 H), 8.59 (s, 1 H),
8.10 (d,J: 1.76
Hz, 1 H), 7.91 (dd,
J : 7.91, 1.88 Hz,
1 H), 7.58 (s, 1 H),
7.46 (d, J: 8.30
Hz, 1 H), 7.43 (d,
J : 5.23 Hz, 1 H),
4.44 (d, J: 13.80
Hz, 2 H), 3.57 (br
s, 4 H), 3.47 — 3.54
(m, 4 H), 3.35 —
3.45 (m, 1 H), 2.95
— 3.04 (m, 5 H),
2.56 (s, 3 H), 2.16
(d, J: 10.79 Hz, 2
H), 1.62 — 1.78 (m,
2 H), [M+H]+ 612
(CD30D): 8.59 —
8.63 (m, 2 H), 7.96
(dd, J: 6.78, 2.26
Hz, 1 H), 7.73
(ddd, J : 8.60,
4.83, 2.13 Hz, 1
H), 7.55 (s, 1 H),
7.45 — 7.47 (m, 1
H), 7.33 — 7.36 (m,
1 H), 2.85 (s, 3 H),
[M+H]+ 464.
(CDgOD): 8.59 —
8.62 (m, 2 H), 7.96
(dd, J: 6.90, 2.13
Hz, 1 H), 7.74
(ddd, J : 6.02 Hz,
1 H), 7.57 (s, 1 H),
7.46 (d, J: 5.38
Hz, 1 H), 7.34 (d,
J: 2.01 Hz, 1 H),
[M+H]+ 450.
1H NMR (400
Amine/alcohol in
MHz) ppm; ESI—
step x.
(CDgOD): 8.59 —
8.64 (m, 2 H), 8.14
(s, 1 H), 8.00 (d, J
: 7.80 Hz, 1 H),
7.74 (d, J: 7.66
Hz, 1 H), 7.55 —
7.60 (m, 2 H), 7.44
(d, J: 5.10 Hz, 1
H), 3.37 (s, 1 H),
2.85 (s, 3 H),
[M+H]+ 446.0.
(DMSO-dg): 11.39
(s, 1 H), 10.97 (s,
1 H), 8.70 (d, J:
.27 Hz, 1 H), 8.51
— 8.54 (m, 1 H),
8.34 (dd, J: 6.90,
2.38 Hz, 1 H), 8.10
(ddd, J : 8.72,
4.96, 2.38 Hz, 1
H), 7.75 (s, 1 H),
7.48 — 7.59 (m, 2
H), 2.72 (d, J :
4.52 Hz, 3 H),
[M+H]+ 464.0.
(CDC13) 12.48-
12.73 (m, 1H),
8.70 (s, 1H), 8.47
(d, J: 1.76 Hz,
1H), 8.04 (d, J :
1.51 Hz, 1H), 7.93
(d, J: 8.53 Hz,
1H), 7.86 (dd, J :
1.76, 8.03 Hz, 1H),
7.73 (br d, J :
6.78 Hz, 1H), 7.52
(s, 1H), 7.40 (d, J
: 8.03 Hz, 1H),
4.43 (s, 2H), 3.66-
3.74 (m, 2H),
3.66-3.74 (m, 2H),
3.60-3.68 (m, 4H),
3.58-3.72 (m, 6H),
1H NMR (400
MHz) ppm; ESI—
3.36-3.44 (m, 3H),
3.11-3.26 (m, 3H),
2.82-2.98 (m, 2H),
2.50-2.60 (m, 3H),
2.04—2.20 (m, 4H),
[M+H]+ 600.2.
(CDC13) 8.57 (dd,
J : 1.26, 8.03 Hz,
1H), 8.29 (s, 1H),
7.90 (d, J : 2.01
Hz, 1H), 7.69 (dd,
J : 2.01, 7.78 Hz,
1H), 7.52 (br s,
1H), 7.25—7.35 (m,
2H), 7.20—7.23 (m,
1H), 3.84 (s, 3H),
3.52—3.59 (m, 2H),
3.43—3.49 (m, 2H),
3.40 (s, 3H), 3.01
(s, 3H), 2.48 (s,
3H), [M+H]+
547.3.
(CDC13) 9.60 (br s,
1H), 8.78 (s, 1H),
8.22 (d, J: 2.01
Hz, 1H), 8.14 (dd,
J : 2.01, 8.53 Hz,
1H), 7.95 (d, J :
2.01 Hz, 1H), 7.84
(d, J : 8.67 Hz,
1H), 7.79 (d, J :
7.64 Hz, 1H),
7.53-7.63 (m, 1H),
7.37 (d, J: 8.03
Hz, 1H), 3.59-3.64
(m, 2H), 3.46-3.54
(m, 2H), 3.43-3.46
(m, 3H), 3.05 (s,
3H), 2.54 (s, 3H),
[M+H]+ 542.3.
Method B
Example 2: 3-((2-(cyclopropanecarboxamid0)thiazolyl)ethynyl)—4-methyl-N-(4-
(trillu0r0methyl)pyridinyl)benzamide (I-49)
I «“40H
N N _N
HBr \
o o | S /
H2N /
N HN HN
_ I: 1c F3 H
/ :Cl fN H — TMS
/ s):N/
r —>Et3NDCM E) —> TBAF H
’ r Ed(PPhs)4:CUI II s)4.CU' N N\
(l_pr)2NEt, DMF (i_pr)2NEt, DMF I
0 MS /
50 0 100°C
1a. 49b 49c |-49 F3
Step 1. N-(S-bromothiazolyl)cyclopropanecarboxamide (49b)
To a on of 2-aminobromothiazole monohydrobromide (1a') (5.2 g, 20.0
mmol, 1.0 eq) in 40 ml of DCM was added 4.2 ml of Et3N. To the resulting mixture was
slowly added a solution of cyclopropanecarbonyl chloride (1.83 ml, 2.09 g, 20.0 mmol, 1.0
eq) in 10 ml of DCM at -78 CC. After stirring at rt for 30 min, an additional 0.5 ml of
cyclopropanecarbonyl de in 5 ml of DCM was added at -78 oC and the mixture was
then stirred at rt for an additional 1h. Sat. aq. N212CO3 (15 ml) was added with stirring at rt
over 15 min. The organic layers were separated and the s layer was extracted with
DCM (1 x 20 ml). The combined organics were washed with brine, dried over Na2S04,
filtered, and concentrated by rotary evaporation to give a white solid (49b) which was
washed with EtOAc, dried under vacuum and then used directly in the next step without
purification (3 g, 60%).
Step 2. N-(S-((trimethylsilyl)ethynyl)thiazol-Z-yl)cyclopropanecarboxamide (49c)
A sealed tube was charged with N—(5-bromothiazol
yl)cyclopropanecarboxamide (49b) (3.0 g, 12.1 mmol, 1.0 eq), Pd(PPh3)4 (583 mg), CuI (191
mg), trimethylsilylacetylene (2.25 ml, 1.57 g, 15.9 mmol, 1.3 eq), DIPEA (2.57 ml) and DMF
(25 mL). After degassing with N2, the reaction mixture was stirred at 50 oC overnight. The
solvents were removed by rotary evaporation and sat. aq. Na2CO3 and DCM were added. The
combined organic layers from extraction were concentrated and the crude mixture was
purified by flash column chromatography on silica gel (eluting with EtOAc/Heptane 1:5) to
provide intermediate 49c as a yellow solid.
Step 3. 3-((2-(cyclopropanecarboxamid0)thiazol-S-yl)ethynyl)—4-methyl-N-(4-
u0r0methyl)pyridinyl)benzamide (I-49)
A mixture of intermediate 1c (1.727 g, 4.25 mmol, 1.0 eq), intermediate 49c
(1.238 g, 4.68 mmol, 1.14 eq), Pd(PPh3)4 (489 mg), CuI (126 mg), DIPEA (6.3 ml) and
TBAF (1.0 M in THF, 5.2 ml) in 10 ml of DMF was degassed with N2 and then heated with
stirring at 100 OC overnight. After removing volatiles by rotary ation, sat. aq. Na2CO3
and DCM were added. The combined organic layers from extraction were concentrated and
the crude mixture was purified by flash column chromatography on silica gel (eluting with
EtOAc/Heptane 1:5) to provide a yellow solid, which was washed with EtOAc, filtered, and
further washed with MeOH to give the title compound I-49 as a light yellow solid.
] The nds in Table 2 were synthesized according to Method B above using
the corresponding acyl chloride in step 1 and the ponding iodopyridinyl- or
iodophenylbenzamides.
TABLE 2:
Acyl 1H NMR (400 MHz) (5
chloride
in ste n 1
(DMSO-dg): 12.74 (br s, 1
H), 11.31 (s, 1 H), 8.69 (d, J
: 5.15 Hz, 1 H), 8.53 (s, 1
H), 8.21 (d, J: 1.76 Hz, 1
H), 7.97 (dd, J : 6.16 Hz, 1
H), 7.84 (s, 1 H), 7.42 — 7.62
(m, 2 H), 1.93 — 2.04 (m, 1
H), 0.86 — 1.04 (m, 4 H).
) 8.15 (d, J: 2.13
Hz, 1H), 8.08 (d, J: 2.01
Hz, 1H), 7.95 (dd, J : 2.07,
8.60 Hz, 1H), 7.87 (dd, J :
1.95, 7.97 Hz, 1H), 7.77 (d, J
: 8.41 Hz, 1H), 7.66 (s, 1H),
7.45 (d, J : 8.16 Hz, 1H),
3.69 (s, 2H), 2.69 — 2.51 (br,
s, 11H), 2.39 (s, 3H), 1.88-
1.95 (m, 1H), 0.86-1.11 (m,
(DMSO-dg) 12.45 (s, 1 H),
11.30 (s, 1 H), 8.70 (br s, 1
H), 8.54 (s, 1 H), 8.22 (d, J :
1.63 Hz, 1 H), 7.95 — 8.03 (m
1 H), 7.84 (s, 1 H), 7.47 —
7.62 (m, 2 H), 2.19 (s, 3 H).
(CDC13): 9.28 (br s, 1 H),
8.79 (br s, 1 H), 8.61 (s, 1 H),
8.41 (br s, 1 H), 7.96 (s, 1 H),
7.74 (d, J : 7.98 Hz, 1 H),
7.66 (br s, 1 H), 7.32 (d, J :
8.03 Hz, 1 H), 7.22 (d, J :
.34, 1 H), 2.48 (s, 3 H), 1.28
(s, 9 H).
Method C
Example 3: N-(3-((2-(3-(2-(dimethylamino)ethyl)—3-methylureid0)thiazol-S-yl)ethynyl)—
4-methylphenyl)—4-(trifluoromethyl)picolinamide (I-61)
O BocgN Boc
HO IN\ | S>=N Boc-N'
| / aO EN/
U 61b 1e
F3 “ —> N IN‘ —> \\
NH2 /
HATU, Et3N, DMF pd(pph3)4, Cul 0
61a (I'_pr)2NEt DMF' N
60 o0 fl \
H2N o
)=N H?
l l CDI/DCM \o/\/N\ /
o H
O 50 C
/ N N\
H |
61e CF3 /
Step I. N-(3-i0d0methylphenyl)(trifluoromethyl)picolinamide (61c)
To a solution of 4-(trifluoromethyl)pyridinecarboxylic acid (61b, 11 g) and 3-
iodomethyl-aniline (6121, 13.4 g) in DMF (70 mL) was added HATU (26.3 g) and
triethylamine (29.6 mL). The resulting mixture was stirred at room temperature overnight and
then diluted with water (400 mL). After stirring for 15 min., the solid was collected by
filtration and washed with water. The solid product was dried in vacuo to give a white solid
(61c, 22 g, 94%).
Step 2. tert—butyl N-tert-butoxycarbonyl-N-[5-[2-[2-methyl[[4-
(triflu0r0methyl)pyridine—2-carb0nyl]amin0]phenyl] ethynyl]thiazolyl]carbamate
(61d)
A mixture of bis-tert-butyl (5-bromothiazolyl)carbamate 1e (6.2 g), N—(3-iodo-
4-methylphenyl)(trifluoromethyl)picolinamide 61c (7.4 g), tetrakis(triphenylphosphine)
palladium(0) (1.3 g), and CuI (0.2 g) in DMF (100 mL) was degassed and DIPEA (4.7 mL)
was then added. After stirring at 60 0C for 2 h, the mixture was concentrated by rotary
ation. The resulting e was dissolved in DCM (200 mL) and washed with water
(100 mL). The organic layer was dried, filtered, and concentrated in vacuo. The crude
t was purified by flash column chromatography on silica gel (eluting with 10% EtOAc
in heptane) to give a solid (61d, 7.5 g, 68%).
Step 3. N-(3-((2-amin0thiaz01yl)ethynyl)—4-methylphenyl)—4-(triflu0r0methyl)
picolinamide (61e)
To a solution of tert-butyl N—tert-butoxycarbonyl-N-[5-[2-[2-methyl[[4-
(trifluoromethyl)pyridinecarbonyl]amino]phenyl]ethynyl]thiazolyl]carbamate 61d (12
g) in DCM (30 ml) was added TFA (30 ml) at room temperature and the resulting mixture
was stirred for 1 h. Volatile components were removed by rotary evaporation and the
resulting residue was dissolved in DCM (300 mL) and washed with water (100 mL). The
organic layer was dried, filtered, and concentrated in vacuo. The crude product was purified
by flash column chromatography on silica gel (eluting with 5% MeOH in romethane)
to give ediate 61e as a light brown solid (7.3 g, 91%). 1H NMR (400 MHz, CD3OD) 5
8.97-8.99 (d, J : 5.15 Hz, 1 H), 8.45 (s, 1 H), 7.92 : 8.28,
— 7.96 (m, 2 H), 7.65-7.68 (dd, J
2.38 Hz, 1 H), 7.28-7.30 (d, J : 8.41 Hz, 1 H), 7.22 (s, 1 H), 2.45 (s, 3 H). EI—MS: [M+H]+
403.1.
Steps 4 and 5. N-(3-((2-(3-(2-(dimethylamin0)ethyl)methylureid0)thiaz01
yl)ethynyl)—4-methylphenyl)—4-(trifluoromethyl)picolinamide (I-61)
] To a solution of intermediate 61e (0.07 g,) in DCM (20 ml) was added CDI (0.07
g). After the reaction mixture was stirred at 50 oC overnight, N,N,N’-
trimethylethylenediamine (0.35 g) was added and then stirred for additional 1 h. After
filtration and tration of the filtrates, the crude product was d by flash column
chromatography on silica gel (eluting with 5% MeOH in dichloromethane) to give the title
compound I-61 (0.049 g, .
The compounds in Table 3 were synthesized according to Method C above using
the corresponding N-(iodophenyl)(trifluoromethyl)picolinamide or N—(3-iodo
methylphenyl)(trifiuoromethoxy)benzamide in step 2, and the corresponding amine in step
TABLE 3:
1H NMR (400 MHz): 5 (ppm)
(CDClg): 9.80 (s, 1 H), 8.74 (d, J :
.02 Hz, 1 H), 8.34 — 8.59 (m, 1 H),
8.08 (s, 1 H), 7.77 (d, J : 2.26 Hz, 1
H), 7.62 — 7.67 (m, 2 H), 7.46 (s, 1
H), 7.18 (d, J : 8.00 Hz, 2 H), 4.12
WO 12136
Cmpd 1H NMR (400 MHz): 5 (ppm)
Compound Structure
(br s, 1 H), 2.81 — 2.90 (m, 5 H), 2.39
(s, 3 H), 2.18 (s, 3 H), 1.92 — 2.09 (m,
2 H), 1.75 (m, 2 H), 1.59 — 1.67 (m, 2
(CDC13) 9.89 (s, 1 H), 9.54 (br s, 1
H), 8.83 (d, J : 5.02 Hz, 1 H), 8.56
(s, 1 H), 7.84 (d, J : 2.38 Hz, 1 H),
7.72 — 7.78 (m, 2 H), 7.56 (s, 1 H),
7.26 — 7.30 (m, 1 H), 3.44 — 3.66 (m,
7 H), 3.08 (s, 3 H) 2.49 (s, 3 H).
(CD30D) 8.98 (d, J : 5.02 Hz, 1 H),
8.46 (s, 1 H), 7.98 (s, 1 H), 7.93 (d, J
: 5.05 Hz, 1 H), 7.70 (dd, J: 8.28,
2.26 Hz, 1 H), 7.57 (s, 1 H), 7.31 (d, J
: 8.41 Hz, 1 H), 3.49
— 3.57 (m, 2 H),
3.05 (s, 3 H), 2.59 — 2.84 (m, 10 H),
2.48 (s, 3 H), 2.36 (s, 3 H).
(DMSO-dg): 11.06 (br. s., 1H), 10.38
(s, 1H), 8.03 (dt, J : 7.8, 1.2 Hz, 1H),
7.93 (d, J : 2.3 Hz, 2H), .75
(m, 4H), 7.33 (s, 1H), 2.98 (s, 6H),
2.41 (s, 3H).
(DMSO-dg): 10.85 (s, 2 H) 9.04—9.05
(d, J : 5.14 Hz, 1 H) 8.35-8.36 (m, 1
H) 8.09-8.11 (d, J : 5.56 Hz, 2 H)
7.80-7.83 (dd, J : 8.28, 2.26 Hz, 1 H)
7.67 (s, 1 H) 7.32—7.34 (d, J: 8.41
Hz, 1 H) 2.72 (d, J : 4.64 Hz, 3 H)
2.41 (s, 3 H).
(CDgOD): 8.98 (d, J : 5.02 Hz, 1H),
8.39-8.51 (m, 1H), 7.97 (s, 1H), 7.93
(d, J : 5.27 Hz, 1H), 7.69 (dd, J :
2.26, 8.28 Hz, 1H), 7.54 (s, 1H), 7.30
(d, J : 8.28 Hz, 1H), 3.60 (t, 2H),
3.06 (s, 3H), 2.69 (t, J : 5.33 Hz,
2H), 2.36-2.53 (m, 9H).
(CD30D): 8.98 (d, J : 5.02 Hz, 1H),
8.44-8.47 (m, 1H), 7.96 (s, 1H), 7.92
(d, J : 5.07 Hz, 1H), 7.69 (dd, J :
2.32, 8.22 Hz, 1H), 7.54 (s, 1H), 7.30
(d, J : 8.41 Hz, 1H), 3.57 (t, 2H),
3.05 (s, 3H), 2.72-2.85 (m, 6H), 2.47
(s, 3H), 1.17 (t, J : 7.22 Hz, 6H).
(DMSO-dg): 10.96 (br d, J : 1.25 Hz,
1H), 10.85 (s, 1H), 9.05 (d, J: 5.02
Hz, 1H), 8.36 (s, 1H), 8.09 (s, 1H),
8.10 (d, J: 5.41 Hz, 2H), 7.82 (dd, J
1H NMR (400 MHz): 5 (ppm)
nd Structure
: 2.26, 8.28 Hz, 1H), 7.73 (s, 1H),
7.33 (d, J : 8.53 Hz, 1H), 3.52-3.62
(m, 2H), 3.50 (t, 2H), 3.28 (t, 1H),
3.02 (s, 3H), 2.41 (s, 3H).
(DMSO-dg): 10.99 (br s, 1H), 10.93
(s, 1H), 9.06 (d, J : 5.02 Hz, 1H),
8.36-8.38 (m, 1H), 8.10-8.16 (m, 2H),
7.93 (ddd, J: 1.00, 2.13, 8.28 Hz,
1H), 7.74 (s, 1H), 7.44 (t, J : 7.97
Hz, 1H), 7.31 (td, J: 1.19, 7.91 Hz,
1H), 3.42-3.63 (m, 4H), 3.29 (s,3H),
3.01 (s, 3H).
(CDgOD): 8.98 (d, J : 5.02 Hz, 1H),
8.46 (s, 1H), 8.04 (dd, J : 2.70, 6.21
Hz, 1H), 7.93 (d, J : 5.06 Hz, 1H),
7.83 (ddd, J : 2.76, 4.52, 9.03 Hz,
1H), 7.60 (s, 1H), 7.22 (t, J : 9.03
Hz, 1H), 3.59-3.67 (m, 4H), 3.43 (s,
3H), 3.10 (s, 3H).
Biochemical Assays
Example 4: c-Kit Assay
Generation of Ba/F3 KIT mutant engineered cell lines
KIT cDNAs were synthesized by GenScript and cloned into the pLVX-IRES-Puro
vector (Clontech). Viral particles were produced by transfecting pLVX-IRES-puro vectors
containing KIT mutant genes into HEK293 cells (Invitrogen) using the Trans-Lentiviral ORF
Packaging Kit (Thermo Scientific). 48 hours post-transfection, virus-containing supernatants
were harvested and incubated for another 48-72 hours with parental Ba/F3 cells (DSMZ) in
the presence of 10 ng/mL lL-3 (R&D Systems). uced Ba/F3 cells were then ed
by IL-3 withdrawal and puromycin (0.5-1 ug/mL, ogen).
Viability assays
Cell lines (e.g., EXl lDEL, EXl 1DEL/D816H, EXl 1DEL/T67OI, and
L/V654A) were plated into 384 well plates using RPMI 1640 supplemented with
% PBS at densities that produced linear growth and incubated at 37 0C in 5% (v/v) C02.
Cells were d with eight concentrations of compound over a 4-fold dilution (10 11M to
0.61 nM) and viability was assessed using Cell Titer-Glo assay (Promega) after 72 hours.
Data were plotted as percent viability relative to vehicle-treated cells. Dose-responses curves
were generated and used to ate IC50 values.
Table 4: c-Kit activity of compounds of the invention in the c-Kit assay. ++++
indicates an IC50 of less than about 10 nM, +++ indicates an IC50 between about 10 nM and
about 50 nM, ++ indicates an IC50 between about 50 nM and about 100 nM, and + indicates
an IC50 greater than about 100 nM and less than about 10 uM.
TABLE 4: cKit Assay.
Hag BAF3 FL KIT BAF3 FL KIT BAF3 FL KIT
9‘0 BAF3 FL KIT
EXllDEL/D816H EXllDEL/T6701 EXllDEL/V654A
EXl1DEL (nM)
l—t ++++
’T‘.5————
’T‘u:
’T‘\l
’7‘co
’7‘so
’T‘ p—x C
lI—l p—x p—x
’T‘ p—x N
’T‘ p—x DJ
’T‘ p—x .k
’T‘ p—x U]
’T‘ p—x OK————
1-17————
’T‘ p—x 0Q
’T‘ p—x \D
.~.~ NN HO
’T‘NN
’T‘N03
’T‘N .5
’7‘N u:
’7‘Na
’7‘N \l
’7‘N co
’7‘N so
’T‘m c:
T103 p—x
’T‘03N
’T‘mm
BAF3 FL KIT BAF3 FL KIT BAF3 FL KIT
BAF3 FL KIT
EXllDEL/D816H EXllDEL/T6701 EXllDEL/V654A
EXl1DEL (nM)
’T‘93 IR
’7‘m u:
’T‘ma
’T‘m \1
’T‘(a co
’7‘w v:————
’7‘ .Bc
T1 .5 p—x
’T‘ .5N
’7‘ IR(A
’T‘ IR .5
’T‘T‘ .54; chm————
1-47————
’7‘ .B so
’7‘ .B so
’7‘ u:c
FI—l U] p—x
’7‘ u:N
’T‘ u:m
’7‘ an IR
’7‘ u: u:
’7‘ an ax
’7‘ u: \l
’7‘ u: so
’7‘ u: so
’7‘ac
FI—l OK p—x
’7‘aN
Eguivalents
Those skilled in the art will recognize, or be able to ascertain, using no more than
routine experimentation, numerous equivalents to the specific embodiments bed
cally herein. Such equivalents are intended to be encompassed in the scope of the
following claims.
Claims (32)
1. A compound of a (I): or a pharmaceutically acceptable salt thereof, wherein: L is –C(O)NR5- or –NR5C(O)-; A is (C6-C10) aryl optionally substituted with one or more R4; R1 is H, (C1-C6) alkyl, -(CH2)qC(O)OH, or –C(O)N(R7)2; R2 is ) alkyl, -C(O)R8, or –C(O)NR9R10; each R3 is ndently at each occurrence (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, halogen, or OH; each R4 is independently at each occurrence (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, halogen, -OH, CN, -(C(R6)2)p-heterocycloalkyl wherein the heterocycloalkyl comprises a 4- to 7-membered ring and 1 to 3 heteroatoms selected from N, O, and S , or -(C(R6)2)p-heteroaryl wherein the heteroaryl comprises a 5- or 6-membered ring and 1 to 3 heteroatoms selected from N, O, and S, and wherein the heterocycloalkyl or aryl is optionally substituted with one or more substituents each independently selected from (C1-C6) alkyl, -NH2, (C1-C6) alkylamino, and (C1-C6) dialkylamino; R5 is H, (C1-C6) alkyl, or ) haloalkyl; each R6 is independently H or (C1-C6) alkyl; each R7 is independently H or (C1-C6) alkyl; R8 is (C1-C6) alkyl, (C3-C7) cycloalkyl, (C2-C6) alkenyl, (C1-C3) alkoxy, ) haloalkyl, (C1-C6) haloalkoxy, or 4 to 7-membered heterocycloalkyl comprising 1 to 3 heteroatoms selected from N, O, and S; R9 is H, (C1-C6) alkyl, (C1-C6) kyl, (C3-C7) cycloalkyl, or 4 to 7-membered heterocycloalkyl comprising 1 to 3 heteroatoms selected from N, O, or S; R10 is H, (C1-C6) alkyl, (C1-C6) haloalkyl, ) lkyl, or 4 to 7-membered heterocycloalkyl comprising 1 to 3 atoms selected from N, O, or S, wherein the cycloalkyl or cycloalkyl is optionally substituted with one or more tuents each independently selected from (C1-C6) alkyl, -NH2, (C1-C6) alkylamino, (C1-C6) dialkylamino, and -OH, and wherein the (C1-C6) alkyl is optionally substituted with one or more R11 ; or R9 and R10 together with the nitrogen atom to which they are attached form a 4- to 7-membered heterocycloalkyl ring comprising 1 to 3 heteroatom selected from N, O, and S, optionally substituted with one or more substituent each independently selected from (C 1-C6) alkyl, (C1-C6) hydroxyalkyl, -(CH2)q-NH 2, -(CH2)q-(C 1-C6) alkylamino, -(CH 2)q-(C 1-C6) lamino, -C(O)(C1-C6) alkyl, -OH, and 4- to 7-membered heterocycloalkyl comprising 1 to 3 heteroatom selected from N, O, and S, and optionally substituted with one or more (C1-C6) alkyl; R11 is (C1-C6) alkoxy, -OH, -NH2, (C1-C6) alkylamino, (C1-C6) dialkylamino, 5- or 6- membered heteroaryl comprising 1 to 3 heteroatoms selected from N, O, or S, or 4- to 7- membered cycloalkyl sing 1 to 3 heteroatoms selected from N, O, or S, n the heterocycloalkyl is optionally substituted with one or more tuents each ndently selected from (C1-C6) alkyl and OH; and each p and q is independently 0, 1 or 2; each n is 0; provided that when A is phenyl and R1 is H, then R2 is not –C(O)CH3.
2. The compound of claim 1, wherein L is a –C(O)NR5-.
3. The compound of claim 1, wherein L is a –NR5C(O)-.
4. The compound of any one of claims 1 to 3, wherein n is 1 and R3 is methyl or F.
5. The compound of any one of claims 1 to 4, wherein A is phenyl substituted with one or more R4.
6. The compound of any one of claims 1 to 5, wherein R5 is H.
7. The compound of any one of claims 1 to 6, having one of the following ae (Ia) or (Ib): (Ia), or (Ib), or a pharmaceutically acceptable salt thereof.
8. The compound of any one of claims 1 to 7, having one of the following formulae (Ic) or (Id) : (Ic), or (Id), or a pharmaceutically acceptable salt tautomer thereof.
9. The compound of any one of claims 1 to 8, having one of the following formulae (Ie) or (If): (Ie), or (If), or a pharmaceutically acceptable salt tautomer thereof.
10. The compound of any one of claims 1 to 9, wherein one R4 is (C1-C6) kyl and the other R4 is (C1-C6) alkoxy, CN, or -(C(R6)2)p-heterocycloalkyl n the heterocycloalkyl comprises a 4- to 7-membered ring and 1 to 3 heteroatoms selected from N, O, and S.
11. The compound of any one of claims 1 to 10, wherein at least one R4 is CF3 and the other R4 is (C1-C6) alkoxy, CN, or )2)p-heterocycloalkyl wherein the heterocycloalkyl comprises a 4- to 7-membered ring and 1 to 3 heteroatoms selected from N, O, and S.
12. The compound of any one of claims 1 to 11, wherein at least one R4 is CF3 and the other R4 is –OCH3, CN, or -(CH2)-pyrrolyl.
13. The compound of any one of claims 1 to 12, wherein R1 is H and R2 is –C(O)NR9R10.
14. The compound of claim 13, wherein R9 is H and R10 is (C1-C6) alkyl.
15. The compound of claim 13, wherein R9 is H and R10 is (C1-C6) alkyl substituted with one R11.
16. The compound of claim 15, wherein R11 is (C1-C6) alkoxy.
17. The compound of claim 16, wherein the (C1-C6) alkoxy is –OCH3.
18. The compound of claim 13, wherein R9 is (C1-C6) alkyl and R10 is (C1-C6) alkyl.
19. The compound of claim 18, wherein R9 is (C1-C6) alkyl and R10 is (C1-C6) alkyl tuted with one R11.
20. The compound of claim 19, n R11 is (C1-C6) .
21. The compound of claim 20, wherein the (C1-C6) alkoxy is –OCH3.
22. The compound of claim 1, wherein the nd is selected from: 3-((2-(3-(2-methoxyethyl)methylureido)thiazolyl)ethynyl)methyl-N-(4-(pyrrolidin- 1-ylmethyl)(trifluoromethyl)phenyl)benzamide (I-46); N-(2-methoxy(trifluoromethyl)phenyl)((2-(3-(2-methoxyethyl)methylureido)thiazol- 5-yl)ethynyl)methylbenzamide ; N-(4-cyano(trifluoromethyl)phenyl)((2-(3-(2-methoxyethyl)methylureido)thiazol yl)ethynyl)methylbenzamide (I-48); 3-((2-(cyclopropanecarboxamido)thiazolyl)ethynyl)methyl-N-(4-((4-methylpiperazin yl)methyl)(trifluoromethyl)phenyl)benzamide (I-50); and N-(3-((2-(3,3-dimethylureido)thiazolyl)ethynyl)methylphenyl) (trifluoromethoxy)benzamide (I-56); N-(3-((2-(3-(2-methoxyethyl)methylureido)thiazolyl)ethynyl)phenyl) (trifluoromethyl)picolinamide (I-61 ); or a pharmaceutically acceptable salt thereof.
23. A pharmaceutical composition comprising a compound of any one of claims 1 to 22, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable diluent, excipient or carrier.
24. Use of a compound of any one of claims 1 to 22, or a pharmaceutically acceptable salt thereof, or the composition of claim 23, in the manufacture of a medicament for treating a c- diated disease or disorder.
25. The use of claim 24, wherein the cKit-mediated disease or disorder is selected from cell erative disorder, a fibrotic er, and a lic disorder.
26. The use of claim 25, wherein said cell erative disorder is cancer.
27. The use of claim 26, wherein said cancer is selected from the group consisting of leukemia, mast cell tumor, small cell lung cancer, testicular cancer, cancer of the gastrointestinal tract, cancer of the central nervous system, cancer of the female genital tract, sarcoma of neuroectodermal origin, and Schwann cell neoplasia associated with ibromatosis.
28. The use of claim 27, wherein said cancer is selected from the group ting of small cell lung carcinoma, acute d leukemia (AML), neuroblastoma, malignant melanomas, colorectal , systemic mastocytosis (SM), and gastrointestinal stromal tumors (GISTs).
29. The use of claim 24, wherein said cKit-mediated disease or disorder is multiple sclerosis, asthma, an allergic reaction, inflammatory arthritis, or mastocytosis.
30. Use of a compound of any one of claims 1 to 22, or a pharmaceutically acceptable salt thereof, or the composition of claim 23, in the manufacture of a medicament for modulating c-Kit.
31. Use of a compound of any one of claims 1 to 22, or a pharmaceutically acceptable salt thereof, or the composition of claim 23, in the cture of a medicament for inhibiting c-
32. Use of a compound of any one of claims 1 to 22, or a pharmaceutically acceptable salt thereof, or the composition of claim 23, in the manufacture of a medicament for treating or preventing a disease in which c-Kit plays a role.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US62/434,845 | 2016-12-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
NZ795495A true NZ795495A (en) | 2022-12-23 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2022200741B2 (en) | Aminothiazole compounds as c-Kit inhibitors | |
AU2022201082B2 (en) | Benzimidazole compounds as c-Kit inhibitors | |
JP2023126907A (en) | Rho-related protein kinase inhibitor, pharmaceutical composition containing the same, and method of preparation and use thereof | |
CN117355299A (en) | Substituted 2- (2, 6-dioxopiperidin-3-yl) -5- (1-piperidin-4-yl) isoindoline-1, 3-dione derivatives and uses thereof | |
CA3202516A1 (en) | Aminothiazole compounds as c-kit inhibitors | |
NZ795495A (en) | Aminothiazole compounds as c-Kit inhibitors | |
NZ795496A (en) | Aminothiazole compounds as c-Kit inhibitors | |
NZ795575A (en) | Benzimidazole compounds as c-Kit inhibitors | |
NZ795572A (en) | Benzimidazole compounds as c-Kit inhibitors | |
EA041051B1 (en) | AMINOTHIAZOLE COMPOUNDS AS c-KIT INHIBITORS |